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Abstract
Haemolytic disease of the fetus and newborn (HDFN) is, without preventive 
action, a common cause of fetal morbidity and mortality. The condition is 
caused by maternal antibody to red cell antigens crossing the placenta and 
mediating the destruction of fetal red cells. This results in fetal anaemia, 
jaundice, and in severe cases, death. In western populations the commonest 
causative antibody is anti-D. For forty years the incidence of alloimmunisation 
to the RhD antigen, and hence HDFN, has been moderated by the 
administration of anti-D immunoglobulin to RhD- mothers. The treatment is 
extremely effective but the mechanism of action remains unresolved.
The aim of this quasi-experimental study is to test the hypothesis that there is a 
significant difference in maternal plasma cytokine expression before and after 
anti-D administration, thereby increasing the understanding of the mechanism 
of action. To recruit a participant cohort, RhD- women called to ant-D 
prophylaxis clinics at 28 weeks gestation were sent a leaflet describing the 
study 3-6 weeks before their appointment, and invited to participate. Blood 
samples were collected from 24 women receiving anti-D at 28 weeks gestation, 
before, and at 1, and 24 hours after administration. The concentration of 
plasma cytokines was measured by flow cytometry, and/or by enzyme linked 
immunosorbant assay (ELISA). Participants were allocated to test and control 
groups by the RhD group of their babies, determined at delivery. Changes in 
cytokine concentration greater than 50% (1.5 fold) were detected by ELISA for 
IL-1 ra and TGF-P1. mRNA of white blood cells of these two cytokines was 
measured by quantitative polymerase chain reaction. When combined, the 
difference in TGF-pi responses in RhD+ and RhD- fetus arms were found to be 
statistically significant (p=0.047). When ELISA and PCR results were 
considered separately, no significant difference was noted in fold changes in 
test and control groups (p>0.05).
TGF-(31 is a powerful immunosuppressant acting on the key cellular elements 
of the humoral immune response. The results of this study suggest that the 
mechanism by which anti-D prevents alloimmunisation includes the induction of
TGF-pi secretion. Monoclonal anti-D selected for trials to replace human 
products have focussed on antibodies capable of causing clearance of fetal red 
cells from the maternal circulation, and have to date had poor results. The 
knowledge that anti-D prophylaxis has additional biological effects which may 
contribute to immunosuppression should inform the selection of monoclonal 
antibodies for future trials.
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Chapter 1 Review of the Literature
Literature Review Strategy
This review was undertaken using LitSearch software supporting 
simultaneous interrogation of: PubMed, Medline, Scopus, Biological Sciences, 
and Intute databases. Key-words used in searches were: anti-D, prophylaxis, 
immunomodulation, immunosuppression, immunology, Haemolytic Disease of 
the Fetus and Newborn, pregnancy, cytokine, and Transforming Growth 
Factor- Beta. This search informed the development and design of this 
research, and identified that no other published study has investigated the 
effect of intravenously administered anti-D on cytokine expression measured 
by ELISA and PCR.
1.1 Haemolytic Disease of the Newborn, Pathogenesis, Treatment and 
Prevention
1.1.1 Introduction
Everyday we encounter compelling and diverse evidence that the strategy of 
mammalian reproduction is effective. An oocyte of maternal origin is fertilised 
by paternal sperm, and develops in a specialised environment within the 
maternal uterus, until the developed fetus is sufficiently mature to survive 
outside the womb (Billington 1992). The manifold physiological and 
developmental advantages of the strategy are evident from the ecological 
dominance achieved by mammals since their evolution. Internal rather than 
external fertilisation has proved a successful strategy shielding the 
development process from external threats such as predators, toxins, and 
adverse environmental conditions. The result is that a high proportion of live 
births is possible and has resulted in greater reproductive success and gene 
transmission (Mor 2006).
Those benefits can be realised only by virtue of elegant biological 
mechanisms supporting the development of the fetus, which carries paternal 
antigens and is, effectively, an allograft, while permitting support of the fetus
l
by the maternal blood circulation via the placenta. Maternal immune 
surveillance protects the mother and her baby from bacterial, viral, fungal, or 
parasitic infection and neoplasms. The relationship between the maternal 
immune system and the fetus is complex. Under some circumstances fetal 
red cells become the target for immune destruction and haemolytic disease of 
the fetus and newborn results. This chapter reviews the biology of the 
maternal-fetal relationship the immunology of HDFN, and the laboratory and 
clinical control, treatment and prevention.
1.1.2 Normal Fetal Haematology
Erythropoiesis has been demonstrated in the fetal yolk sac at 3 weeks 
gestation, and the Rh (previously known as Rhesus) peptide detected on fetal 
red cells from the 3rd week of gestation (Bowman 1994). By 12 weeks, 
erythropoeisis is proceeding in the liver, and to a lesser degree, the spleen. 
From 20 weeks, haemopoiesis is transferred to the bone marrow of the long 
bones and by birth this is the main site (Testa 2001). Where bone marrow 
production of red cells is insufficient to prevent anaemia due to blood loss or 
haemolysis, at any stage of life, erythropoiesis may occur in other tissues 
especially the liver and spleen (Lewis 2001). In the developing fetus and 
neonate, unlike adults, bone marrow fills every bone cavity available and any 
requirement for excess erythropoeisis transferred to extra medullary tissues 
(Pallister 1998). This results in the hepatosplenomegaly characteristic of 
fetuses and neonates with inadequate bone marrow function.
The control of red cell maturation is poor in extramedullary tissue, in the liver 
and spleen, resulting in the release of nucleated red cells into the circulation 
Bowman 1994).
1.1.3 The Function of the Placenta
The function of fetal nourishment has been ascribed to the placenta for more 
than 2,000 years (Huppertz 2007). Until 8-10 weeks gestation, the regulatory 
and nutritional functions of the developing fetus are provided by the yolk sac. 
The increasing complexity and scale of the needs of the developing fetus
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requires direct maternal support (McNabb 2004) and, from that point the 
placenta provides all the substrates for fetal growth and allows fetal 
respiration by gaseous exchange (Smith 2007).
The human placenta facilitates interactions between the maternal and fetal 
circulation through interdigitating placental villous tree-like structures which 
extend into the maternal bloodstream (Huppertz 2007).Transport across the 
placenta is by simple diffusion for oxygen and carbon dioxide. Other species 
are transported via specific transporter molecules on the villous membrane 
and large molecules, such as immunoglobulin class G (IgG), by receptor 
mediated endocytosis (Dunihoo 1990).
1.1.4 The Immunology of Pregnancy
The immunological balancing act of pregnancy requires the maternal immune 
system to tolerate the fetal allograft, while maintaining immune surveillance to 
defend against infection. This is unique in nature though Medowar, in the 
early 1950s, recognised the analogy between the fetal allograft and the new 
science of transplantation (Mor 2006). The focus of maternal tolerance is on 
the placenta not the fetus; the cells of the placenta are adapted for routine 
interaction with the maternal immune system without eliciting responses 
incompatible with viable pregnancy. The array of evasive mechanisms 
employed by the trophoblast and placental cells is complex and highly 
developed (Mor 2006).
The placenta fulfils the role of a physical barrier between the mother and fetus 
but also acts as a mechanism by which the immune privilege status of the 
fetus is maintained. The barrier is not impregnable to cell migration between 
fetus and maternal circulations, with cells of maternal origin being detectable 
in the offspring to adulthood, and fetal cells, derived chiefly from budding of 
trophoblasts, being detectable in the maternal circulation (Trowsdale 2006).
Fetal evasion of the maternal immune system occurs through a number of 
routes. The potential for damage to the fetal-placental unit by the maternal
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immune system is further reduced by the induction of regulatory T cells 
(Treg), which are recruited to the materno-fetal interface and down regulate 
cytotoxic T cells, and NK cell responses. Induction of Treg occurs within 48 
hours of fertilisation and is probably stimulated by hormones (Hanson 2009).
There are several mechanisms for the protection of the fetus from the 
maternal immune system including:
• Trophoblasts do not express the highly polymorphic HLA class I A and 
B locus, or class II antigens (Hanson 2009). These are replaced by the 
much less variable HLA-E, F, and G molecules, indeed HLA-G is 
monotypic (Trowsdale 2008). HLA-C is retained and is a ligand for 
uterine maternal Natural Killer (NK) cells, the binding of which 
facilitates placental vascularisation (Trowsdale 2008).
• Expression on trophoblasts of complement downregulatory proteins 
CD46, CD55 and CD59 (Weetman 1999).
• Shift in cytokine patterns from Th1 to Th2/Th3. Mothers in whom Th1 
cytokines predominate are subject to recurrent abortion of pregnancies, 
and normal, successful pregnancies are considered to require a shift to 
predominantly Th2 profile (Ragupathy 2000, Levy 2007).
Th1 cytokines, IL-2, IFN-y, and TNF-p have been shown to be associated with 
cytotoxic T cell damage to placental cells. Th2 cytokines, IL-4, IL-5, IL-6, IL-10 
and IL-13 are strongly associated with successful pregnancy (Ragupathy 
2001). The classification of immune responses by Th1/Th2 is simplistic, and it 
is acknowledged that T cells with other profiles contribute to the support of the 
fetal allograft. In particular Th3 cells secreting TGF-|31 an anti-inflammmatory 
cytokine with a role in mucosal immunity and downregulation of Th1 
responses may be important (Ragupathy 2001, Costeas 2004). HDFN is an 
antibody mediated pathology which may be exacerbated by the strategy of 
deviating the maternal immune system to Th2/Th3 . Accidental exposure of 
fetal tissue to the maternal immune system results in such powerful 
pathologies as HDFN, is indicative of the efficacy of immune evasion (Mor 
2006).
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1.1.5 The Placental Transfer of IgG
The fetal immune system is immature, leaving the neonate vulnerable to 
extracellular infective agents. Specific immunity transferred from mother to 
fetus was first reported by Paul Ehrlich in 1892 (cited in Kristofferson 2002). 
From approximately 12 weeks gestation, maternal IgG is actively transferred 
across the placenta, conferring passive immunity on the fetus. In humans, 
maternal IgG is transferred to the fetal circulation by a placenta bound 
receptor, FcRn which is unlike other IgG receptors both in structure and 
function, being part of the Major Histocompatibility Complex (MHC) class I 
protein family and being dependent on dimerisation with P2 microglobulin 
(Klein 2005). It is widely distributed on endothelial cells and functions include: 
IgG conservation and salvage, transport in the gut lumen, and into colostrum 
(Antohe 2001). IgG transport across the placenta is initiated by non-specific 
pinocytosis, with other plasma proteins including IgM and IgA by 
syncytiotrophoblasts at the fetomaternal interface (Figure 1.1). IgG is 
trafficked to vesicles lined with FcRn, the low pH in that environment 
promotes binding of the IgG to FcRn via specific amino acids at the junction 
between IgG heavy chains. These are isoleucine 253, histidine 310, and 
histidine 435 (Firan 2001). Each IgG molecule has two heavy chains and 
causes dimerisation of the FcRn. Protein not ligated to FcRn bound IgG is 
directed to lysosomes for enzymatic degradation: IgG is trancytosed (Simister 
2003). The vesicles fuse with the basement membrane exposing the 
FcRn/IgG complex to higher pH and resulting in disassociation and release. 
(Hadley 2002, Kristofferson 2000). The mechanism by which IgG is 
transported into the fetal circulation is not known, though the presence of 
FcRII on fetal vascular endothelium may be important (Simister 2003).
By 24 weeks gestation, the concentration of serum IgG may be up to 1.8g/L in 
the fetus compared to 12.6g/L in the maternal serum. At this gestation the 
cytotrophoblast layer, which lacks FcRn and represents a barrier to IgG, 
transport, becomes discontinuous allowing IgG transfer to the fetus (Simister 
2003).
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Figure 1.1 Steps in the transport of IgG across the placenta.
Maternal IgG enters the syncytiotrophoblast by endocytosis (A). Vesicles fuse 
and material is transported in a low pH, IgG binds to FcRn and is rescued 
from enzymatic degradation (B). Unbound material is degraded (C). At the 
basal membrane the IgG/FcRn complex dissociates (D). FcRn is recycled (E), 
and maternal IgG enters the fetal circulation (F) (from Kristoffersen 2000)
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From that point, IgG transfer rates increase until, at delivery, overall fetal IgG 
concentrations, exceed those in the maternal serum (Simister 2003). lgG1 in 
particular is preferentially transported to the fetal circulation, and lgG2 is 
transported least, or possibly later. Fetal and maternal lgG3 concentrations 
are similar at the end of the third trimester, and lgG4 levels very variable 
(Simister 2003). It may be that the rate of transfer of IgG across the placenta 
is the rate limiting step in the progression of HDFN (Hughes-Jones 1971). 
Indeed, HDFN before 24 weeks gestation is rare (Hadley 2002). The transport 
of pathological maternal autoimmune IgG, specific for fetal tissue antigens, 
can transfer the maternal condition to the fetus, resulting in heart block and 
rarely renal dysfunction in the fetuses of women suffering from Systemic 
Lupus Erythematosus (SLE) (Dahmane 2005) or neonatal Myasthenia Gravis 
(Telez-Zenteno 2005). Variation in placental transfer of antibody may account 
for unaffected RhD+ fetuses in pregnancies with high levels of maternal anti- 
D. This may be associated with placental morphology changes due to fetal 
anoxia (Lubenko 1994) or antibodies to the paternally derived HLA class II 
antigens on fetal leucocytes blocking binding sites on FcRn (Dooren 1993). It 
is when maternal alloantibody is specific for fetal red cells that HDFN occurs.
1.2 Aetiology of Haemolytic Disease of the Fetus and Newborn (HDFN)
1.2.1 Introduction
HDFN is an unusual disease being discovered, characterised and almost 
eradicated within a single scientist’s career span. An examination of that 
process illustrates how advances in the understanding of biology in the mid 
and late 20th century facilitated and informed observation and hypothesis. 
Unexplained symptoms were translated into understanding of disease 
pathology, then into treatment and eventually into prevention. The story is 
punctuated by startling examples of insight and oversight, solutions derived 
both from the most exquisite technologies and serendipitous application of the 
mundane. So immediately successful was the prophylaxis, which prevents 
most HDFN, little attention was paid to the mechanism of its action, a state 
which perhaps surprisingly persists to the present day.
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The first recorded report of HDFN was made in 1609 by Louyse Bourgeois, a 
French midwife. She described the birth of twins, the first of whom was 
bloated with hydrops, the other developed severe jaundice and died at a few 
days of age (Bowman 1994). In view of data from epidemiological studies 
from the second half of the 20th Century (Clarke 1983, Hussey 1992), many 
midwives must have encountered these and other symptoms now associated 
with HDFN. In fact there were many reports of cases of hydropic and 
jaundiced fetuses in the burgeoning scientific literature of the late 19th and 
early 20th centuries. Diamond (1932) reviewed a large number of such case 
reports, which reflected the diverse nature of disease presentation but were 
characterised by anaemia (congenital anaemia of the newborn), jaundice 
(icterus gravis neonatorium), and the presence of an abnormally large 
proportion of erythroid blast cells (erythroblastosis fetalis) in the fetal 
circulation. The authors recognised the relationship between the conditions by 
the common clinical features: enlarged fetal liver and spleen 
(hepatosplenomegaly) resulting from red cell production outside the bone 
marrow (extramedullary erythropoeisis), fetal oedema and anaemia with 
jaundice. They also recognised the familial nature of the condition in many 
cases. Though recognising the common symptoms and suspecting a common 
cause, the authors favoured the hypothesis that dysfunction of fetal 
erythropoeisis was the most likely cause of disease.
Interestingly the authors wrote:
"the presence of toxins and haemolytic substances derived from the mother 
have frequently been offered as an explanation for anaemia and icterus"
Regrettably no reference is offered and they indicate that this might be a 
separate condition entirely.
The first insight into the pathology of HDFN was provided in 1938 by Ruth 
Darrow, a pathologist who had herself lost babies to kernicterus. She 
undertook a comprehensive review of the clinical and pathological 
presentation of cases classified broadly as icterus gravis neonatorum (Darrow
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1938). In this paper Darrow critically considered all the available literature, 
summarised in a series of observation-based statements, and sequentially 
eliminated hypotheses that were contradicted by evidence. At the end of the 
process she was left with a single theory: that, following a leak of fetal red 
cells into the maternal bloodstream, the immune system had recognised the 
haemoglobin of the fetal red cells as foreign and had formed an anti-fetal 
haemoglobin antibody. That fetal haemoglobin differed from adult, and could 
be antigenic, were both recent discoveries. This remarkable piece of 
reflection was very close to the truth, only the specificity of the antibody being 
incorrect. In fact, fetal haemoglobin is formed in small quantities by almost all 
adults and as a result the alloimmune response described by Darrow is 
unlikely (Bowman 1994). The causative antibody was discovered one year 
later following a severe and unexpected transfusion reaction in a group O 
woman transfused with her husband’s group O blood shortly after delivering a 
stillborn fetus (Levine 1939). At that time the only recognised blood group 
incompatibility was in the ABO system, and this reaction could not be 
explained. The patient bled both before and after a subsequent hysterectomy, 
and was supported with blood transfusions from a further eight professional 
blood donors selected by the Blood Transfusion Betterment Association, 
resulting in uneventful and therapeutic transfusions. The crossmatch 
techniques employed, though unspecified, were described as a “delicate 
technic”. The incompatibility between the patient and her husband’s blood 
was detected, and allowed selection of eight from fifty (16%) compatible 
professional donors for subsequent transfusion.
This case was the first description of alloimmunisation resulting from 
pregnancy, though there were previous reports of occurrence subsequent to 
blood transfusion. The authors hypothesised that the woman had formed an 
antibody to a red cell antigen expressed on fetal cells, which the child had 
inherited from its father. In common with alloimmunisation events resulting 
from blood transfusion, the antibody usually appeared to be transient being 
undetectable one year after delivery. It is likely that the authors were in fact 
detecting IgM red cell antibodies in the woman’s plasma, incapable of 
placental passage and hence not the cause of the HDFN, rather a marker for
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the co-existing IgG antibody (Issitt 1998). Though transfusion had been used 
therapeutically for infants born with HDFN, this was the first report of the 
growing discipline of transfusion science, adding to the understanding of the 
condition, a link which would strengthen over the subsequent decades in 
diagnosis, treatment and prevention.
The specificity of the antibody implicated in HDFN was revealed in an 
experiment in which blood from Rhesus monkeys was used to raise 
antibodies in guinea pigs. (Landsteiner 1940). When tested against red cells 
from humans the authors found that red cells from 85% of individuals were 
agglutinated by the serum (i.e. were Rhesus positive) and 15% remained 
unagglutinated (i.e., were Rhesus negative). The serum of Levine and 
Stetson’s patient was shown to have a similar pattern of reactivity with panels 
of human red cells, the woman being confirmed as Rhesus negative and her 
husband Rhesus positive.
The transient nature of the detectable antibody, in contrast to the recurrence 
of the disease in subsequent pregnancies, continued to perplex investigators. 
It was clear that a variant of the detectable (IgM) anti-Rhesus antibodies 
existed in some bloods detectable only by its ability to prevent agglutination of 
Rhesus positive red cells by known examples of Rhesus agglutinins. The 
mechanism for this seemed to be antigen site blocking by an agent specific 
for the Rhesus antigen but incapable of causing agglutination directly. Within 
a short period a range of techniques evolved to allow detection of this (IgG) 
blocking antibody. (Mourant 1983, Tovey 1992), which binds specifically to 
red cell antigens, without causing direct agglutination. The most significant of 
the new techniques was the Coombs’ test, using anti-human globulin raised in 
animals to cross-link red cell bound IgG and providing a visible agglutination 
endpoint (Coombs 1994).
1.2.2 The RhD Antigen
The human RhD antigen is expressed on a polypeptide comprised of 417 
amino acids expressed only on erythroid tissue. The peptide, has a molecular
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mass of 45,000, is strongly hydrophobic and traverses the red cell membrane 
12 times (Daniels 2002) (Figure 1.2). The RH gene locus on chromosome 
1 p34-p36 is comprised of the homologous RHCE and RHD genes coding for 
RhD and CcEe peptides and their associated antigens (Van Kim 2006). 
Genomic rearrangement between the two genes is not uncommon resulting in 
the creation of RHD-CE-D and RHCE-D-CE hybrids where the hybrid 
component may range from a single amino acid to substantial peptide 
segments. These rearrangements, together with other single amino acid 
deletions and substitutions, make RhD one of the most polymorphic antigens 
encountered in red cell immunohaematology (Daniels 2002).
Rh is the most complex of the blood group systems described to date with 48 
known variant alleles (Wagner 2004). More than 30 D epitopes are 
recognised (Scott 2002) with more being encountered regularly in pre­
transfusion testing (Daniels 2002). There is no RHd gene. D negative 
phenotypes are the result either of an RHD deletion or any inactive RHD 
gene. In Caucasians the D- phenotype occurs due to a homozygous deletion 
of the RH gene, which is also widely expressed in non-Caucasian 
populations. Other inactive genes including the RHD^ pseudogene 
expressed in Africans present challenges to accurate genotypic 
characterisation of D zygosity (Wagner 2004).The RhD antigen is highly 
immunogenic. Some 80 percent of D- people transfused with an single unit of 
D+ red cells form anti-D (Issitt 1998), though a more recent study suggests a 
much lower immunisation rate in the region of 30% (Frohn 2003).
Nevertheless this is higher than the immunisation rate for all the other 
recognised red cell antigens in aggregate, which is unlikely to exceed 5% 
(Issitt 1998). Most blood group polymorphisms represent single amino acid 
deletions or substitutions. The immune system of an individual challenged 
with red cells of a different blood group is presented with relatively small 
changes in antigen. RhD differs from its nearest homologue, RhCE by 36 
amino, acids which are clustered in exofacial portions of the D peptide, 
representing a much more easily recognised non-self antigen (Figure 1.2, 
Wagner 2004).
l l
The frequencies of D+ (85%) and D- (15%) in the US populations in the initial 
report (Landsteiner 1940) and corroborated widely in Caucasian populations 
since but are not reflected in other populations (e.g. Daniels 2002). The 
frequency of RhD- is reduced in Asian populations, and is extremely rare in 
the Far East. In Chinese populations, other red cell antibodies (anti-c, anti-Dia) 
are more frequent causes of HDFN as the D- phenotype is very rare (Issitt 
1998).
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Figure 1.2 The Rh polypeptide showing transmembrane domains.
Black spots identify sites of amino acid substitutions and deletions leading to 
variant phenotypical expression. Clusters of polymorphisms (yellow spots) on 
exofacial portion of peptide are particularly immunogenic, and are the sites of 
polymorphism accounting for partial RhD types, and the difference between 
the RhD and CE polypeptides (From Avent 2000)
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1.2.3 The Biology of Alloimmunisation to the RhD Antigen
Maternal anti-D production is almost always stimulated by exposure to fetal 
D+ red cells. Transfusion stimulated anti-D is now extremely rare in women of 
childbearing potential as transfusion protocols proscribe the infusion of D+ red 
cells for such patients except in extremis (BCSH guidelines 2004). Instances 
of stimulation by other means such as shared needles for administration of 
recreational drugs have been reported (Dimer 1999). For other HDFN 
causative antibodies, in particular anti-c and anti-K, transfusion is a major 
cause of alloimmunisation (Koelwijn 2009). In Caucasian populations 
approximately 10% of pregnancies are D- women carrying one or more D 
positive fetuses (Kumpel 2002).
Stimulation of anti-D antibody production is much more likely when the fetal 
red cells are ABO compatible with the mother. Maternal iso-agglutinins are 
almost universally present in group O , A or B individuals, and cause the rapid 
destruction of non-compatible fetal red cells either by complement mediated 
intravascular lysis or extravascular destruction in the liver, where antibody 
stimulation is much less likely than in IgG mediated splenic destruction 
(Urbaniak 2000). It has been estimated that group A:0 incompatibility confers 
90% protection and B:0 55% protection against RhD immunisation (Murray 
1965).
The ability of D- individuals to form anti-D in response to D+ red cells is 
variable (Mollison 1984). Humoral responses to platelet antigens have been 
demonstrated to be linked to HLA-DR phenotypes, but the evidence that a link 
exists between HLA types and alloimmunisation to RhD is less clear. Peptides 
derived from lysis of the RhD protein have been demonstrated to activate T 
lymphocytes derived from alloimmunised blood donors (Urbaniak 1999).
Some groups have attempted to demonstrate a link between HLA type and 
RhD alloimmunisation (Issitt 1998, Urbaniak 1999, Kumpel 2002) with 
remarkably varied findings. HLA DRB*1 1501 has been found to be 
significantly overexpressed in RhD- blood donors who are deliberately 
alloimmunised with D+ cells (Hall 2005) and 100% of patients alloimmunised
14
to the Fya antigen were found to express HLA DRB1* 04 compared to 19% in 
the general population (Noizat-Pirenne 2006). The difficulty in obtaining a 
large cohort of individuals with anti-D, and the extreme polymorphism of HLA 
make reliable demonstration of a link problematic. In fact the high 
immunisation rate amongst D- people exposed to D antigen indicated that 
many HLA types must support the immunisation to D.
Antibody stimulation is more likely in donor alloimmunisation programmes 
when multiple small doses of antigen are administered rather than single than 
single large doses (Urbaniak 2000). Seven of eleven volunteers given 
fortnightly doses of the equivalent of either 0.01 mL or 0.1 mL of RhD+ whole 
blood, went on to develop anti-D (Jakobowicz 1972). The frequency of 
stimulation of anti-D is dose dependent with 15% responding after a single 
intravenous (IV) injection of 1mL of D+ cells and 70-90% after 250mL 
(Mollison 1984). Secondary stimulation requires a lower dose; 14/14 
volunteers with weak Rh antibodies having the titre boosted by administration 
of 0.28mL of D+ cells (de Silva 1985). In a programme for immunising 
volunteers for the production of anti-D immunoglobulin, 26 out of 28 formed 
anti-D after an initial dose of 200mL of red cells followed by six monthly 
booster doses of 0.5-1.OmL (Urbaniak 1981). Experimental studies, such as 
these, present antigen via intravenous injection to non-pregnant, typically 
male volunteers that may not accurately reflect immunisation rates when 
Fetomaternal Haemorrhage (FMH) occurs in utero and care must be taken in 
generalising these findings outside the experimental cohort.
That haemorrhage could be the cause of fetal anaemia was known (Weiner 
1948), though the bleeding was considered to be from the fetal side of the 
placenta into the amniotic cavity. It was not until a case of fetal anaemia was 
rigorously examined that the presence of red cells of fetal origin was 
demonstrated in the maternal bloodstream (Chown 1954). The imaginative 
application of the techniques of the burgeoning science of transfusion in this 
investigation allowed, in addition, the estimation of the size of the feto­
maternal haemorrhage in this case as 90-180mL by simple assessment of the 
proportion of agglutinated cells as viewed by light microscopy and
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multiplication by the maternal blood volume. The authors observed that the 
fetal D+ cells were cleared from the maternal bloodstream shortly after the 
woman was alloimmunised and formed anti-D antibodies.
The frequency and size of FMH only became apparent with the discovery that 
fetal haemoglobin was resistant to acid lysis. The proportion of fetal cells in a 
maternal blood sample and hence the volume of the FMH can be estimated 
by microscopic examination of maternal blood films from which adult 
haemoglobin has been eluted by acid, and in which fetal haemoglobin is 
stained with haematoxylin and eosin (Kleihauer 1957).
1.3 The Clinical Effects of HDFN
1.3.1 Introduction
Maternally derived IgG may be detected on fetal red cells from as early as the 
8th week of gestation and death in utero may occur from 18 weeks (Urbaniak 
2000, Klein 2005). These are the earliest manifestations of the disease. The 
spectrum across which HDFN presents is wide indeed. Some cases are only 
apparent in laboratory tests with no clinical symptoms, other mildly affected 
infants show anaemic pallor, but deep jaundice, oedema and neurological 
involvement may occur in the severely affected fetus. Kernicterus occurs in as 
few as 1/50,000 otherwise well full term babies, and 1-3% of pre-term infants 
(Ahlfors 2001).
Neonatal jaundice occurs in up to 60% of full term pregnancies as a normal 
physiological event (Stevenson 2001). Jaundice usually peaks around 3 days 
after delivery, and becomes undetectable by 5 days. Apparent jaundice, less 
than 24 hours after delivery of a full term infant requires investigation, as most 
physiological levels of red cell breakdown in the fetus should be cleared 
through the maternal liver up to delivery, with no significant increase in fetal 
bilirubin (Meeks 2004).
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Hyperbilirubinaemia occurs in 60-70% of all term infants and virtually all pre­
term infants (Stevenson 2001). Fetal red cell breakdown occurs before 
delivery on a considerable scale associated with the switch from fetal to adult 
haemoglobin, in preparation for the change from intrauterine to extrauterine 
life (Meeks 2004). The neonate is faced with a considerable load of bilirubin, 
as the lifespan of red cells falls from 90 to 70 days, and the delivery process 
interrupts the flow of unconjugated bilirubin to the maternal circulation 
(Stevenson 2001).
Bilirubin is formed as a normal breakdown product of haem. It is soluble in 
lipid but not water. Under normal circumstances, unconjugated bilirubin is 
conjugated in the liver to albumin forming a complex which is soluble in water 
and can be excreted. Other causes of neonatal jaundice include re-adsorption 
of bilirubin through the gut and genetic disorders such as glucose-6 
phosphate dehydrogenase deficiency (Meeks 2004).
In some cases, the chief clinical signs of anaemia and hyperbilirubinaemia do 
not occur due to the ameliorating effects of compensatory mechanisms; 
marrow hyperactivity replacing lost red cells and the fetal hepatic excretory 
system exporting red cell breakdown products to the maternal liver. Where 
haemolysis is severe, the serum bilirubin of the fetus may exceed 350pmol/L. 
This cannot be rendered non-toxic by albumin conjugation. Where the 
capacity to conjugate bilirubin to albumin is compromised, or exceeded either 
by excess red cell destruction (e.g. HDFN) or insufficiency of the neonatal 
liver then hyperbilirubiunaemia results (Meeks 2004).
Unconjugated bilirubin has an affinity for lipid and may bind to tissues in the 
brain or other parts of the central nervous system and is particularly toxic to 
brain tissue, the resulting condition being known as kernicterus (Urbaniak 
2000). The risk to the fetus associated with kernicterus is a complex product 
of factors. Rates of bilirubin production and clearance, serum concentration, 
and duration of exposure, all exacerbate the condition. Rates of excretion, 
gestational age and plasma albumin concentration, all reduce the risk to the 
neonate (Ahlfors 2001). Nevertheless, 70% of infants who develop kernicterus
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die between the second and fifth days of life. Of those who survive, a high 
proportion have suffered permanent cerebral damage resulting in spasticity 
or, in mild cases, high frequency deafness (Klein 2005).
1.3.2 The Epidemiology of HDFN
HDFN affects fetuses and neonates, with the associated loss or impairment of 
a whole lifetime, and presents in the most distressing ways. The frequency 
with which the untreated condition affects lives is considerable. In Canada in 
the early 1940s the perinatal mortality rate was 40 per 1000 births. HDFN 
accounted for 10% of these deaths (Bowman 2003). In Queen Charlotte’s 
Hospital, London, between 1946 and 1949 fetal deaths due to HDFN occurred 
at the rate of 3.2 per 1,000 births. Some 0.5% of all women developed Rh 
antibodies, and 20% of these lost their babies in subsequent pregnancies 
(Tovey 1990).
Prior to 1945, 50% of babies suffering from HDFN died of hydrops or 
kernicterus. Improved treatment of the condition reduced mortality in affected 
cases to 2-3% by the early 1980s (Bowman 2003). Between 1940 and 1970, 
the proportion of perinatal deaths in cases of HDFN in the UK fell from 50% to 
5.9% (Urbaniak 2000). The introduction to the UK in 1969 of routine post­
partum anti-D immunoglobulin prophylaxis for RhD- mothers of RhD+ babies 
reduced Rh alloimmunisation by 70%. The reduced incidence of HDFN in the 
same period was also associated with a reduction in the birth rate in the 
1970s, and that many alloimmunised women, advised by obstetricians, were 
choosing not to have further pregnancies (Tovey 1978). By the 1990s, the 
death rate due to HDFN had fallen to around 50 per year (Consensus 
statement of the Royal College of Obstetricians and Gynaecologists 1997).
It was estimated that by 2002 (NICE guidance 2002) there were 
approximately 105,000 births to RhD- women annually in the UK. Of these 
59% (or 62,000) were RhD+ fetuses, representing 10% of all UK births. In 
England and Wales at that time, there were an estimated 25-30 fetal or 
neonatal deaths and 20 spontaneous abortions each year due to HDFN.
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Fifteen children were born with major, and a further 30 with minor 
developmental problems (NICE 2002).Fetal morbidity and mortality due to 
antibodies other than anti-D (chiefly anti-c and -K) is less common, but there 
remains no available prophylaxis to prevent alloimmunisation to these 
antigens. Continued progress in the prevention of anti-D HDFN make these 
non-anti-D cases an important and increasing proportion of the residual cases 
(Koelewijn 2009).
1.4 The Pathobiology of HDFN
1.4.1 Introduction
HDFN is mediated by maternal IgG specific for antigens expressed on fetal 
red cells. For that antibody to be formed and synthesised in sufficient quantity 
and quality to cause immune destruction resulting in clinical HDFN, a series of 
events triggering the maternal humoral alloimmune response must occur. In 
the first instance, the maternal immune system must be exposed to fetal red 
cells as a result of Fetomaternal Haemorrhage (FMH). Fetal red cell antigens 
must be taken up by antigen presenting cells (APC), including B lymphocytes. 
Interaction and co-stimulation between APC, and T and B lymphocytes leads 
to activation and differentiation of B-lymphocytes resulting in a powerful 
alloimmune response leading to the synthesis and release of immunoglobulin, 
and the development of memory cells capable of staging an even more 
powerful anamnestic response in the event of repeat challenge with the same 
antigen ( Hadley 2002, Bowman 2003; Figure 1.3).
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Figure 1.3 The interaction of cells of the immune system leading to red cell 
alloimmunisation (From Hadley 2000).
Red cells are phagocytosed by antigen presenting cells (APC), and peptides 
from processed antigen are expressed at the cell surface by MHC II. 
Interaction between expressed peptide MHC II complex and TCR leads to T 
cell activation in the presence of costimulatory molecules. B cells bind to red 
cell antigen expressed at the surface of APC and cross-link with activated T 
cells. Activated T cells drive B cell activation and expansion by co-ligation and 
release of cytokines, leading ultimately to the production of plasma cells and 
the synthesis of antibody specific to the red cell antigen.
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1.4.2 The Frequency and Pathology of FMH
The dose of antigen delivered into the maternal circulation is dependent on 
the size of the haemorrhage of fetal cells. FMH is common, with 76% of 
women having a detectable bleed at some stage of pregnancy, and 45% by 
the start of the 3rd trimester (Bowman 1994). Only 3% have detectable bleeds 
in the 1st trimester. The minimum size of FMH required to cause primary or 
secondary immunisation is unclear and, of the measurable FMH, the 
proportion that are capable of causing Rh sensitisation is unknown. A dose of 
0.1 mL of fetal cells has tentatively been suggested, based on red cell doses 
deliberately administered to blood donors to stimulate anti-D production (see 
section 1.7.3) (Bowman 1986).
1.4.3 How Red Cell Antigens are Encountered by Cells of the Immune 
System
T cell dependent humoral responses in humans, such as alloimmunisation to 
red cell antigens, require that antigen specific T and B lymphocytes are 
exposed to blood borne antigens presented by antigen presenting cells (APC) 
such as opsonised red cells. Antigen specific T and B cells are rare. To 
facilitate contact, secondary lymphoid organs (SLO) including lymph nodes 
and the spleen have evolved complex microarchitecture. These organs are 
well connected to the lymphatic system and blood supply, respectively. Their 
structure concentrates antigen, compartmentalises cell types to allow complex 
interactions triggering differentiation, supported by chemokine gradients 
maintained on specialised extra-cellular matrix structures required to mount 
and sustain an effective immune response (Arana 2008, Batista 2009).
Unlike lymph nodes, the spleen lacks an afferent lymphatic supply, instead it 
specialises in dealing with blood borne antigens (Bastista 2009). It is located 
in the abdominal cavity and is 8-13 cm long and typically weighs 200-300g in 
adults (Hoffbrand 2001). Under normal conditions, other than pregnancy or 
other events leading to the exposure to non-self red cells such as transfusion, 
the red cells processed by the spleen are autologous. The major mechanism 
for destruction of senescent red cells is phagocytosis in the spleen mediated
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by IgG autoantibodies. These bind to red cell antigens which are exposed as 
the aging membrane loses integrity. Removal from the circulation occurs 
before reduced plasticity results in impaired function (Hadley 2002). IgG 
mediated removal of aged red cells is necessary as macrophages lack 
receptors for red cell antigens, but do express FcyR (Kumpel 2006), though 
stress induced by high hematocrit and low oxygen levels in the spleen lead to 
shape changes which promote phagocytosis by macrophages of any 
abnormal cells (Lewis 2001). Autologous red cells express no foreign antigen 
and do not cause alloimmunisation. When red cells from another individual 
enter the circulation, due to FMH or transfusion, then alloimmunisation may 
occur through the actions of immune cells in the spleen.
The spleen is organised into two zones, the red pulp and the white pulp, 
reflecting the two chief functions of the organ which are removal of senescent 
red cells and micro-organisms from the blood, and mounting an immune 
response (Roitt 2001, Kumpel 2006; Figure 1.4). Compartmentalisation of the 
spleen allowing controlled contact of the cells types present is key to function 
(Lokmic 2008). The organ contains 25% of the T lymphocyte pool and 15% of 
the B lymphocyte pool, representing the largest accumulation of lymphoid 
tissue in the body (Lewis 2001).
The white pulp is organised into T and B cells zones containing follicles and 
conduits comprising laminin chains, expressing chemokines, along which DCs 
and lymphocytes migrate (Lokmic 2008). The T cell zone comprises a network 
of reticular cells and specialised capillaries which form the periarteriolar 
lymphoid sheath. This is separated from the red pulp by the marginal zone 
which is rich in macrophages, dendritic cells and polyreactive B lymphocyte 
clones (Batista 2009).
Within the B cell zone of the white pulp are aggregates of B lymphocytes, 
forming follicles which contain DCs. Following exposure to antigen, these cells 
form germinal centres, which are key to mounting humoral responses to T- 
lymphocyte dependant antigens, and to the expansion and refinement of
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Figure 1.4 Diagrammatic representation of the spleen showing organisation 
and architecture of B cell follicle including follicular B cells and periarteriolar 
sheath containing T cells (From Pillai 2009)
Blood borne antigens such as red cells enter the spleen through the central 
arteriole, then pass through the marginal zone which is populated with 
macrophages, T and B lymphocytes and dendritic cells. Circulating 
lymphocytes home to the white pulp and migrate within the spleen along 
chemokine gradients. Activated lymphocytes and antigen presenting cells 
migrate to follicles where B cell expansion and maturation occurs, leading to a 
humoral immune response to blood borne pathogens.
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antibody synthesis (Batista 2009). DCs in the white pulp collect and 
concentrate antigen by interaction with circulating immune complexes through 
Fc and complement receptors (Gonzalez 2009), though the latter is unlikely 
to be relevant in processing Rh antigen as Rh antibodies are incapable of 
fixing complement (Issitt 1998). The white pulp is organised to permit 
migration of lymphocytes to support interaction between T and B cells.
On entering the spleen, blood cells move through a network of vascular 
sinusoids in the marginal zone between red and white pulp. Here antigens are 
first encountered by B cells, macrophages and DC, which remove material 
from the circulation. Macrophages have excellent phagocytic properties but 
are poor antigen presenting cells (Roitt 2001). This process as part of normal 
homeostasis, is non-inflammatory, and results in no tissue damage other than 
to the opsonised cells (Kumpel 2006). DCs in contrast are less effective as 
phagocytes, but are armed with an array of receptors which allow detection of 
pathogens and activation of innate and adaptive immune responses (Bergtold 
2005). In processing large particles expressing antigen, such as red cells, it is 
likely that macrophages and DCs are both involved (Roitt 2001).
1.4.4 The Phagocytosis of IgG Opsonised Red Cells
Phagocytosis of IgG opsonised particles, including red cells coated either with 
auto- or specific IgG alloantibody, is effected through Fey receptors (FcyR). 
FcyR are immunoglobulin-like molecules, which are widely expressed on the 
effector cells of the immune system including monocytes, macrophages, and 
dendritic cells (Janeway 2001).
There are four major groups of Fey receptors, FcyRI-lll and FcRn. The 
structure of the groups is variable, and functions include control of IgG 
catabolism (FcyRI), mediation of phagocytosis (FcyRIIA), endocytosis leading 
to antigen presentation (FcyRIIB-2, and FcyRIII), and regulation of cellular 
responsiveness (FcyRIIB). Most cell types express FcyR both activatory and 
inhibitory types. The exceptions are NK cells which express only activatory
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FcyRI, and B cells which express only inhibitory FcyllRB-1, which in this form 
has low affinity for its ligand and is a poor mediator of phagocytosis (Heyman 
2003). In particular FcyR are key to the humoral immune response through 
participation in immune complex maturation of DCs, the presence of both 
activatory and inhibitory FcyR of DC is key to maintaining activation thresholds 
for these cells (Nimmerjahn 2008).
In particular, FcyllR which is the most widely expressed of the group has a 
strong inhibitory effect on DC and B lymphocytes when cross linked by 
multiple, bound IgG molecules, FcyRI is a high affinity receptor for lgG1 and 
lgG3 in humans, binding with an affinity 100-1000 times that of the other 
receptors (Nimmerjahn 2008)
When FcyRI and III are cross linked by multiple binding of Fc domains, other 
FcyR are activated to capture and enclose the particle in an internal 
phagosome. Fusing of the phagosome with one or more lysosomes leads to 
enzyme lysis of protein at low pH (Janeway 2001), making available antigen 
derived peptide for loading on to MHC I and II for presentation to T cells 
(Bergtold 2005). Large particles such as red cells may not be internalised in 
their entirety, but fragments of membrane may be degraded (Petz 2004).
When bound and cross-linked by their ligand, phosphorylation of intracellular 
domains results in cell signalling (Roitt 2001). FcyR can initiate both activating 
and inhibitory signals and are key elements of the balance, in healthy 
individuals between pro-and anti-inflammatory conditions.
1.4.5 The Role of T Lymphocytes in the Humoral Response
When DCs present antigen derived peptide at the cell surface on MHCII they 
recruit naive CD4 T cells which can bind to the peptide complex through TCR 
(Fazilleau 2007). The accompanying information about the immunological 
threat, imparted through co-stimulation, causes those T cells to differentiate 
into specific subsets with characteristic functions. There is some evidence that
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the affinity of the bond between MHC I l/peptide and TCR positively influences 
the subsequent degree of T cell clonal expansion (Malissen 2009). Classically 
these were described as Th1, and Th2 sets based on signature cytokine 
profiles, but this paradigm is now considered simplistic, and several other 
subsets have been characterised, including Th3, Tho, Th17 and Treg. Each of 
these is reported to have characteristic surface markers and cytokine profiles, 
Th3 cells are a major source of TGF-P, and have distinct functions (Malissen 
2009). Follicular T helper cells (TFH) have been described which derive from 
naive T cells expressing TCR with particularly high affinity for antigen. 
Functionally they are characterised by expression of IL-21 which drives B cell 
differentiation, and by expression of CXCR5, a chemokine receptor which 
directs lymphocytes in the direction of germinal centres (Malissen 2009).
With the presented peptide localised to the binding groove on MHCII on the 
APC, the T cell receptor (TCR) on T helper cells can bind to the peptide MHC 
complex. This interaction is facilitated by co-stimulatory and cell adhesion 
molecules including Lymphocyte Functional Antigen 3 (LFA-3) binding to 
CD2, Intercellular Adhesion Molecule-1 (ICAM-1) binding to LFA-1, and 
CD80/86 binding to CD28. Without this co-stimulation providing a second 
signal T cell activation cannot occur. Th activation is facilitated by interleukins 
(IL) -1, -6, -12, and -15 and tumour necrosis factor-a (TNF-a) and proliferation 
is driven by IL-2 (Roitt 2001, Janeway 2001, Kumpel 2000).
1.4.6 Lymphocyte Homing in the Spleen
Circulating lymphocytes entering the spleen home to the white pulp; T 
lymphocytes to the periarteriolar lymphatic sheath, and B lymphocytes to the 
adjacent lymphoid nodules (Pillai 2009). Naive B cells enter the spleen from 
the circulation to optimise potential to encounter specific antigen. Most B cells 
migrate to follicles dependent on expression of the chemokine receptor 
CXCR5 and the expression of its ligand CXCL13 on the extracellular matrix of 
follicular tissue (Okada 2006, Pillai 2009).
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Follicular B cells are highly mobile, migrating within the follicle at up to 6pm 
per minute, presenting opportunities to survey antigen presented on follicular 
DCs (Okada 2006). As part of those movements within the follicle, B cells 
migrate toward the T cell zone dependent on moderate expression of CCR7, 
its ligand CCL21 is expressed in T cell zones (Okada 2006). This movement 
facilitates interaction between B and T cells. Naive B cells migrate through 
follicles for 12-18 hours, and may migrate to other follicles before leaving the 
spleen. It is estimated that more than 99% of cells encounter APC, before 
leaving the spleen (Schwickert 2007).
If follicular B cells fail to encounter specific antigen, they return to the 
circulation. In the event of B cells encountering specific antigen they migrate 
within hours to the border of the B cell and T cells zones, having rapidly 
upregulated CCR7 expression upon engagement, and can remain there for 
several days (Okada 2005).
Photon microscopy studies have demonstrated the role of antigen engaged B 
lymphocytes in binding to specific, activated T cells at the T-B border, and 
leading the migration of both cells to the germinal centre (Okada 2005).
1.4.7 Antigen Uptake by B Lymphocytes
The production of a significant humoral response to thymus dependent protein 
antigens, such as Rh on red cells, requires the action of T and B lymphocytes. 
(Janeway 2001). In B cells, the B cell surface antigen receptor (BCR) has a 
function analogous to the TCR in T cells. The B cell receptor is 
immunoglobulin, IgM and IgD being expressed on mature B cells. When 
cross-linked by antigen, surface immunoglobulin effects intracellular signalling 
via immunoreceptor tyrosine-based activation motifs (ITAMS) expressed on 
two associated heterodimeric proteins Iga and IgP (Lydyard 2005, Arana
2008). Other molecules key to cell function are expressed early in the cell’s 
development including MHC class II to permit antigen presentation, and co-
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receptors including complement receptors (CD2), FcRyll-B1 (McHeyzer 
Williams 2006).
The co-ligation of BCR and antigen along with these and other B cell surface 
molecules with ligands on T cells (e.g. CD40 and CD40L) is required to avoid 
clonal anergy, and to permit intracellular signalling resulting in B cell 
proliferation (Lydyard 2005).
Through the BCR, B cells are capable of recognising soluble or membrane 
bound antigen, the latter when associated with professional APCs is both a 
more frequent and more important route for lymphocyte activation due to co­
stimulation (Bergtold 2005, Batista 2009). The presentation of antigen to 
follicular DCs is undertaken by marginal zone B cells, which migrate between 
marginal zone and follicle by alternate expression of CXC chemokine 
receptor 1 (CXCR1) and sphyngosine 1-phosphate receptor (S1PR). This is 
achieved through receptors other than BCR, and the high level of complement 
receptors on marginal B cells may be important for presentation of immune 
complexes including complement (Batista 2009), though this is unlikely to 
occur in Rh alloimmunisation as Rh antibodies do not cause complement 
fixation.
1.4.8 The Activation of B Lymphocytes
Activated T helper cells interact with antigen primed B lymphocytes via HLA 
class ll/peptide complex (Figure 1.2). Additional co-stimulatory and adhesion 
molecules on T and B cells are required for activation (CD28 binding to 
CD80/86; CD40 ligand to CD40; LFA-1 to ICAM-1 or ICAM-3; and CD2 to 
LFA-3). B-cell activation and division are stimulated by IL-4 and IL-6. In 
particular the interaction between CD40 and CD40 ligand, upregulates IL-4 
receptors on B-lymphocytes and the release of IL-4 from Th2 cells drives B- 
lymphocytes, into the cell cycle resulting in proliferation and expansion 
(Janeway 2001). On contact with DCs, B cells undergo a conformational 
change, spreading along the antigen presenting surface to form a synapse
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which supports the BCR interaction with antigen and the required co­
stimulation to drive B cell expansion (Arana 2005). Under further influence 
from Th derived cytokines, B-lymphocytes switch the class of antibody 
production, the combined effects of IL- 4, -5, -6, -13 and IFN-y resulting in the 
production of IgG (Roitt 2001). In particular IgG production is down regulated 
by TGF-p1, both by direct inhibition of B cell proliferation, and by 
immunoglobulin class switching to IgA (Li 2006).
Unregulated B cell expansion carries the risk of tissue damage due to 
proliferation of autoreactive B cells, and among regulatory mechanisms the 
action of the inhibitory FcyllB-1 expressed on B cells offers a checkpoint to 
prevent development of autoreactive antibodies (Nimmerjahn 2008). Reduced 
expression or absence of FcyRIIB-1 results in exacerbation of antibody 
mediated autoimmune conditions. Inhibitory signals are generated by IgG 
ligated FcyllRB-1 through immunoreceptor-tyrosine-based inhibitory motifs 
(ITIMs), FcyllRB-1 cannot bind monomeric IgG and requires immune complex, 
allowing multiple crosslinking of FcyllRB-1 with BCR (Heyman 2003). This 
results in inhibitory signalling through ITIMs, which can down-regulate 
activatory signals from activatory tyrosine based motifs (ITAMS) linked to 
BCR. This leads to B cell downregulation and ultimately to apoptosis (Kumpel 
2002).
Once activated, B cells can recruit specific CD4+ T helper cells by processing 
and presenting antigen through their own MFIC class II molecules (Batista
2009). Activated B cells can differentiate along two lines. Firstly extrafollicular 
plasmablasts which are essential for rapid, protective antibody production, 
and secondly plasma cells in germinal centres can produce a long lasting 
antibody response that can, after affinity maturation, result in high titre, high 
affinity antibody production (Batista 2009). The development of B cells is 
summarised in Figure 1.5.
In the event of a second challenge with the same antigen, an enlargement of 
existing germinal centres is induced along with formation of new ones. B-
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lymphocytes, primed with newly presented antigen migrate, and divide in 
response to stimuli from dendritic cells and Th cell derived cytokines. Through 
a competitive process in which B-lymphocytes become centrocytes and 
undergo apoptosis (unless continuing to be bound to antigen) which is 
reduced in concentration. Clonal selection ensures that only antibody 
producing cells with high affinity for the antigen survive, mature and expand to 
secrete antibody in significant quantities (Roitt 2001, Fazilleau 2007). By this 
competitive mechanism of refinement, antibody response to low doses of 
antigen results in high affinity antibodies. High antigen doses generate much 
lower affinity antibodies. As FMH are typically less than 4mL of fetal packed 
cells (Mollison 1972), affinity of anti-D antibodies is generally high, leading to 
powerful mediation of immune destruction. There is little evidence to indicate 
that anti-D prophylaxis can prevent or reduce secondary immune responses 
(Mollison 1984). Follicular dendritic cells store antigen and can present it long 
after the initial challenge. This is key to the process of affinity maturation 
associated with T cell dependent antibody responses (Batista 2009).
1.4.9 IgG Biology
There are five classes of immunoglobulin, IgM, IgG, IgA, IgE, and IgD. Of 
these IgG is the most abundant in human plasma, diffusing rapidly through 
tissues to neutralise bacterial toxins and enhance phagocytosis of 
microorganisms (Roitt 2001). IgG is further differentiated in structure and 
function by four subclasses lgG1-4, which are characterised by variation in 
the heavy chains. IgG classes 1 and 3 are: bound more effectively by Fc 
receptors on macrophages, more readily transported across the placenta 
(Roitt 2001) and more pro-inflammatory in humans than lgG2 and lgG4. The 
heavy chains of IgG are glycosylated with galactose residues, which stabilise 
the tertiary structure of the protein. This is required to permit binding with FcR. 
The degree of glycosylation varies between individuals and increases during 
pregnancy (Nimmerjahn 2008).
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The evidence that IgG isotype is strongly linked to the severity of HDFN and is 
therefore a potential predictor of HDFN severity has been the subject of much 
research (Hadley 2002). The anti-D antibody in pregnant women was shown 
predominantly to be a mixture of lgG1 and lgG3, in a study of 98 pregnancies 
of women with alloimmune anti-D. A third of these cases contain only lgG1, 
and of 3 pregnancies in which only lgG3 was detected, none were affected by 
HDFN (Pollack 1990). The ratio between fetal and maternal lgG1 
concentration, but not lgG2, 3, or 4, was found to be much higher in 
pregnancies affected by HDFN than those unaffected, suggesting that IgG 
transport is a key factor in determining disease severity (Lubenko 1994). In 40 
affected pregnancies, the concentration of lgG1 detected by ELISA in eluates 
prepared from fetal cells was found to be higher than in maternal plasma 
(Lambin 2002). In vitro studies have indicated that lgG3 is a more effective 
mediator of red cell lysis, prompting speculation that the longer hinge region is 
more effective in bridging the gap between negatively charged red cells and 
effector cells, than IgG classes with shorter reach (Hadley 2002). Though this 
conflicts with the limited evidence that lgG3 in isolation is a poor effector of 
HDFN (Pollack 1990).
1.4.10 Red Cell Destruction in the Fetus
Very few studies have examined the mechanisms of fetal red cell destruction. 
The mechanisms observed in adults and in vitro studies are generally 
accepted as relevant to the fetal environment (Hadley 2002).
Once maternal anti-D has been transported across the placenta it binds via 
the Fab domains to fetal D antigen. Opsonised red cells are recognised by 
macrophages bearing receptors which bind to the IgG molecules mediating 
phagocytosis and red cell destruction (Hadley 2002). The presence of 
competent macrophages has been demonstrated in the fetal spleen as early 
as 13 weeks gestation (Billington 1992). The severity of HDFN due to 
antibodies to antigens not restricted to red cells, is reduced by antibody 
binding to antigen expressed on other tissues including placenta and 
endothelium (Kumpel 2002).
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1.5 Laboratory Testing to Support Prevention and Prediction of HDFN
1.5.1 The Role of the Laboratory in Predicting HDFN
Historically HDFN has been a disease which progresses, unseen to the 
clinician, until it presents at birth, too late for remedial action. As a result, a 
generation of clinicians and scientists have sought predictive examinations or 
laboratory tests that might indicate pregnancies in alloimmunised women in 
which the risk of intervention is exceeded by the risk of the disease. Fetal 
examination, either by clinical observation or by laboratory tests is inherently 
hazardous. Observation of the mother, and tests on maternal peripheral blood 
much less so, and that has been the basis of clinical and laboratory practice 
(Abdel Fattah 2002).
In fact, laboratory testing has been more successful in support of prevention 
through prophylaxis than prediction of disease severity. The human immune 
system is exquisitely complex and the multifactorial nature of the 
pathogenesis of HDFN has not adequately been captured, either by individual 
or by panels of laboratory tests, to predict the clinical course of HDFN with 
confidence. (Figure 1.6). In fact the evolution of informative laboratory assays 
has happened in parallel with the development of clinical techniques to allow 
diagnosis and treatment of HDFN.
The pathological mechanisms of HDFN are similar in many respects to that of 
the immune response to transfused red blood cells. As a result, the laboratory 
tests associated with HDFN are performed in transfusion laboratories. Safe 
blood transfusion requires matching donor red cells with the ABO and Rh 
groups of the recipient. Transfusion scientists employ simple reliable and 
cost-effective techniques for determining patient blood groups using, in almost 
all cases: automated test systems interfaced with information technology that 
allow safe interpretation, storage and dissemination of test data to support 
transfusion practice (BCSH 2006).
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In the UK, all women should have ABO and RhD group determined twice in 
pregnancy, at the time that they book with a midwife at 10-14 weeks gestation 
and at the beginning of the third trimester (BCSH 2006). The determination of 
ABO group is of little significance for HDFN, but may be useful in the event of 
requirement for maternal blood transfusion at delivery. The RhD group is used 
to determine the need for, and plan the administration of routine anti-D 
prophylaxis if required, at 28 weeks and at delivery, and to allow timely 
treatment (BCSH 2006a).
Antibody screening techniques for pre-transfusion testing are suitable for use 
in detection of antibodies which may cause HDFN. Again automated tests are 
in use in most laboratories. Red cells used for screening are obtained from 
two or three blood donors, selected for strong expression of antigens to 
clinically significant red cell antibodies. Tests are performed by the Indirect 
Antiglobulin Technique (IAT) standardised to detect IgG antibodies to red cells 
that are active at 37°C, which might mediate red cell destruction either in 
reducing the survival of transfused red cells or destruction of fetal red cells in 
HDFN (BCSH 2006). Not all antibody specificities are associated with immune 
destruction of red cells, due either to the characteristics of antigen (likely to 
detach from red cell surface or low antigen density) or to those of the antibody 
(cold-reacting antibodies with low thermal amplitude) (Daniels 2002a).
An alternative approach for laboratory investigation of HDFN is the detection 
of IgG bound to fetal red cells by Direct Antiglobulin Test (DAT). Anti-human 
IgG (AHG) is added to a suspension of patient’s cells in saline. If IgG is bound 
then the AHG cross-links the red cells causing visible agglutination (Poole 
2002). Though indicative of the presence of IgG on fetal red cells, a positive 
DAT is not diagnostic for clinical HDFN. The pathogenesis of HDFN is 
dependent on many factors including IgG subclass, extent of IgG 
glycosylation, and the efficiency of the fetal reticulo-endothelial system. As a 
result, in some cases, fetal red cells coated with maternal IgG may survive 
normally with no evidence of red cell destruction (Stevenson 2001, Klein 
2005).
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It is recognised that many examples of antibodies to red cell antigens, even of 
significant specificities, do not cause accelerated destruction of transfused 
antigen positive red cells. No simple, reliable and timely tests are available to 
differentiate between benign and lytic antibodies (Hadley 2002). When an 
antibody significant for transfusion purposes is identified, biomedical scientists 
select blood lacking the corresponding antigen for transfusion. The 
differentiation between lytic and benign antibody is non-critical as risk can be 
managed simply. In the majority of cases this is straightforward and results in 
little extra work, expense or delay. In contrast, in the case of antibodies in 
pregnant women the actions a practitioner might undertake are much more 
hazardous for mother and baby. Invasive techniques such as amniocentesis 
or fetal blood sampling, to determine the severity of disease have been 
practiced with significant process-related loss of fetuses. Consequently, it has 
been the focus of many immunohaematologists over more than last forty 
years to develop tests which would accurately and reliably allow the prediction 
of HDFN severity from maternal peripheral blood samples, in order to allow 
clinicians to reduce the requirement for invasive procedures, to minimise risk 
and maximise predictive benefit (Hadley 2002).
1.5.2 The Assessment of Antibody Concentration
Red cell agglutination assays have been used with serially diluted patient 
serum or plasma to measure the concentration of antibodies. The IAT has 
been used for this purpose since the 1950s (Bowman 1994). The “strength” of 
the antibody is reported as the reciprocal of the last dilution which causes 
agglutination of test cells. Titration, however, is inherently imprecise with 
variation associated with test conditions, operator and endpoint interpretation 
(AuBuchon 2008), though rigorous application of more modern serological 
techniques, including column agglutination technologies, may improve 
performance.
More reproducible, objective and effective in testing large numbers of samples 
is autoanalyser quantification. The technique also uses diluted patient plasma 
against red cells treated with a proteolytic enzyme to promote agglutination in
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a continuous flow system. The mixture is passed through a settling coil, to 
separate agglutinated from non-agglutinated cells. These are lysed and 
passed through a colorimeter that measures the concentration of released 
haemoglobin, which is inversely proportional to that of the antibody. Antibody 
concentration in test samples is calculated using a calibration curve against 
an international standard (National Institute for Biological Standards and 
Control, South Mimms, UK) gives a result in International Units per mL 
(lU/mL) (Hadley 2002).
As well as technical deficiencies, IAT titration has a poor record as an 
indicator of disease severity. In the USA, where the technique is still widely 
practiced for anti-D, a critical titre of 16 is generally accepted as an indicator 
that intervention is required. Some authors point to data indicating that 20% of 
anti-D cases with titres below 16 require exchange transfusion suggesting that 
titration is an unreliable predictor of HDFN (van Dijk 1995). Autoanalyser 
quantification has a marginally better record with clinical HDFN recorded in 
very few pregnancies with anti-D concentrations of less than 4IU/mL, though 
many pregnancies with anti-D concentration greater than 4IU/mL are 
unaffected by HDFN. The limitation of agglutination assays is that they 
measure the effectiveness of the Fab region of the antibody to bind to red 
cells antigen whereas it is the Fc domain which effect immune destruction 
through FcyR mediated phagocytosis by splenic macrophages.
A range of cellular assays has been developed with a view to offering a better 
in vitro model of the in vivo process and hence better reliability as a predictor 
of disease. In fact these tests, involving the measurement of the interaction of 
effector cells with red cells sensitised with maternal antibody, have all to some 
degree succeeded at being better predictors of disease severity than titration 
or autoanalyser quantification (Hadley 1993, Urbaniak 1985). However the 
specialised nature of these tests, the length of time they take to complete and 
the requirement for referral to a distant centre, means the timelines of results 
is compromised. More importantly the ability to detect even relatively mild 
HDFN by ultrasound has made much of this work redundant. The role of the
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laboratory is now to flag moderate levels of risk to obstetricians as a trigger for 
non-invasive investigation (Hadley 2002).
1.6 Clinical Assessment and Treatment of HDFN
1.6.1 Pre-natal Assessment of HDFN
In much the same way that the assessment of severity of HDFN has changed 
in the laboratory as new technologies have promoted better modelling, the 
approach to clinical assessment has evolved. In fact, the ability to base 
clinical judgements on non-invasive clinical assessments has greatly reduced 
emphasis on laboratory based diagnosis and has improved focus on deferral 
of potentially dangerous invasive techniques.
The most accurate way to assess fetal anaemia remains the measurement of 
haemoglobin concentration by direct fetal blood sampling by cordocentesis. 
The risks are high, both of fetal loss (estimated at 1%) and boosting the 
maternal antibody by induced FMH exacerbating HDFN (Abdel Fattah 2002). 
Some clinicians aim to time the first intervention in the current pregnancy at 
around 10 weeks before that in a previous affected pregnancy (Abdel Fattah 
2002). This reflects the incremental exacerbation of HDFN in successive 
pregnancies, and the lack of firm evidence on which practice is based.
Ultrasonography is a widely applied technology for assessing pregnancy. The 
symptoms of hydrops as an indicator of fetal anaemia, ascites, pleural 
effusions and oedema, are visible to the ultrasonographer and are indicators 
of profound anaemia, requiring urgent intra-uterine transfusion. Attempts to 
find an earlier indicator of fetal anaemia have been less successful (Abdel 
Fattah 2002, Divakaran 2001). Hepatosplenomegaly resulting from 
extramedullary erythropoeisis measured by ultasonography is a useful 
indicator of anaemia, but optimally after 30 weeks gestation. Similarly, 
abnormal fetal heart rate patterns are indicative of severe fetal anaemia late in 
pregnancy (Abdel Fattah 2002).
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Recently applied techniques, particularly Doppler velocimetry, allow relatively 
accurate estimation of fetal haemoglobin concentration. Measurement of fetal 
blood flow in the median cerebral or splenic arteries is possible and is 
indicative of fetal haemoglobin concentration due to changes associated with 
the haemodynamic compensation in the fetal circulation to manage anaemia 
(Scheier 2004, Bahado-Singh 2000). Though Doppler screening is less 
accurate than cordocentesis, sufficient sensitivity can be achieved with an 
acceptable false positive rate to allow the procedure to be used as a screen.
In a study of 55 scans of 26 fetuses, a threshold measurement of 1.5 times 
the median peak systolic velocity gave 100% detection of affected fetuses, 
with a 20.6% false positive rate (Badaho Singh 2000). The associated 
reduction in risk of procedural loss of the fetus, and further alloimmunisation 
associated with reduced numbers of cordocentesis procedures makes this a 
considerable improvement to antenatal surveillance (Divakaran 2001).
1.6.2 Post natal Assessment of HDFN
Even after delivery, diagnosis of mild HDFN is problematic. Neonatal 
haemoglobin concentrations fall over the first 2 months of life (physiological 
anaemia of the newborn) in unaffected infants. This is associated with 
reduced erythropoeisis and in particular low level of erythropoietin, as the 
baby matures from the low oxygen environment of the uterus and to breathing 
oxygen-rich air. Serum bilirubin rises over the first 2-3 days after birth occurs 
in almost all infants (Klein 2005).
1.6.3 The Treatment of HDFN
By the time the effects and mechanism of HDFN were being clarified and 
characterised in the late 1930s and early 1940s, blood transfusion was 
emerging as a useful, if incompletely understood therapy. Its use to correct 
anaemia in babies presenting with HDFN was unsuccessful in many cases, 
being ineffective against kernicterus (Bowman 1994). A more successful 
strategy for transfusion of the affected neonate was exchange transfusion in 
which fetal RhD+ red cells were drawn from the fetal circulation and replaced
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with RhD- donor red cells, both maintaining haemoglobin levels and removing 
the source of the bilirubin. By this means some clinicians were able to reduce 
the fetal mortality rate associated with HDFN from 50% to 25% (Bowman 
1994).
For women with high concentrations of alloantibody, particularly early in 
pregnancy, exchange plasmapheresis has been used. The process involves 
regular removal of large volumes of maternal plasma and replacement 
variously with albumin, normal immunoglobulin, or whole plasma. It is a 
disruptive and sometimes uncomfortable treatment for the mother, often 
requiring multiple large exchanges per week (Bowman 1994, Gottval 1995). It 
is common for antibody production to increase such that levels cannot be 
diluted below pathological levels: such a “bounce-back” effect can be noted as 
early as 48 hours after plasma exchange. (Knott 1987, Moise 2002). IgG 
synthesis is controlled by feedback mechanisms (Bouchard 1995), it is 
possible that the sudden removal of large quantities disturbs such 
mechanisms resulting in a significant increase in IgG synthesis and release. 
The effectiveness of the process is difficult to assess from the available 
literature, as other therapies including IUT and IVIg, have been applied as an 
adjunct to plasmapheresis in some cases (Moise 2002). Since ultrasound 
guided intravenous fetal transfusion has become widespread, plasmapheresis 
is rarely used to treat HDFN, though some authors believe the treatment may 
delay or make unnecessary the use of more invasive techniques (Knott 1987). 
Exchange plasmapheresis continues to be a treatment option for other fetal 
pathologies associated with maternal antibodies including prevention of fetal 
heart valve damage from maternal anti-Rho associated with SLE (van der Leij 
1994).
1.6.4 Induced Premature Delivery
When presented with a pregnancy in which the fetus is likely to become 
hydropic, clinicians are faced with balancing the considerable risk of early 
delivery against the risk associated with the disease process (Bowman 1994). 
The point at which the risk of immaturity is exceeded by the risk of hydrops
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was established as 32-34 weeks (Chown 1954), though a more modern view 
of the same question may reduce that gestational age in view of 
improvements in neonatal care. By 1961 early induced delivery had reduced 
the mortality rate of babies suffering from HDFN from 25% to 16% (Bowman 
1994).Though the risk was understood, there was no means of discerning 
high from low risk pregnancies. The presence of anti-D in the maternal 
plasma was no indicator of fetal RhD type and many RhD- pregnancies were 
exposed to the risks associated with early delivery. Spectrophotometric 
analysis of amniotic fluid at 450nm allowed accurate estimates to be made of 
bilirubin concentration, hence levels of haemolysis and anaemia (Liley 1961). 
Assessment of risk of frank HDFN by amniocentesis allowed clinicians to 
choose the pregnancies for which early delivery would be therapeutic. In 
Manitoba between 1961 and 1964 the perinatal mortality rate from HDFN fell 
further to 13% (Bowman 1994).
The risk to the fetus of early delivery decreases with fetal maturity. In the 
1960s premature fetuses were unlikely to survive before 32 weeks gestational 
age but 8% of affected fetuses become hydropic before that gestational age 
(Bowman 1994). The prognosis in these cases was poor until the first in utero 
transfusions (IUT) were performed. Guided by radiography, blood was 
transfused into the peritoneal cavity, to be adsorbed via the right lymphatic 
duct into the venous circulation, with 10-12% of cells transfused in this way 
being adsorbed per day. Absence of fetal breathing movements and moderate 
to severe ascites both inhibit the process. Though offering a therapy where 
previously there was none, the risks of intraperitoneal transfusion in utero are 
considerable. The procedure has a 7% traumatic death rate and 30% 
spontaneous labour rate and has largely been discarded as a treatment 
option (Bowman 1994).
For transfusion outside the uterus, intraperitoneal transfusion had long been 
replaced by venous infusion. The potential benefits of venous transfusion in 
utero were apparent: rapid increase in fetal haemoglobin levels and the 
potential to be therapeutic for moribund ascitic fetuses lacking breathing 
movements (Bowman 1994). Early attempts to transfuse directly into fetal
41
veins had little success, apart from a very few highly skilled practitioners who 
were able to overcome the turbidity in the amniotic fluid to visualise accurate 
placing of a needle in the umbilical vein by fetoscopy (Tovey 1992). The 
process became widely available with the advent of ultrasound guidance.
Fetal blood sampling and intra-uterine transfusion become part of the same 
process (Urbaniak 2000). The procedure is superior to intraperitoneal 
transfusion in survival rates, and risks to both mother and fetus. Fetal survival 
rates after IUT are 84%, 70% of hydropic fetuses survive, though if the first 
IUT is administered before hydrops occurs the survival rate is 94% (Moise 
2002) By contrast intraperitoneal transfusion resulted in traumatic death in 7% 
of procedures, and spontaneous labour in 30% (Bowman 1998).
The risk of fetal loss due to IUT is moderated by ultrasound guidance; further 
maternal alloimmunisation remains a risk and may exacerbating FIDFN, as 
well as making selection of blood for further IUT problematic. Of 91 women 
whose fetuses received lUTs, 24 (26%) formed alloantibodies resulting from 
exposure to donor or fetal red cells exacerbating risk of FIDFN in current and 
subsequent pregnancies (Vietor 1994).
1.7 Anti-D Prophylaxis
1.7.1 The History of Anti-D Prophylaxis
That the presence of passive antibody prevents active immunisation to the 
corresponding antigen had been demonstrated as early as 1900 with 
passively administered anti-ox antibodies preventing a humoral response to 
ox red blood cells injected into rabbits (Von Dungern 1900 cited in Urbaniak 
2000). It was sixty years later, and twenty years after the discovery that RhD 
was the chief causative agent of HDFN, that antibody mediated immune 
suppression (AMIS) was attempted experimentally in association with HDFN 
(Clarke 1963). In that study, RhD positive red cells, previously coated with 
anti-D in vitro, were injected on four or five occasions into each of 16 
volunteers in the test group. None of the volunteers developed anti-D
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antibodies. When 10 of the group were subsequently injected with uncoated 
D+ red cells, 5 produced anti-D antibodies (Stern 1961).
At the same time a similar experiment was prompted by the observation of 
partial protection from RhD immunisation by ABO incompatibility (Finn 1961). 
Using high titre anti-D antibodies injected into volunteers shortly after 5mL of 
Cr51 labelled RhD+ red cells, rapid clearance of 50% of the injected cells was 
noted, demonstrating the potential for protection and the antibody dose- 
dependent nature of red cell clearance. This striking experiment prompted 
studies in the prevention of Rh alloimmunisation in Liverpool (Clarke 1963) 
and New York (Freda 1963). The Liverpool group expanded on Finn’s work 
exploring the importance of the anti-D dose administered, showed that 
“complete” (IgM) anti-D enhances rather than suppresses immunisation and, 
importantly, recognised the greater safety, consistency and convenience of 
using the IgG plasma fraction rather than whole plasma.
The New York group delayed their experiment until they had a concentrated 
anti-D immunoglobulin prepared by the Ortho Research Foundation (Freda 
1963). This was safer than the whole plasma, used initially by the Liverpool 
group, being sterile and lacking some immunogenic plasma proteins and 
minimising the risk of enhanced alloimmunisation. In addition, the concentrate 
provided a standard product, which could be administered in small volumes; 
these were pre-requisites if prophylaxis on a population scale was to be 
realistic. Initial experiments, on nine inmates at Sing-Sing Prison, consisted of 
administration of anti-D immunoglobulin twenty-four hours before five, monthly 
doses of 2mL of whole RhD+ blood. Six months after the last administration, a 
period chosen to allow decay of the exogenous anti-D to below detectable 
levels, none of the four individuals in the protected arm, compared to four of 
the five in the unprotected arm, had been alloimmunised. Realising that in 
clinical situations anti-D would be administered after the potential sensitising 
event; the authors undertook a further study in which anti-D was administered 
72 hours after a single dose of 10mL whole RhD+ blood. The 72 time period 
between sensitising dose, and anti-D administration was dictated by prison 
visiting times. Of the 13 “unprotected” controls 6 were immunised, none of the
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“protected” volunteers formed anti-D. This experiment was so successful in 
demonstrating the effectiveness of administration anti-D after the potentially 
sensitising episode that the 72 hour period remains accepted as the maximum 
safe elapsed time some 45 years later (BCSH 2006a). Evidence to support or 
challenge this regime would be difficult to generate but would be valuable in 
revisiting our perception of best practice.
Use of the newly described technique for detecting and accurately measuring 
feto-maternal haemorrhage (Kleihauer 1957) provided evidence that 
transplacental haemorrhage is most common at delivery (MRC Combined 
study report 1974). That, and the concern that exogenous IgG anti-D might 
cross the placenta and destroy fetal RhD+ cells, prompted workers to attempt 
antibody mediated immunosuppression (AMIS) shortly after delivery.
The first clinical trials were conducted soon afterwards (MRC Combined study 
report 1974). The first study was designed to provide information as rapidly as 
possible on the efficacy of AMIS with the limited amount of anti-D 
immunoglobulin available. In this multi-centre trial the authors attempted to 
randomise treatment and non-treatment alternately to primiparous women in 
whom there was demonstrable feto-maternal haemorrhage at delivery. In a 
refreshing display of openness the authors describe the difficulties in 
randomisation associated with obtaining test results for weekend deliveries, 
and the intermittent availability of anti-D immunoglobulin. This resulted in the 
default allocation of some participants from the treatment group to the control 
group. Nevertheless, in tests performed 6 months after delivery, of the 78 
participants in the control group 19 (24%) became alloimmunised forming 
anti-D. Of the 78 participants in the test group none were confirmed to be 
immunised, though 3 had inconclusive antibody screens (MRC Combined 
study report 1974).
1.7.2 The Introduction of Anti-D Prophylaxis
In 1966 a working party established by the Medical Research Council (MRC) 
began a further controlled trial to demonstrate the effectiveness of anti-D. 
Within a year of the commencement there was sufficient evidence of the
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effectiveness of anti-D prophylaxis. As the UK supply of anti-D allowed 
treatment of only 12% of at risk primiparous women, the trial was converted to 
establishing the minimum protective dose (MRC combined study report 1974). 
Approximately 200 women in each of 4 dose groups 
(200 pg, 100pg, 50pg and 20pg) received anti-D immunoglobulin at delivery 
were followed to the end of a second RhD+ pregnancy. Each participant was 
screened for alloimmunisation. Dose group immunisation rates between 1.5% 
(200pg) and 2.9% (20pg), approximately one tenth of that in untreated 
pregnancies. The authors concluded that a dose of 100pg (500 IU) of anti-D 
was optimal.
A further study included experimental elements designed to determine the 
alloimmunisation rate in unprotected volunteers, whether alloimmunisation 
was dose dependent, and how the characteristics of the anti-D 
immunoglobulin preparation affected function (Pollack 1971). In this 
experiment, volunteers (200 men 2 post menopausal women, aged 20-65 
years, mean age 37 years) were protected with a standard dose of anti-D 
approximating to 180IU were separated into 6 groups, each with an untreated 
control, and challenged with RhD+ whole blood doses ranging from 11.6- 
37.5mL (Pollack 1971).The results confirmed that antibody response was 
dose dependent, as was AMIS with volunteers receiving the largest dose red 
cells being the most frequently alloimmunised (untreated group), and least 
protected (treated group). Interestingly the authors speculate in their 
discussion that a mechanism other than simple antigen destruction was in 
operation.
Routine post partum anti-D prophylaxis was introduced in the United Kingdom 
through the early 1970s for RhD- women bearing RhD+ babies, with a 
significant reduction in the morbidity and mortality rates from HDFN (Tovey 
1978). The incidence of Rh alloimmunisation was reduced from 17% to 
approximately 1% in less than a decade (Urbaniak 1998, Tovey 1978).
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Many authors comment on the continued residual alloimmunisation rates. 
Failure to prevent alloimmunisation includes cases in which anti-D was not 
given after abortion, representing a third of all new cases, or failure to 
determine and report the D group of the baby (Tovey 1978, Clarke 1983, 
Urbaniak 1985). Guidance was subsequently issued that anti-D should be 
offered after all abortions, spontaneous or therapeutic and other specified 
potentially sensitising episodes during pregnancy. These include: invasive 
prenatal diagnostic techniques such as amniocentesis, ante partum 
haemorrhage, and external cephalic version to correct breech presentation. 
Standard doses of 250IU for pregnancies before 20 weeks gestation, and 
500IU thereafter were specified based on maximum bleed size associated 
with fetal blood volume (BCSH guidelines 2006a). A small proportion of FMH 
are larger than 4mL and hence require larger doses of anti-D to be protective. 
Failure to recognise these events, and act accordingly, accounts for some 
cases of alloimmunisation. The rate of decline of clinical HDFN slowed 
through the 1970s. Some recurring cases related to women who had been 
immunised before the introduction of post-natal prophylaxis (Tovey 1978), 
others to continued failure of prophylaxis.
The residual alloimmunisation rate continued to concern clinicians. The 
consensus conference of the Royal Colleges of the Physicians of Edinburgh 
and of Obstetrics and Gynaecology in1997 made a statement addressing the 
problem and potential solutions. In that statement the successes of post natal 
prophylaxis are celebrated, though the lack of awareness of guidance among 
patients and some clinicians, and the failure systematically to follow 
established protocols, was highlighted. Importantly, despite an acknowledged 
lack of evidence of the scientific or economical benefit, the expert opinion was 
strongly in favour of adoption of routine antenatal prophylaxis as a means of 
further reducing the alloimmunisation rate among RhD- women (Royal 
College of Obstetricians and Gynaecologists Consensus statement 1997).
Routine postnatal prophylaxis was introduced in the UK in the early 1970s 
Thirty years later, the childbearing span of a generation of women, routine 
antenatal prophylaxis was recommended by NICE-the National Institute for
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Clinical Excellence (NICE 2002). The NICE assessments committee 
undertook a meta-analysis of 8 studies in which women were given 500IU of 
anti-D at 28 and 32 weeks (4 studies), 1500IU at 28 weeks only (3 studies) or 
1500IU at 28 and 34 weeks (1 study). The studies included 5 non-randomised 
trials, and 5 trials which used historical control data with the attendant risk of 
overestimating the effect of anti-D prophylaxis because of the beneficial effect 
of improved clinical care. The committee concluded from sensitisation rates 
that the regimes were equally effective and recommended both for routine 
practice. A subsequent review in 2008 used the same data augmented with a 
single randomised controlled trial (RCT) that was designed to investigate the 
benefit of IV rather than IM administration of a single 1500IU dose. Based on 
this review the committee recommended consideration of cost effectiveness in 
choosing between the approaches. The committee also commented that their 
decision was based on financial evidence in the absence of clinical data, and 
that an RCT should be undertaken to investigate the relative merits of anti-D 
administration protocols. Modelling of the effect on mortality in the UK based 
on these analyses, indicate that deaths from HDFN might be reduced from 
approximately 27 per year to approximately 10 (NICE 2008).
1.7.3 The Use of Monoclonal Anti-D for Prevention of Alloimmunisation
Though the supply of anti-D is adequate in the UK and North America, some 
countries have ceased production of anti-D immunoglobulin on the grounds of 
cost (Bowman 2003, Kumpel 2007). The alternative is a monoclonal or 
recombinant anti-D preparation. The potential benefits to patient safety and 
securing adequate supplies are significant. The first anti-D immunoglobulin 
preparations used plasma from alloimmunised women as source material; 
indeed, plasma from women undergoing apheresis procedures in which their 
own plasma was exchanged with that of blood donors was used in some 
centres. To this extent the anti-D prophylaxis programme has been a victim 
of its own success. Fewer women are alloimmunised and, as the existing 
donors retired, they were replaced by volunteer blood donors who were 
deliberately alloimmunised with cells from accredited RhD+ donors (Urbaniak 
1981). Ethical concerns about this process (Tovey 1990), lead to bans in
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some European countries (Beliard 2006) but these concerns were overtaken 
in the UK by the presence of variant Creutzfeld-Jacob Disease (vCJD) in the 
donor population and the associated risk of transmission via transfusion. As a 
result all UK plasma for fractionation, including the production of anti-D 
immunoglobulin is sourced from the USA. The discovery of vCJD in American 
cattle further threatens the ongoing supply of anti-D (Hall 2005). Though anti- 
D is regarded as a safe product, there remains a finite risk associated with, as 
yet, unknown pathogens, from the infusion of any product of human origin, as 
demonstrated by Hepatitis C infections associated with anti-D immunoglobulin 
in Eire, before donor screening was available (Power 1995).
In view of these benefits and not inconsiderable commercial interest there 
have been many in vitro and clinical trials of monoclonal and recombinant 
anti-D products. Studies include the injection of autologous 51 Cr labelled red 
cells coated with anti-D to male RhD+ volunteers. In these trials monoclonal 
antibodies have been shown to clear red cells, but more slowly than 
polyclonal anti-D preparations. Similarly monoclonal anti-D administered to D- 
volunteers cleared 51Cr labelled D+ cells, unless administered at saturating 
doses clearance was slow. In this study 0 of 24 participants were 
alloimmunised (Beliard 2006). A further study recruited 95 male D- volunteers 
who were injected with 51 Cr labelled D+ red cells 24 hours before a mixture of 
lgG1 and lgG3 monoclonal antibodies (BRAD-5 and BRAD-3). One 
participant was alloimmunised to the D antigen at 12 weeks. To confirm that 
the participants could mount a response to D+ cells the remainder were given 
further D+ cells 24 and 36 weeks later. One participant mounted a strong 
response to the second challenge by 28 weeks, suggesting that the 
monoclonal anti-D had not prevented a primary response. Only 24% of the 
cohort was alloimmunised after two unprotected challenges with D+ red cells. 
This low figure was taken by the authors to indicate the possibility of long term 
protection afforded by the anti-D treatments (Kumpel 2002).Both 
alloimmunised participants had cleared the D+ cells within 3 days of 
administration (Kumpel 2007).
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An assumption made by workers undertaking trials is that the ability to 
mediate rapid red cell clearance is the key property of monoclonal anti-D in 
effecting AMIS (Kumpel 2002, 2007, Beliard 2006). The important 
characteristic of antibodies useful in AMIS is the immunosuppressive effect. 
Overall the results of these trials, examining protection from immunisation 
rather than clearance, have been disappointing, with many preparations 
failing to clear red cells in vivo, or doing so slowly, or variably. Some 
antibodies appear to have enhanced alloimmunisation; none to date have 
been as effective as human polyclonal preparations (Kumpel 2007). 
Monoclonal and recombinant antibodies differ from polyclonal IgG in the 
degree and quality of glycosylation, and sialylation. Potentially adverse effects 
on the interaction with FcR on effector cells and on mediation of inflammation 
as an enhancement of the humoral response have been attributed to these 
characteristics (Kumpel 2007, Kaveri 2008).
Anti-D in association with HDFN prophylaxis is the most widely applied 
example of the therapeutic administration of exogenous immunoglobulin 
Beliard 2006). Other specific therapies include anti-tetanus or anti-rabies 
products which may be administered prophylactically or in response to 
specific exposures to infective agents and are effective in preventing disease 
onset (Kobayashi 1996).
1.7.4 IgG in Therapeutic Immunomodulation
Intravenous Immunoglobulin (M g) has long been used to treat primary or 
secondary immune deficiencies including ataxia telangectasia, Wiskott Aldrich 
Syndrome and DiGeorge Syndrome (Mazer 2005). Since the early 1980s,
IVIg has, in addition, been used to treat other conditions associated with allo- 
or auto-immune reactivity or systemic inflammatory states. These include 
Immune Thrombocytopaenic Purpura, Guillaine-Barre syndrome, Myasthenia 
Gravis and Kawasaki syndrome (Ephrem 2005). The effectiveness of these 
treatments is supported by clinical data, but there is some clinical and 
experimental evidence to suggest that IVIg might be therapeutic in other 
diseases of the immune system (Ephrem 2005). The range of functions of
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circulating normal immunoglobulin is wide and diverse and that is reflected in 
the range of mechanisms by which IVIg has been shown, or is considered to 
exert its therapeutic effects. These effects are non-mutually exclusive and are 
considered to be synergistic (Tha-ln 2008).
IVIg is prepared from pools of plasma from thousands to tens of thousands of 
blood donors, and contains immunoglobulin expressing a wide array of the 
variable and constant regions and of immunoglobulin isotypes expressed on a 
population scale (Mazer 2005). Preparations consist mainly of IgG, with 
smaller amounts of IgM and IgA, reflecting the characteristics and levels of 
circulating immunoglobulin in the donor population (Tha-ln 2008). In 
autoimmune cases IVIg may be administered in doses up to 2.0g/kg leading 
to serum levels of 5-25 mg/mL (Dussault 2008) consistent with the normal 
concentration of 8-16mg/mL (Roitt 2001). In antibody deficiency cases, lower 
doses of 400-600 mg/kg are used (Mazer 2005). A high proportion of the 
antibody molecules are of self-reactive specificities associated with the 
regulation of self and non-self recognition, destruction of senescent cells, and 
maintenance of the idiotype-anti-idiotype network (Ephrem 2005).
The mechanisms of action of IVIg are both unclear and controversial. Many of 
the disease states which can be treated exist in an inflammatory immune 
environment. Licensed use includes Kawasaki Disease, chronic inflammatory 
demyelinating polyneuropathy, and Guillain-Barre syndrome, though “off- 
label” applications are increasing resulting in short supply, and increasing 
product price (Ascherman 2009).
There is evidence from clinical and in vitro studies that IgG has an anti­
inflammatory effect through:
• modulation of FcR expression
• T and B cell activation,
• anti-idiotype antibodies, and IgG dimers,
• the induction of anti-inflammatory cytokines
• the inhibition of IFN-y
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(Ephrem 2005, Clynes 2007) .Though the complexity and number of putative 
mechanisms is challenging, it does reflect the diversity of function of 
circulating, native immunoglobulins. The presence of soluble HLA class I and 
II molecules and CD40 in IVIg preparations may interfere with antigen 
recognition by T and B lymphocytes and subsequent co-stimulation. 
Immunomodulation of B lymphocytes by IVIg has been shown to be via 
phosphorylation of intracellular signalling kinases (Dussault 2007). In vitro 
studies have demonstrated down regulation of expression of co-stimulatory 
molecules on DCs by exogenous IgG resulting in reduced secretion of IL-12 
(Ephrem 2005).
There is some evidence that the anti-inflammatory effect of IgG is attributable 
to a fraction of IgG which expresses a terminal sialic acid residue on 
asparginine 297 linked glycan. This has been demonstrated experimentally 
both with IgG recovered from plasma pools made from blood donations, and 
with a recombinant !gG1 fraction. The immunomodulatory effect appears to 
occur through up-regulated expression of the inhibitory FcRyllB, or may reflect 
the presence of a novel receptor for sialic residues on IgG (Nimmerjahn 
2008a).
In a study using a mouse model, IVIg was demonstrated to have multiple 
immunosuppressive effects. Mice immunised with ovalbumin and treated with 
IVIg were shown to generate fewer splenic antigen specific T cells, as 
measured by cytokine release than mice in an untreated control group. The 
authors also demonstrated lower titres of antibodies to ovalbumin in the 
treatment groups, and speculate that this may be the result of reduced T-cell 
activation, Using ex vivo APC and T cells, the author demonstrated almost 
complete inhibition of T cell response to APC previously treated with IVIg 
suggesting that the mode of action is mediated through APC rather than 
directly on T cells (Aubin 2010).
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The potential for improving the cost, risk and effectiveness of IgG therapies if 
recombinant product can successfully applied clinically is significant (Kaveri 
2008).
1.7.5 Use of High dose IVIg in Alloimmunised Pregnancies
An alternative application for IVIg is in improving fetal cytopaenias, by 
administration to alloimmunised women who are at high risk of having 
affected pregnancies due to HDFN, or neonatal alloimmune 
thrombocytopaenia (Urbaniak 1999, Gottstein 2003). The practice is 
considered less risky than alternative treatments such as early delivery, IUT, 
or exchange transfusion at delivery, particularly as administered by those 
unfamiliar with the practice. Some workers (Gottval 1995) report good results, 
with concentrations of maternal alloimmune anti-D apparently being controlled 
despite repeated cordocentesis procedures, and better conservation of fetal 
haemoglobin levels than in an untreated control group. The authors report 
similar ratios of maternal to fetal serum anti-D levels, and conclude that 
placental transfer of IgG is unaffected by the therapy and the means of action 
is fetal Fc blockage by the exogenous IVIg. Other authors report reduced 
requirement for exchange transfusion, with the associated extended hospital 
treatment (Gottstein 2003). There is some in vitro experimental evidence that 
IVIg preparations can inhibit placental transfer of anti-D (Urbaniak 1999a). 
Some workers have administered IVIG directly to babies soon after delivery, 
with similar beneficial effects on reducing the need for exchange transfusion 
(Gottstein 2003, Miqdad 2004).
Though offering a limited insight into possible mechanisms of AMIS when high 
doses of antibody are used, these studies are small scale, with mixed results. 
Improvements in the safety and efficiency of ultrasound guided IUT (Abdel 
Fattah 2002) mean that the use of IVIg in treating HDFN has not been widely 
adopted.
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1.7.6 The Use of Intravenous Anti-D to Treat Immune 
Thrombocytopaenic Purpura
The role of IV anti-D in the treatment of immune thrombocytopaenic purpura is 
similarly celebrated as an effective therapy, but authors continue to debate 
the means of action. The treatment has been in use since 1983, and theories 
on the mechanism of action include: FcR blockade, anti-idiotype regulation, 
and modulation of cytokine networks (Semple 2008). Fc blockade is 
supported by the evidence that anti-D therapy is only effective in RhD+ 
patients. IgG anti-D bound in multiple copies to D+ red cells might conceivably 
block and/or cross-link FcR on the patient’s phagocytic cells, thereby 
preventing destruction of platelets.
In a study investigating the effect on serum cytokines of anti-D treatment of 
ITP, 7 patients were given 50pg/kg of anti-D when their platelet counts were 
below 30x109/L. Blood samples were collected before treatment, and 3 hours 
and 8 days afterwards. Significant rises in the concentrations of both pro- and 
anti-inflammatory cytokines (IL-1 ra, IL-6, GM-CSF, MCP-1a, and TNF-a) was 
noted at 3 hours, with return to baseline at 8 days after treatment. The authors 
suggest that interaction between IgG opsonised red cells and FcyR induce a 
cytokine storm which downregulates the function of the reticulo-endothelial 
system (Semple 2002).
In another study (Cooper 2004), 27 ITP patients were administered 50- 
75pg/kg of anti-D in response to low platelet counts; samples were taken 
before treatment, and 2 hours, 24 hours, and 7 days after treatment. In 24 of 
this cohort, polymorphisms in FcyllR (HH/HR) and FcylllR (VF/W) were 
determined. Increases in the concentrations of the 4 analytes measured were 
noted at 2 hours (IL-6, IL-10, MCP-1, TNF-a). Higher responses were 
recorded in individuals expressing HH FcyllR than HR, and higher platelet 
increments in individuals expressing VF FcylllR than W . In a cohort receiving 
IVIg (1 g/kg), only IL-10 showed an increase at 2 hours. The authors
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concluded that IVIg and anti-D relieve ITP by different mechanisms and that 
anti-D bound to D+ red cells interacts with the patients Fc receptors.
The pathology of transfusion reaction is analogous to AMIS by anti-D in D+ 
patients, and some of the clinical features of transfusion reactions, particularly 
fever and rigors have been associated with the release of cytokines and are 
common to both groups of patients. Pro-inflammatory cytokines IL-1 (3, TNF- 
a, IL-6 and IL-8 were detected in monocytes challenged with D+ red cells in 
an in vitro model (Davenport 1993). The same cytokines were detected at 
elevated concentrations in a patient undergoing a delayed haemolytic 
transfusion reaction due to anti-D (von Zabern 1998).
1.7.7 The Mechanism of Action of Anti-D: Antibody Mediated 
Immunosupression.
That anti-D prophylaxis is effective in suppressing Rh alloimmunisation is 
clear, though in common with other immunoglobulin therapies, the mechanism 
underpinning this suppression is not. The parallel chronologies of anti-D 
prophylaxis, the advance of the science of immunology, and the tightening 
control on studies involving human participants have contributed to our lack of 
understanding of the mechanism of antibody mediated immunosuppression 
(AMIS). Two measures of the efficacy of anti-D prophylaxis have been widely 
applied: the ability to clear fetal D+ red cells rapidly from the maternal 
circulation, and the prevention of maternal alloimmunisation. For many 
practitioners and some scientists, the link is perceived to be directly causal, 
though there is little direct evidence to support the hypothesis.
1.7.7.1 The Clearance of RhD+ Red Cells
It is suggested that anti-D antibody binding to RhD antigen on fetal red cells 
causes clearance of cells expressing alloantigens, before they can be 
recognised by the immune system (Brine 2009). In fact anti-D coated fetal red 
cells are cleared to the maternal spleen, a secondary lymphoid organ which is
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the chief site supporting humoral immune responses to blood borne antigens 
(Batista 2009, Kumpel 2002). Trafficking of alloantigen positive cells to the 
spleen is likely to enhance rather than suppress the humoral response in the 
absence of other other suppressive mechanisms. This theory of antigen 
deviation away from main immunogenic sites is consistent with the protection 
offered by fetomaternal ABO incompatibility. In this case maternal ABO IgM 
isoantibodies effect destruction of fetal cells either by complement mediated 
lysis in the intravascular compartment or by phagocytosis in the liver where 
there are relatively few APC (Kumpel 2002). Other evidence from animal 
models suggest that AMIS correlates more closely with the quantity of IgG 
bound to target cells, and to its ability to interact with FcR rather than the rate 
of cell clearance (Heyman 1984).
Small FMHs appear to need clearance within 5 days to avoid 
alloimmunisation (Mollison 1984). There is some evidence that in larger 
bleeds, or sensitising episodes associated with inadvertent transfusion of 
RhD+ blood to RhD- patients, clearance facilitated by large doses of anti-D 
immunoglobulin can take much longer without alloimmunisation occurring 
(Lubenko 1999, Mollison 1984). These case reports are based on small 
cohorts of patients and, experimental confirmation of these findings would be 
problematic.
1.7.7.2 The Suppression of the Humoral Response by Antigen Blocking
This theory demands that exogenous anti-D binding to fetal RhD+ red cells 
does so in sufficient quantity to prevent interaction with B lymphocytes. It is 
clear that AMIS is dose dependent, with too small a dose being ineffective 
(Pollack 1971, Mollison 1984). There are estimated to be 10-40,000 RhD 
antigen site per red cell (Daniels 2002). As little as 20pg of anti-D can effect 
AMIS against 1mL of D+ red cells containing 1010 red cells and 1014 D 
antigens. Under these conditions it has been calculated that fewer than 5% of 
D sites are blocked (Klein 2005). In the context of the small volumes of red 
cells required to elicit an alloimmune response to the D antigen, it is hard to
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see how routine doses of anti-D immunoglobulin could block sufficient antigen 
sites to prevent an immune response by the mechanism of steric hindrance. 
Further, in animal models, the use of Fab and Fab2 fragments fails to 
suppress alloimmunisation, whereas whole IgG with Fc region intact does 
(Urbaniak 2000). It has been demonstrated that the effect is particle, rather 
than epitope specific by experiments in which alloimmunisation to the RhD 
antigen was suppressed in volunteers injected with D+K+ red cells and potent 
anti-K. The K antigen is co-expressed with RhD on red cells but much less 
densely with 2-5,000 sites per cell (Woodrow 1975).
1.7.7.3 Down-Regulation of B lymphocytes
At least one author (Kumpel 2002) favours the theory that 
immunosuppression is the result of down regulation of B cells. The proposed 
mode of action is co-ligation of multiple RhD antigens on red cells with the 
BCR, and the Fc portion of red cell bound anti-D with the FcyRllb IgG receptor 
which is also expressed on B lymphocytes. Interaction between the BCR and 
antigen is stimulatory through tyrosine based activation motifs in the 
cytoplasmic domains of proteins associated with the BCR. When 
phosphorylated, this motif activates a signalling pathway which results in B 
cell activation, proliferation and, ultimately, production of antigen specific 
antibody. Where co-ligation occurs, tyrosine based inhibitory motifs activate 
an inhibitory signal resulting in down-regulation of the B lymphocyte response 
and possibly apoptosis (Kumpel 2002). The argument is supported by some in 
vitro studies, and by the evidence that immunosuppression is effected by 
whole IgG but not F(ab')2 portions (Brine 2009) reinforcing the role of the Fc 
portion of IgG. In contrast experiments using FcyRIIB'7' mice have 
demonstrated that the inhibitory FcyRIIB is not required for AMIS to be 
effective, suggesting that more than one mechanism in effective (Heyman 
2003, Brine 2009). lgG3 has been shown to be an effective AMIS agent, but 
does not bind to FcyRII (Heyman 2003). Though FcyRII B may have a role in 
immunosuppression, there is good evidence that this is not the sole 
mechanism.
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Experiments using mice injected with sheep red blood cells as a model of 
AMIS showed that B cells from mice protected with anti-sheep antibodies 
were much less effective than those from untreated mice in presenting sheep 
red blood cells to T cells in vitro, indicating inhibition of B cell priming in vivo. 
The same authors report no significant effect on T cell priming in the same 
model. Caution must be exercised in extrapolating the results obtained in 
murine in vitro or ex vivo studies into a human clinical setting (Brine 2008).
Alternative hypotheses, involving the inhibition of B lymphocytes by IgG 
opsonisation of red cells, include prevention of B-cell spreading and synapse 
formation with APC, and that bound IgG prevents MHC II presentation of 
antigen, internalised by B lymphocytes (Brine 2009).
This collection of hypotheses to explain a clinically demonstrable effect has 
strong analogies with the ongoing debate on the mechanism by which IVIG is 
effective in modulating a number of inflammatory autoimmune diseases, and 
the mechanism by which IV anti-D improves platelet counts in patients with 
Immune Thrombocytopaenic Purpura (ITP). Perhaps as a result of this, some 
researchers have focussed on the effect that anti-D administration in 
pregnancy has on maternal cytokine profiles (Branch 2006). The authors, 
noting the documented effect of IV anti-D on cytokine profiles when used to 
treat ITP, undertook a small study on a cohort of pregnant women at the time 
that anti-D prophylaxis was administered.
In this study, ten women between 28 and 32 weeks gestation were recruited 
who were known either to be carrying a D+ fetus or to have a D+ partner. 
Samples of whole blood were collected before and 48 hours after 
intramuscular administration of 1500IU of anti-D antibody (WinRho, Cangene 
Corp. Winnipeg, Canada). The levels of 17 different inflammatory mediators 
in the participant’s plasma were measured by Enzyme Linked Immunosorbent 
Assay (ELISA), of which 10 were below the detectable level in all samples 
tested and 4 others showed no change. Of the three remaining analytes 
IL-1 ra showed a moderate increase after treatment in 7 of the 10 women, 
though this was not statistically significant, and 2 analytes (PGE2, and TGF-
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(31) showed significant increases with 5/10 women giving 1.5 or greater fold 
increase in PGE-2, and 7/10 volunteers having 1.3 or greater fold increase in 
TGF-p1. Of these, one woman had a >5 fold increase.
The authors suggest a causal link between administration of exogenous anti- 
D and changed anti-inflammatory cytokine profiles, and in particular highlight 
the recognised role of TGF-p1 in modulating humoral immune responses.
The study of Branch et al (2006) had a small cohort of participants, with no 
control group. The time series involved just two points before and after 
treatment, and there was no attempt to correlate the presence or absence of 
fetal D+ cells in the maternal circulation with any observed effect. Nonetheless 
the findings point to the potential to further investigate a causal link between 
anti-D administration and changed cytokine profiles, which may offer an 
insight into the mechanism by which AMIS operates.
1.7.8 Cytokines and Control of the Immune System
Cytokines are small soluble proteins which can be produced by almost any of 
the nucleated cells in the body and may act on in an autocrine or paracrine 
manner (Mantovani 2000, Janeway 2001). Cellular interaction of the immune 
system is regulated by cross-talk, mediated by a system of cytokines, which 
are released in response to different stimuli by a range of cell types, and can 
be inhibitory or synergistic (Theze 1999) and the effect on cell growth, 
differentiation, function and death are complex and variable (Mantovani 2000). 
Functions of cytokines involve driving T cell responses and coordinating the 
immune response between the cell mediated, and humoral arms. Individual 
cytokines may have a range of functions, and some effects may be achieved 
by alternative cytokines, offering flexibility and versatility in the immune 
response by redundancy of cytokine function. For example, B cell antibody 
production is driven by IL-2 but even in the absence of IL-2, IL-4 and-10 can 
stimulate immunoglobulin synthesis (Theze 1999). Changes in cytokine 
expression both locally at the site of implantation, and more generally in the 
maternal immune response, are key to establishment and maintenance of 
successful pregnancy (see section 1.1.4). That cytokine profiles change in
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response to exogenous IgG is well documented (Sewell 1999, Semple 2008), 
and the interaction between anti-D and red cell antigens has also been 
reported to result in a powerful cytokine response (Zabern 1998). Of 
particular interest is the evidence that TGF-pi expression is altered by the 
administration of exogenous anti-D antibody (Branch 2006).
TGF-p is a 25kDA homodimer which is highly conserved among mammalian 
species (Lawrence 2001), the evolution of the TGF-P system can be traced to 
the split of arthropods from vertebrates more than 1 billion years ago (Li 
2006). TGF-p1 is secreted by Type 1 regulatory T cells and Th3 lymphocytes, 
which are induced from primed CD4+ lymphocytes and possibly naive 
lymphocytes, when activated by appropriate antigen (Taylor 2006).
Three forms of TGF-p are expressed in humans: TGF-(31, TGF-P2 and TGF- 
P3, of these, TGF-p1 is predominant in the immune system, though the in 
vitro functions of all three forms are similar. TGF-p is secreted by almost all 
nucleated cells as high molecular weight, latent complexes (Lawrence 2001), 
with latency associated protein, and in some cases latent TGF-P binding 
protein (Li 2006). Secretion as a latent complex is an effective mechanism to 
control TGF-P biology, averting damaging pathologies associated with 
uncontrolled active TGF-p. In addition, the release of latent complex increases 
the circulating half life of TGF-p from two to ninety minutes (Lawrence 2001). 
Activation can be achieved in vitro by heating, or low pH (Li 2006). in vivo this 
occurs by the action of cell surface proteases, such as plasmin, cathepsin, 
and metalloproteinases, that cleave the active form of TGF-P from the 
associated protein (Lawrence 2001).
TGF-p is a potent and versatile mediator of immunosuppression, instigating 
and maintaining immune tolerance, with diverse effects on hemopoeitic cells 
(Li 2006, Wahl 2006). The effects are dose, cell type, and context dependent 
and in many cases are modulated by other cytokines (McKarns 2003). In 
addition, TGF-p has an important role in the repair of tissue damage, released 
by platelets at the site of injury or infection acting as a chemoattractant for 
monocytes, lymphocytes and fibroblasts, and stimulating the deposition of
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extracellular matrix (McKarns 2003, Wahl 2004). The effect of TGF-P1 is 
modulated by the presence of inflammatory cytokines including (IFN-y), and 
signalling derived from co-stimulatory molecules such as CD28 and CD40, 
which results in control over immune response to self or non-harmful 
antigens whilst permitting immune surveillance or, and response to 
pathogens. TGF-|31 has a profound effect on T lymphocytes including 
proliferation: differentiation and survival, especially anti-proliferatitve effects 
on naive T cells. The effects are dependent also on co-stimulation, the state 
of differentiation of the target cells, and the presence of inflammatory 
cytokines, so that the final outcome of the action of TGF-p1 may very 
according to the immunological environment (Li 2006). Antigen presentation 
by macrophages is inhibited by TGF-(31 by reduction of IFN-y induced MHC 
class II expression (Wahl 2006). In addition TGF-(31 inhibits the expression of 
co-stimulatory molecule CD40 and IL-12p40, which together reduce the 
antigen presenting effectiveness of macrophages (Li 2006).The effect of TGF- 
p i on B cells is analogous to that on T cells, with powerful inhibitory effect on 
proliferation, activation and antibody class switching to isotypes other than IgA 
and lgG2 (Li 2006, Taylor 2006).
The most important receptor for TGF-P is TGFpRII. Signalling occurs through 
associated activin receptor-like kinases (ALK-5 and ALK-1), the cytoplasmic 
domains of which directly phosphorylate Smad signalling proteins which in 
turn form an enzyme cascade leading to regulation of transcription of target 
genes (Li 2006). The effect of TGF-p on T cell proliferation is generally 
suppressive , through the down regulation of IL-2, though TGF-P induces the 
differentiation of naive T cells to Foxp3+ T reg cells, which themselves 
produce TGF-p on exposure to epitopes of a-fetoprotein (Alisa 2008). Th3 
cells express TGF-p and drive oral tolerance, and class switching of 
immunoglobulin synthesis to IgA (Li 2006). B cell proliferation and 
differentiation are inhibited by TGF-p, and maturation of differentiated DCs is 
similarly regulated (Li 2006).
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IgG and TGF-p can form a complex, which has a powerful suppressive effect 
on B cell proliferation (Bouchard 1995). TGF-pi IgG complexes have been 
reported with an immunosuppressive effect estimated as 500 fold that of 
unbound cytokine, and it has been proposed that the conformational change 
required for binding is effective in activating TGF-P (Lawrence 2001).
Our understanding of the mechanism of anti-D AMIS is limited, further 
evidence of the effect of the treatment on cytokine profiles, and how that 
might mediate immunosuppression will improve our knowledge. In this study 
the authors intend to generate new knowledge in a quasi-experimental inquiry 
including a control group, an extended time series, and to seek evidence of a 
link between detectable FMH and cytokine response following the 
administration of anti-D.
1.8. Aims, Hypotheses and Objectives
This study aims to investigate the effect of anti-D prophylaxis on the 
expression of cytokines in the maternal circulation, and that any alteration is 
dependent on the presence of fetal RhD+ red cells.
Two pairs of hypotheses are presented:
Hypothesis 1
H0 There is no significant difference in cytokine expression in maternal 
circulation before and after anti-D prophylaxis
and
Hi There is a significant difference in cytokine expression in maternal 
circulation before and after anti-D prophylaxis
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Hypothesis 2
H0 There is no significant difference in cytokine expression in maternal 
circulation after anti-D prophylaxis in the presence or absence of D+ cells 
and
Hi There is a significant difference in cytokine expression in maternal 
circulation after anti-D prophylaxis in the presence or absence of D+ cells.
Thus the objectives of this study were to:
1) Recruit up to 30 women to participate
2) Determine the role of fetal RhD group by establishing the group, and 
measuring the presence of fetal D+ cells in the maternal circulation
3) Measure cytokines before and after anti-D prophylaxis.
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Chapter 2 Materials and Methods
2.1 Introduction
Experimental inquiry, generally in the form of randomised controlled trials, is 
regarded as the best approach by which to establish causal relationships in 
healthcare research. In true experiments, the researcher identifies a variable 
within a system then manipulates it and measures the effect on other 
variables. The internal validity of the inquiry is maintained by the use of 
control groups in which the treatment is withheld. Participants are allocated 
randomly to either test or control group to avoid accidental or deliberate bias 
in the samples, which might produce results that are misleading and cannot 
be generalised to the population from which the sample is drawn (Field 2003).
In some circumstances, including those pertaining to the current study, true 
experiments in which the investigator is in full control of the variables cannot, 
for logistical and ethical reasons, be undertaken. NICE guidance is clear that 
all D- women must be offered prophylaxis at 28 weeks gestation, and 
although a small number of women choose not to accept treatment, forming a 
cohort from these would be logistically challenging, and ethically questionable. 
There are alternatives to in vivo human studies in many cases. Animal models 
and in vitro experimental models might be applied to gain the advantages of 
internal validity associated with experimental inquiry, without the ethical 
problems associated with withholding proven prophylaxis to patients.
(Mollison 1984).
The animal models used in AMIS experimentation have limitations however, 
in that significant differences between animal and human immunology prevent 
generalisation of results. Mice, for example have no blood groups, and 
challenge with non-mouse erythrocytes leads to rapid complement mediated 
destruction, unlike the slow lymphocyte mediated response in human Rh 
alloimmunisation (Kumpel 2006). The immunology of human pregnancy is 
exquisitely complex (Weetman 1999) and no adequate in vitro model has 
been created, which allows true experimental research on the immunology of
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pregnancy, without serious doubts as to how the results apply to the in vivo 
condition.
For these reasons a quasi-experimental methodology was selected to allow 
investigation of the in vivo effects of anti-D administration in human 
participants, rather than accept the confounding variables associated with in 
vitro or animal models, in this complex immunological environment.
In this model, the researcher relinquishes control over a number of variables, 
including the timing of the experimental manipulation and the random 
assortment of patients into test or control groups. Quasi-experimental 
investigation offers advantages over true experimental research in supporting 
investigation when participants cannot be allocated randomly to treatment, or 
non-treatment groups by researchers such as the current study. The use of in 
vivo models facilitated by quasi-experiment reduces the risk of results being 
adversely affected by the artifice of laboratory investigation. The approach 
does bring limitations to the study, being less effective than true experimental 
research in establishing causal relationships between treatment and effect, as 
non-random assignment of participants to groups risks the associated 
allocation of confounding variables, beyond the control of the researcher.
(Field 2003).
2.2 Study design and Ethical Approval
2.2.1 Ethical approval
This study required the collection and testing of peripheral blood samples 
from pregnant women being treated in the NHS, beyond that required in 
standard care protocols. As a result Research Ethics Committee approval was 
sought from York Local Research Ethics Committee and granted. (REC 
reference number 08/H131/22, copy of approval in Appendix I). NHS R&D 
approval was granted by Leeds Teaching Hospitals (Appendix II).
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2.2.2 Selection of Women for Test and Control Groups of the Study
The purpose of this study was to investigate the mechanisms underlying 
antibody mediated immune suppression caused by anti-D prophylaxis. This 
effect occurs only when D- mothers carry D+ fetuses. Approximately 40% of 
D- mothers carry D- fetuses, with no risk of alloimmunisation or any possible 
specific immunomodulation of the maternal response to fetal red cells, as they 
are D-. Use of a placebo group of D+ pregnant women to which saline was 
administered was considered, and ethical approval obtained. This group 
would have comprised women attending antenatal clinic at 28 weeks 
gestation for glucose tolerance tests. It is acknowledged that inclusion of a 
placebo control would have offered evidence of non-specific alteration of 
cytokine expression, induced, for example by phlebotomy, but as that was not 
the primary research question, and any non-specific reaction would be 
detectable in the control arm, a placebo group was not included. The use of 
women bearing D- fetuses was considered a better model of the immune 
process, being more similar to the test arm, and as the D group status of 
participants’ babies was not known and could not be predicted at the time of 
recruitment, offered better randomisation. Accordingly patients were allocated 
to test and control groups of the study based on fetal blood group, described 
from this point as “D+ fetus group” and D- fetus group”. The fetal blood group 
is determined routinely at delivery by standard automated blood grouping 
technologies when D- women deliver, to support appropriate anti-D 
prophylaxis, treatment is not being offered to the mothers of D- babies (BCSH 
2006). The information required for this allocation was obtained from the 
records of Leeds Teaching Hospitals after completion of recruitment and 
testing phases of the study.
2.2.3 Calculation of sample size
The raw data from Branch’s 2006 work on cytokine profiles were obtained to 
inform the current study (Donald Branch personal communication). The data 
(n=10) were demonstrated to be normally distributed using the Anderson- 
Darling test., and detected fold changes were found to have a standard
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deviation of 1.43. A power calculation to determine sample size required to 
detect a 1.5 fold difference in cytokine concentration in pre- and post­
treatment samples with a power of 90% and a significance level of 5%, using 
Minitab software (Minitab Ltd, Coventry, UK), the minimum sample size 
required was found to be 15. It was anticipated that 40% of recruited 
participants would have D- fetuses and therefore would not be included in this 
test group. Accordingly a minimum cohort size was set at 24, in the 
expectation that 15 participants would be recruited to the D+ fetus group and 
9 to the D- fetus group. Numbers of participants recruited to each group are 
reported in section 3.1.
2.2.4 Criteria for Inclusion in the Study
Pregnant RhD- women are routinely invited to anti-D clinics at St James’ 
University Hospital, Leeds, at gestation between 28 and 32 weeks. All 
attendees at 24 clinics were invited to participate in the study, and no other 
selection criteria including age, ethnicity, parity, or health were considered. It 
is acknowledged that this strategy may result in the introduction of 
confounding variables. It is not intended that the generalisation is extended to 
individuals who are outside the core selection criteria of pregnant women, and 
28 weeks gestation receiving anti-D prophylaxis. The value of the study would 
be enhanced if the results were applicable to all individuals meeting those 
criteria. It must be recognised that other variables in other patient groups, in 
particular route of administration, dose size or source of anti-D might limit the 
generalisation of the results of this study (Field 2003).
2.2.5 Timing of Samples
The short duration of the time series of this study (approximately 24 hours) 
offers some advantages in avoiding some confounding variables associated 
with longer time series. Participants once recruited and informed of the nature 
of the study are unlikely in the short time of the investigation to be exposed to 
factors, either associated with their own circumstances, publicly available 
information, or the study itself, which might cause them to withdraw from the
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study. Longer time series are much more likely to be subject to these 
problems (Field 2003).
The administration of routine anti-D prophylaxis by the intravenous route, was 
unusual at the time of the current study, although the practice is increasing, 
following NICE guidance update (NICE 2008), indicating the need for cost 
effective prophylaxis. Conventionally anti-D is administered through the 
intramuscular route. The advantages of IV administration are largely logistical 
and financial, but in this study IV administration ensures that the kinetics of 
anti-D dispersal through the maternal circulation are more predictable, along 
with the timing of any cytokine burst, which may be a response to IgG 
administration is likely to be both rapid, and short lived (Semple 2002, 
Malinowska 2001).
2.2.6 Testing Strategy
Testing the hypotheses which define this study requires estimation of cytokine 
release in test and control groups, the detection of low levels of fetal D+ cells 
in the circulation of participants, and correlation of the data gathered.
For cytokine estimation, a strategy was selected which involved screening 
plasma for a panel of cytokines by flow cytometry (FC). This method was 
selected as rapid, sensitive and cost effective for investigating a number of 
analytes. The second stage of the strategy was to use FC data, or that from 
previous studies (Branch 2006) to identify specific cytokines for further 
analysis by ELISA. These data were then used to select analytes for 
investigation by real time quantitative PCR (q PCR) on samples of peripheral 
blood.
2.2.7 Selection of Analytes
A range of analytes was selected based on literature reports indicating 
modulation by anti-D AMIS IL-1 ra, TGF-(31, IL-12p70 (Branch 2006), 
modulation by IVIg TNF-a, IL-10, IL-6 (Cooper 2004), IFN-y (Clynes 2007),
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as well as IL-1 p, and IL-17 as key pro-inflammatory cytokines, and IL-4 for its 
role in Th2 type immunity (Fazilleau 2007).
2.2.8 Recruitment of Participants to the Study
Lists of women invited to anti-D administration clinics at St James’ University 
Hospital in Leeds, were obtained from the clinic administrators 3-6 weeks 
prior to each appointment. From the details on the list, patient addresses were 
obtained using the NHS patient tracing system. The study information leaflet 
(Appendix III) and Participant information sheet (appendix IV) was sent by 
mail to each potential participant, at least one week before the scheduled 
clinic visit. The recruitment leaflet was designed to inform potential 
participants of the study in a concise format, giving an indication of the aims of 
the research, and what would be required of participants. The participant 
information sheet offered greater detail on the nature of the study, bothe 
documents were included in the ethics committee application. Contact details 
for the chief investigator were included. This gave potential participants 3-6 
weeks to consider whether to join the study or seek additional information.
One hundred and three potential participants were sent leaflets and 
information sheets, of whom seven contacted the chief investigator before 
their clinic appointment indicating willingness to participate, all of whom did 
so. The remaining seventeen participants agreed to join the study at the 
clinic. Of the women who agreed to participate in the study, all gave a full set 
of samples, all of which were of sufficient volume to test.
At the clinic, the study was explained by the chief investigator to each 
potential participant in the presence of a midwife, with an invitation to join the 
study. A copy of the leaflet and the participant information sheet was offered.
In discussion with potential participants it was stressed that participation was 
voluntary, participants could withdraw at any stage, and that that the decision 
whether to join the study would not affect their care. Women agreeing to 
participate completed 2 copies of the consent form (Appendix IV), one copy
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being retained by the chief investigator in the research site file, the second 
being stored in the patient held notes.
A full antenatal check was performed by the midwife on each woman 
comprising: blood pressure, urine analysis, abdominal palpation, and a check 
on the baby’s heartbeat. Venesection was performed by midwives using a 21 
gauge % inch butterfly needle, one 6mL EDTA sample was collected by the 
vacutainer system for routine antenatal blood group and antibody screen, and 
a further 6mL EDTA and 4mL into RNA preservative (Tempus tube, Applied 
Biosciences Ltd) sample collected, for the current study. Immediately after 
collection the Tempus tube was shaken for 10-15 seconds (Applied 
Biosystems product insert) to promote cell lysis and stabilisation of free RNA, 
then stored at room temperature pending transfer to storage at 
-20°C within 2 hours of collection.
1500IU (300 pg) of Rhophyllac anti-D immunoglobulin, in a volume of 2mL 
was then administered to the patient via the same butterfly needle.
Rhophyllac is a human polyclonal anti-D product, fractionated from plasma 
donated by volunteers known to have high titre IgG anti-D antibodies, and is 
marketed by CSL Behring (Marburg, Germany). Rhophyllac is presented in 
single use pre-filled 2mL glass syringes. Each syringe nominally containing 
1500IU (300pg) anti-D immunoglobulin and in addition a maximum of 
30pg/mL of other human plasma proteins, of which 10 pg/mL is human 
albumin as a stabiliser, 95% of the remainder being IgG (Rhophyllac package 
insert, CSL Behring). The product is licensed in the UK for intravenous or 
intramuscular injection, and the recommended dose for routine antenatal 
prophylaxis is a single dose between 28 and 30 weeks. Alternative 
prophylaxis regimes are recommended following potentially sensitizing 
episodes. Rarely, allergic (<1 in 100) or anaphylactic (<1 in 1000) reactions 
occur, anti-D recipients are observed in clinic for 10-20 minutes before 
release from hospital (Rhophyllac package insert).
Women remained in clinic for 20 minutes after anti-D administration, then 
travelled to the Blood Transfusion Centre at Seacroft, Leeds some 5 miles
69
away, either by their own transport or taxi arranged by the chief investigator. 
Blood samples were collected into Tempus and EDTA tubes as before, 
nominally 1 hour after Rhophyllac injection (mean 57 minutes range 35-105 
minutes). The final samples were collected on the following day at the Blood 
Transfusion Centre (mean time 21 hours 45 minutes, range 17 hours 15 
minutes to 26 hours 5 minutes, after anti-D administration).
EDTA samples collected at St James’ University Hospital, were transferred to 
a laboratory facility on site and centrifuged for 5 minutes at 3000g (Sorvall 
Legend centrifuge) to remove cellular components from the plasma. Four to 
six, 0.5mL aliquots of plasma were transferred to labelled 1 mL cryotubes 
(Nunc Ltd) using 1mL Pastettes (Alphalabs, Eastleigh, UK). The plasma 
aliquots were transferred to a freezer at -65°C within 1 hour of collection, and 
subsequently to -80° C at the Blood Transfusion Centre for long term storage. 
The same protocol was used for samples collected at the Blood Transfusion 
Centre, but plasma was transferred directly to -80°C storage. The collection 
period comprised 24 clinics held between 6th January and 7th April 2009, with 
a cohort totalling 24 participants.
2.3 Method Estimation Of The Size Of Fetomaternal Haemorrhage By 
Flow Cytometry
2.3.1 Introduction
Kleihauer Betke Technique (KBT) is widely used in Western Europe both as a 
screening and semi-quantitative test. The technique has been well described 
elsewhere (BCSH 2009) and is rapid, inexpensive and requires no specialised 
equipment, but is laborious, difficult to automate and subjective in its 
interpretation. The technique is prone to false positive results associated with 
staining of adult cells in patients with haemoglobinopathies or hereditary 
persistence of fetal haemoglobin. KBT is recognised as having intrinsically 
high intra- and inter-assay variance, associated with the subjectivity in
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interpretation and the relatively small sample examined; typically 50,000 cells 
are observed (BCSH 2009).
Flow cytometry (FC) using monoclonal anti-D directly conjugated to 
fluorochromes offers a robust, objective assay for fetal D+ red cells and is 
generally recommended as the technique of choice for confirmation of positive 
screen results obtained by Kleihauer and for accurate determination of the 
size of FMFI larger than 4mL (BCSH 2009). Though widely accepted as the 
reference technique, FC has a reputation for being less effective at detecting 
small FMH than KBT .
2.3.2 Principles of Flow Cytometry
Flow cytometry is a versatile technique which allows assessment of the 
characteristics of particles by causing a single stream of particles to pass 
through the beam of a laser. Collection of light scattered by the particles 
allows characterisation of size shape and granularity. The presence of 
intracellular and extracellular markers can be detected by fluorescent dyes 
conjugated to specific antibodies. Light emitted by the fluorophores is 
detected and measured by specific detectors (Figure 2.1).
2.3.3 Flow Cytometry for the Estimation of Fetomaternal Haemorrhage
As well as robust laboratory technique, the reliable and reproducible detection 
and estimation of levels of rare events, such as D+ cells in the circulation of a 
D- mother after FMH, is dependent upon the number of events analysed. 
Lower coefficients of variance (CV) and narrower confidence intervals can be 
obtained by increasing sample size (Hoy 1994). This study incorporated an 
investigation of the characteristics of FMH estimation by FC in our laboratory, 
the specific objectives being to determine the lower level of sensitivity of flow 
cytometry in our laboratory in detecting FMH. In this optimisation study 
artificial mixtures of adult RhD- cells and fetal RhD+ cells were prepared in a 
range of concentrations, nominally at and below the 4mL bleed size, above 
which an anti-D greater than the standard 500IU dose would be required.
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These were tested by the standard flow cytometric method (BCSH 2009).
Data was collected in a format to allow comparison of performance across as 
range of data set sizes: 25,000, 50,000, 100,000, 250,000, 500,000, and
1,000,000 event collections for cells incubated both with FITC-conjugated 
BRAD-3 and AEVZ5.3. Both reagents are recombinant IgG antibodies, BRAD- 
3 has been characterised as reacting with all D+ and most partial D 
phenotypes, AEVZ is specific for Varicella zoster, and is not does not react 
specifically with red cells, and is used as an isotype matched control (Lloyd- 
Evans 1999).
Validation was performed using group O ccddee donor and group O CcDee 
fetal red cells less than 48 hours after collection. These were used to prepare 
test mixtures of D+ and D- at the following concentrations: 0.2%, 0.1%,
0.05%, 0.025% and 0.01% (approximately simulating bleed sizes of 4mL,
2mL, 1mL, 0.5mL and 0.025mL) as well as D- cells as a negative control.
Cells were stored in CellStab (DiaMed Ltd) at 4 °C for up to 4 weeks, in 
accordance with the manufacturer’s recommendations.
2.3.4 Method: FMH Detection by Flow Cytometry
EDTA samples from study participants were tested within 48 hours of 
collection. All samples were thoroughly mixed on an orbital mixer for at least 
10 minutes, 100pL aliquots were removed and the red cells were washed 
twice in PBS pH 7.0+/- 0.2 (Inverclyde Biologicals, Bellshill, Scotland). 
Centrifugation for these steps was at 1000g for 2 minutes in a centrifuge with 
a full swing-out rotor, and aspiration was undertaken carefully to avoid 
removal of fetal cells, which are less dense than those of adults (BCSH 
guidelines 2009). Red cell suspensions of approximately 3% were prepared 
by adding 1mL of PBS to the resuspended cell pellet.
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Figure 2.1 Diagram of flow cytometer flow cell. Showing single stream of 
particles created by fluidics of flow cell (A). Laser light incident on particles is 
scattered forward or to the side allowing characterisation of particles by size, 
shape and granularity all of which affect light scatter. The light emitted by any 
adherent fluorophore labelled antibodies is measured by fluorescence 
detectors (B)
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BRAD-3 anti-D and inert AEVZ5.3 control FITC conjugates (both IBGRL, 
Bristol, UK) were prepared by diluting 1 in 10 in PBS. Six, 50 pL aliquots of 
diluted FITC BRAD-3 and AEVZ were dispensed into 75x12mm polyethylene 
tubes and to each was added 50 pL of mixed cell preparation, using clean 
pipette tips for each aliquot. Tubes were covered and incubated for 30 
minutes in the dark in a 37°C water bath. After incubation, each cell 
suspension was washed once in 3mL of PBS with centrifugation at 1000g for 
2 minutes in a centrifuge with a swing-out rotor and the pellet re-suspended in 
1mL of PBS. Analysis was performed on a Beckmann Coulter Epics XL flow 
cytometer at 498 nm. Red cells were gated on forward and side scatter and 
data regions for positive and negative events were set equidistant between 
peaks obtained for a standard 1% control (Figure 2.2).
Each dilution was analysed 5-7 times, and results captured in Windows Excel 
for analysis. The number of events in corresponding AEVZ 5.3 controls was 
subtracted from corresponding counts obtained using FITC BRAD-3 to 
remove background fluorescence, and the estimated size of simulated bleed 
calculated using the standard formula, in which 1800mL is assumed to be the 
standard circulating maternal red cell volume, and fetal red cells are assumed 
to be 22% larger than adult red cells (Mollinson 1972).
Formula for calculation of the volume of D+ fetal red cell in the maternal 
circulation
% fetal cells x 1800 x 122 
100 100
p values for the difference between means of each cell dilution with the D- 
data, 95% confidence intervals, and %CV for each dilution were calculated 
using Microsoft Excel software.
Samples from study participants were run by the same protocol, except that 
data acquisition was managed to collect a total of 1x106 events in 2 aliquots.
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Total: 64998 Events
Figure 2.2 , Scatter graph (left) showing gate (B) around red cell population 
drawn on forward (y axis) and side scatter (x axis), and histogram (right) 
showing fluorescence (x-axis) and events gathered (y-axis) and the position of 
data regions, defined by vertical red line. Unstained (D- cell) events are in the 
population on the left, stained (D+ cells) to the right.
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2.4 Measurement of Plasma Cytokine Concentration by Flow Cytometry
2.4.1 Introduction
Cytokine detection by flow cytometry is a technique which uses the capacity of 
flow cytometry to measure multiple analytes by means of specific monoclonal 
antibodies immobilised on beads, which can be recognised by pre-determined 
fluorescent characteristics when exposed to laser light at 635nm. Samples 
containing the analyte are mixed with the beads and bound material is 
detected in a sandwich assay by adding fluorochrome labelled detector 
antibody (Figure 2.3). Measurement of fluorescence from the detector reagent 
when exposed to light at 532nm, associated with each bead type, allows rapid 
and cost effective analysis of multiple analytes from small samples of test 
material (Becton Dickinson, product insert). Quantification is achieved by 
comparison with reactions obtained with recombinant cytokine standards 
(Figure 2.4) The technique offers similar sensitivity to standard ELISA, though 
the range of analytes covered by available, validated flow cytometry assays is 
not as extensive, in particular TGF-p, a key analyte for this study was 
unavailable as a bead assay.
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Figure 2.3 Multiplex bead assay. Analyte capture, and reporter mechanisms in 
multiplex cytokine flow cytometry assay, showing fluorochrome labelled bead 
with bound antibody (red circle), analyte (yellow triangle) and reporter 
antibody labelled with fluorochrome (orange circle)
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2.4.2 Method for Cytokine Detection by Flow Cytometry
Cytokines IFN-y, IL-ip, IL-4, IL-10, IL-6, IL-12p70, IL-17A, TNF-a were 
assayed by flow cytometry Using Becton Dickinson reagent kits. All reagents 
and consumables were obtained from Becton Dickinson, unless stated 
otherwise. Kits included lyophilised cytokine preparations for use as 
standards. See Figure 2.5 for summary of method. Standard samples were 
prepared by pooling the lyophilised standards for all the analytes in a conical 
15mL plastic tube labelled “Top Standard”, and reconstituted by the addition 
of 4mL of assay diluent. The tube was mixed gently and left on ice in the dark 
for 30 minutes. Dilutions for the standard curve were prepared by adding 
500pL of assay diluent to each of 9, 12x75mm plastic tubes labelled 1:2, 1:4, 
1:8;, 1:16: 1:32 1 :64:1:128, and 1:256, the last tube labelled “true zero” 
contained only dilution buffer. A 500pL aliquot of the top standard was 
pipetted into the tube labelled 1:2, the contents were well mixed and doubling 
dilutions performed through to the 1:256 standard.
The capture beads sufficient for 90 tests (10 standards+72 participant 
samples+working volume) were prepared, pooled and placed in a labelled 
tube on ice in the dark until required. The volume of PE detection reagent 
required was calculated as 1 pL per analyte per test and dispensed into a 
labelled tube. To this was added 45pL of each detector, labelled PE detection 
reagent, and stored on ice in the dark until required.
Tests were prepared in polypropylene tubes (ELKAY laboratories Ltd, 
Basingstoke, UK) by adding 2 5 jliL of bead mixture to each test and standard 
tube. 25pL of standard or freshly thawed test plasma was added to each 
labelled tube. Tests were incubated for 1 hour in the dark at ambient 
temperature to allow binding of analyte to antibody immobilised on capture 
beads.
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Cytokine Flow Cytometry
Incubate
Incubate
2h
Prepare capture beads Prepare PE detection reagent
Dispense standards/test plasma 
into assay tube
Dispense capture beads to 
assay tubes
Prepare standards/ test plasma
Wash, transfer to microplate and 
analyse
Add detection reagent
Figure 2.5 Workflow diagram for cytokine detection by flow cytometry 
method.
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After 1 hour, samples were washed once in 300jaL of wash buffer centrifuged for 
5 minutes at 200g (Sorvall Legend Centrifuge) and 25jaL of detection reagent 
was added to each tube followed by mixing by gentle pipetting. Samples were 
incubated for a further 2 hours in the dark at room temperature to allow PE 
conjugated antibody to bind to analyte bound to capture beads. After incubation 
samples were washed once as before and the supernatant was aspirated to 
leave approximately 50pL in the tube, and a further 200jiL of wash buffer added. 
Samples were transferred using a pipette to a 96 well Falcon microplate with 
gentle mixing. Samples were analysed on a Facs Array flow cytometer (BD 
Biosciences, Oxford , UK), and data gathered using Facs Array system software. 
Analysis and reporting was through FCAP array analysis software (SoftFlow Inc, 
Minnesota, USA).
Beads were identified by type within the multiplex analysis, within gates drawn 
from red and near infra-red fluorescence characteristics associated with each 
bead, and detected at 635nm filter. Analyte was detected from red fluorescence 
from PE conjugated detector reagent at 532nm.
2.6 Measurement of Plasma Cytokine Concentration by ELISA
2.5.1 Introduction
ELISA is a well established technique widely used in immunology and virology, 
which can be used to detect soluble antigen or antibody. A ligand for the analyte 
which may be antibody or antigen is fixed to the solid phase. The test material is 
added and any analyte present binds to the solid phase. Free material is washed 
away and peroxidase conjugated secondary antibody added followed by washing 
and then addition of substrate, tetramethylbenzidine chromogen (TMB) which, on 
exposure to the peroxidase conjugated antibody, causes a measurable colour 
change proportional to the amount of bound analyte. A pure, standard 
preparation of the analyte is required to allow the results of the assay to be
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expressed as a concentration of analyte, by preparation of a calibration curve 
(Janeway 2001).
A variation of the technique, used in this study to quantify TGF-p, IL-1 and IL-1 ra, 
is the sandwich or antigen capture ELISA. The principle of which is that a 
monoclonal antibody specific for the analyte is bound to the wells of the test 
microplate (Figure 2.6). The target molecule added to wells in standards or test 
samples binds to the immobilised monoclonal antibody. After the initial 
incubation, wells are washed to remove unbound material and a conjugate of 
enzyme and analyte-specific monoclonal antibody added. An incubation phase 
allows the development of the sandwich of analyte between plate bound and 
enzyme conjugated monoclonal antibodies. A further wash stage removes free 
conjugated antibody. Enzyme substrate is added resulting in a colour change 
proportionate to the amount of analyte bound in the initial incubation. After a 
further incubation the colour reaction is stopped by the addition of 2N sulphuric 
acid. Absorbance is measured at 450nm with a correction for optical variation of 
the plate made at 570nm, which is subtracted from the 450nm reading. Values 
obtained from the standards were used to prepare a standard curve, the slope of 
which was calculated and used to calculate analyte concentrations in test 
samples using Microsoft Excel software.
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Analyte Substrate
K.
HgP
Y v ' y
\  ,-u j TMBAntibody- h r p  Substrate
coated microplate j  i
V Y ^Stop Yellow
Figure 2.6 Illustration of sandwich ELISA, showing monoclonal antibody 
immobilised on solid phase of microplate capturing analyte (left). The reaction is 
detected by addition of horse radish peroxidase labelled antibody binding to 
captured analyte, then causing measurable blue to yellow colour change on the 
addition of TMB substrate (right)
Diagram reproduced with permission from R+D systems website 
http://www.rndsvstems.com/product detail obiectname elisa assay product.as 
px
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2.5.2 Method for Measuring the Concentration of IL-1 p by ELISA
All kits were supplied by R+D systems Ltd. Tests and assays were performed in 
accordance with the manufacturer’s instructions (R+D Systems Ltd, Europe). 
Briefly, all reagents were brought to room temperature. IL-1 p standard was 
prepared by adding 5mL of calibration diluent (product RD6C) to the supplied 
lyophilised standard to prepare a 250pg/mL standard. Reconstitution was over 30 
minutes with occasional gentle mixing. Dilutions were prepared by adding 500pL 
of calibrator diluent to each of six 1 mL polypropylene tubes (Eppendorf, Hamburg 
Germany), then adding 500pL of reconstituted standard to the first tube. Doubling 
dilutions were prepared using a clean pipette tip for each step, tubes were mixed 
thoroughly by vortex to prepare standards of: 250, 125, 62.5, 31.2, 15.6, 7.8, and 
3.9 pg/mL. The zero control was the calibrator diluent.
Plates were removed from foil pouches, and 50juL of assay diluent (RD1-83) 
added to each well. Using a clean pipette tip for each, 200pL of standard, diluent 
control or test plasma was added to duplicate wells. Plates were sealed with 
adhesive strip and incubated for 2 hours at room temperature. Wash buffer was 
prepared, by adding 20mL of supplied concentrate to 480mL of deionised water. 
Plates were aspirated by inversion and flicking the contents of wells into a sink, 
wash buffer was added to fill the wells, using a wash bottle, a total of 3 washes 
were performed. After each wash, the buffer was removed as above and the 
plate vigorously blotted on a paper towel.
200^L of anti-IL-1(3 secondary antibody conjugated to horseradish peroxidase 
was added to each well. Plates were sealed and incubated for a further 2 hours. 
Substrate solution was prepared by mixing equal volumes of stabilized hydrogen 
peroxide and TMB chromogen immediately before use.
After incubation, plates were washed three times as before, blotted and 200pL of 
substrate solution added to all wells. Plates were incubated uncovered at room 
temperature in the dark for 20 minutes. The colour reaction was stopped by the
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addition of 50pL of 2N sulphuric acid and a colour change from blue to yellow 
was noted. Tests were read on a Wallac plate reader using Wallac Software 
reading at 450nm. Readings at 570nm were made and subtracted from 450nm 
readings, to correct for any optical imperfections in the plate.
2.5.3 Method for Measurement of IL-1ra Concentration by ELISA
All reagents were brought to room temperature. IL-1 ra standard was prepared by 
adding 1.0mL of deionised water to the supplied lyophilised standard to prepare a 
20,000 pg/mL standard. Reconstitution was over 30 minutes, with occasional 
gentle mixing. Dilutions were prepared by adding 900pL of calibrator diluent 
(RD5-33) to the first of 7 polypropylene tubes, and 500pL to the remaining 6 
tubes. One hundred pL of reconstituted standard were added to the first tube. 
Doubling dilutions were prepared using a clean pipette tip for each step, and 
vortexing dilutions to facilitate thorough mixing, to prepare standards of 2,000,
1,000, 500, 250,125, 62.5, and 31.2 pg/mL. The zero control was the calibrator 
diluent.
Plates were removed from foil pouches, and 100pL of Assay Diluent (RD1S) 
added to each well. Using a clean pipette tip for each dispense 100pL, of 
standard, diluent control or test plasma was added to duplicate wells. Plates were 
sealed with adhesive strip and incubated for 2 hours at room temperature. Wash 
buffer was prepared, by adding 20mL of supplied concentrate to 480mL of 
deionised water. Plates were washed as above for the 1-1(3 ELISA assay.
200pL of anti-IL-1 ra secondary antibody conjugated to horse radish peroxidase 
was added to each well and plates were sealed and incubated for a further 2 
hours. Tests were completed and read as in 2.5.2.
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2.5.4 Method for Measurement of TGF-(31 Concentration by ELISA
TGF-(31 is secreted as a latent complex with another protein, which must be 
dissociated before the active form can be measured (Lawrence 2001). In this 
assay latent secreted TGF-(31 was activated to the immunoreactive form by 
acidification. 40pL of each test plasma sample was placed in a polypropylene 
tube and 20pL of 1N HCI added. Acidified samples were incubated on the bench 
at room temperature for 10 minutes, then neutralised with 20pL of 1.2N 
NaOH/0.5M Hepes (Sigma Ltd, Poole, UK) to pH 7.2-7.6.
All reagents were brought to room temperature. TGF-p1 standard was prepared 
by adding 2.0mL of calibrator diluent RD5-53 to the supplied lyophilised standard 
to prepare a 2,000 pg/mL standard. Reconstitution was over 5 minutes with 
gentle agitation. Dilutions were prepared by adding 400juL of calibrator diluent 
(RD5-53) to each of 6 polypropylene tubes. 400pL of reconstituted standard were 
added to the first tube. Doubling dilutions were prepared using a clean pipette tip 
for each step, and vortexing dilutions to facilitate thorough mixing, to prepare 
standards of: 2,000, 1,000, 500, 250, 125, 62.5, and 31.2 pg/mL. The zero 
control was calibrator diluent.
Plasma samples from participants were further diluted by adding 10pL of 
activated plasma to 190pL Calibrator Diluent in a polypropylene tube to make a 
final dilution of 1 in 40). Plates were removed from foil pouches, and 50pL of 
assay diluent (RD1-73) to each well. Using a clean pipette tip for each dispense, 
50juL of standard, diluent, control or diluted test plasma was added to duplicate 
wells. Tests were completed and read as in 2.5.2.
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2.6 Method for Reverse Transcriptase Quantitative Real Time PCR for 
Measurement of IL-1ra and TGF-p1 mRNA
2.6.1 Introduction
Real time quantitative PCR allows measurement of mRNA, using synthetic 
oligonuceotide primers, and is a well established technique for quantifying the 
expression of specifically transcribed genes in cells and tissues. By synthesising 
cDNA from RNA using reverse transcriptase (RT) it is possible to assess those 
genes which are expressed by RT PCR. The more recent development of real 
time PCR facilitated by the development of probes, which emit fluorescence only 
at the extension phase of the PCR cycle, allows assessment of the level of 
expression of genes (Overburgh 2003).
In the current study TaqMan technology was used (Applied Biosystems, Foster 
City, California, USA). TaqMan probes are designed to bind to cDNA in the target 
sequence between forward and reverse primers and carry both a reporter 
fluorophore and a quencher, and do not fluoresce when intact. As Taq 
polymerase effects extension of the new DNA chain its exonuclease activity 
degrades the Taq probe, releasing the reporter from the quencher, resulting in 
measurable fluorescence (Figure 2.7). The measured fluorescence is 
proportional to the quantity of specific cDNA for that gene in the sample, and can 
be expressed numerically as the number of PCR cycles required to raise the 
level of fluorescence above background or cycle threshold (CT value, Figure 2.8). 
Relative gene expression is best measured by comparison with an endogenous 
control gene, which is selected for widespread and consistent expression 
between tissues (Bustin 2005). The difference in CT values between endogenous 
control gene and test gene is expressed as ACT, and changes in ACT across a 
time series, as in the present study are described as AACT.
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5’ Nuclease Assay Using TaqMan® Probes
Forward
Primer
!3.--------------------------------------------------------------------------- 5 ’
Reverse
Primer
PCR specificity (primer)
Hybridization specificity (probe)
5’ Nuclease Assay Using TaqMan® Probes
5’
TaqMan
3’ 
5’
Fluorescence Resonance Energy Transfer (FRET) from 
high energy (Reporter) to low energy (Quencher) dye
No reporter signal with intact probe
Figure 2.7 Illustration of TaqMan chemistry. The primer bonds to specific DNA 
sequence with reporter and quencher in close proximity (top). Taqman 5’ 
exonuclease activity releases quencher resulting in fluorescent signal (bottom). 
Reproduced with permission of Applied Biosystems Ltd
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Comparison of Target Gene and Endogenous Control
ARn
ACt = 2 4 - 1 4  = 10
Ct = 24 CyclesCt =14
□  Endogenous control
□  Target gene
Figure 2.8 Illustration of amplification curves for analyte and endogenous control. 
Showing CT vale on the x-axis, and fluorescence on the y-axis, the point at which 
fluorescence exceeds background, and ACT value representing the difference in 
CT values between the test gene and the endogenous control 
Reproduced with permission from AB systems
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2.6.2 RNA Extraction
Blood samples collected in Tempus tubes (Applied Biosystems Ltd) were stored 
at -20°C until extraction (period 6-10 months). The supplier’s product advice 
indicates that mRNA is stable indefinitely when stored in this way. Extraction and 
purification was performed using Tempus Spin RNA extraction kits (Applied 
Biosystems Ltd). All reagents and consumables used were supplied with the kit, 
unless otherwise stated.
Samples were thawed at room temperature and decanted into clean, labelled 
50mL tubes (Falcon, BD UK Ltd). Phosphate Buffered Saline (PBS) was added 
to bring the volume to 12mL (typically 3mL of PBS was added). Each tube was 
mixed by vortex for 30 seconds then centrifuged at 3000g for 30 minutes at 4°C 
(Sorvall 6000D). After centrifugation, the supernatant was gently poured off and 
the RNA pellet re-suspended by the addition of 400^iL of RNA purification 
suspension solution, with a brief vortex mix. Re-suspended RNA samples were 
stored on ice between process steps from this point.
RNA purification filters were labelled and pre-wetted with 100pL of RNA 
purification wash solution 1, taking care to dispense the solution to the centre of 
the filter, the re-suspended RNA was added to filters, which were placed inside 
RNase free, 2mL elution tubes. Tubes were centrifuged at 16,000g for 30 
seconds at4°C (Hereus Fresco 17). All subsequent centrifugation steps used this 
protocol, unless stated otherwise. After centrifugation, filters were removed; liquid 
waste discarded from the bottom of the elution tube, and filters replaced. 500pL 
of purification wash solution 1 was added to each filter before centrifugation and 
waste then discarded as before. Two washes were performed using Purification 
Wash Solution 2, then the filters were air dried by performing one further 
centrifugation step without addition of wash solution. Filters were transferred to 
clean, labelled elution tubes, and elution of RNA from the filter performed, by 
adding 100pL of nucleic acid elution purification solution, then incubating the tube
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at 70°C in a heating block for 2 minutes. Tubes were centrifuged and the eluate 
harvested and returned to the filter. Tubes were centrifuged again, this time at 
16,000g for 2 minutes at 4°C. Filters were removed and discarded. The purified 
RNA was transferred to clean, labelled PCR grade 0.5mL Eppendorf tubes 
(Sigma, Poole, UK) in four 20pL aliquots, which were immediately transferred to - 
80°C for storage, with a small additional aliquot reserved on ice for assessment.
The quantity of RNA extracted from each sample was assessed using Nanodrop 
ND-1000 spectrophotometer by measuring the percentage absorbance of light at 
280nm, which is proportional to the concentration of analyte. The ratio of 
absorbance by the sample at 260 and 280 nm indicates sample purity, a ratio of 
greater than 2 representing acceptably pure RNA. (nanodrop manual 
www.nanodrop.com).
2.6.3 cDNA Synthesis Method
cDNA synthesis was performed using Superscript II Reverse Transcriptase (RT) 
(Applied Biosystems Ltd) as part of a mastermix solution prepared on ice as 
described in Table 2.1.
Reagent Supplier Product code X1 OiL)
DEPC treated water Invitrogen 750024 2
5x 1st strand buffer Invitrogen 18065-014 4
Dithiothreitol 0.1M Invitrogen 2
RNase out Invitrogen 1077-019 0.5
Random primers Invitrogen 48190-011 0.5
dNTP Bioline Bio-39025 0.5
Superscript II RT Invitrogen 18065-014 0.5
Table 2.1 Reverse transcriptase mastermix reagent volumes for 1 preparation 
(x1). Mastermix for multiple preparations prepared to the same formula.
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Mastermix was prepared without reverse transcriptase and a 9.5pL aliquot 
removed for the No RT control. Reverse transcriptase was added to the 
mastermix, which was mixed gently by pipette aspiration and transferred to 
labelled, RNase free Eppendorf tubes in 1 OjliL aliquots. RNA samples were 
removed from -80°C storage thawed on ice and 20pL added to 10pL aliquots of 
mastermix. Negative control tubes were prepared as in Table 2.2
Control Mastermix no RT Mastermix +RT DEPC water Pooled random RNA*
No RT 9.5pL 10.5pL
Negative 10pL 10piL
Table 2.2 qPCR Negative control reagent volumes. *Prepared from a pool of 4 
randomly selected participant RNA samples from the study.
All tubes were capped, spun gently to ensure mixing of reagents, then incubated 
for 2 hours in a heating block (Biometra trio thermablock) at 42°C, and 
synthesised cDNA transferred to -20°C for storage.
2.6.4 Method for the measurement of IL-1ra and TGF-p1 mRNA by q-PCR
PCR primer mix was prepared on ice in RNase free 1.5mL Eppendorf containers 
as detailed in Table 2.3
Reagent Supplier Product code Per well(pL)
DEPC treated water InVitrogen 750024 3.5
TAQMAN mastermix
Applied Biosystems 4366072 5
Gene Specific Primer Applied Biosystems See table 2.4 0.5
Table 2.3 PCR primer mix
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TaqMan probe Supplier Product
GAPDH Applied Biosystems Hs99999905-m1
Cyclophilin Applied Biosystems Hs99999904-m1
B actin Applied Biosystems Hs99999903-m1
IL-1 ra Applied Biosystems Hs00610318-m1
TGF-p Applied Biosystems Hs00893626-m1
Table 2. 4 Primers used in study for assessing test RNA and as endogenous 
controls
PCR primer mix was transferred to labelled 0.5mL RNase free Eppendorf tubes 
in 18pL aliquots. cDNA samples were retrieved from storage, thawed on ice, then 
2pL aliquots added to primer mix. Controls were included from each batch of 
cDNA synthesis performed. All tubes were centrifuged briefly to ensure reagents 
were mixed.
Dilution templates were obtained for the endogenous control and each target 
gene by preparing dilutions of pooled cDNA from the study at neat, 1/10, 1/100, 
and 1/1000 to demonstrate the efficiency of the primers. Tests were transferred 
to Microamp Optical 96 well plates (Applied Biosystems) in duplicate in 9pL 
aliquots. Plates were sealed with adhesive sealers (Applied Biosystems) and 
centrifuged briefly (Sorvall 6000D) to ensure plate contents were mixed and 
located at the bottom of the wells. PCR and analysis were performed using the 
StepOne Plus instrument (Applied Biosystems Ltd).
2.6.5 Quantification of IL-1ra and TGF-p1 mRNA from qPCR Results
CT values were captured from StepOnePlus software (Applied Biosystems Ltd), 
and the mean of values of replicates of endogenous control target gene tests 
calculated. The differences between the CT for the endogenous control gene and 
target genes for the pre-test sample from each participant were established and
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expressed as ACT. The difference between this value and the ACT of the one 
hour and twenty four hour post- test samples was calculated and expressed as 
AACT. Fold changes were calculated using the formula.
Fold Change= 2*AACT
2.7 Statistical Analysis
2.7.1 FMH Estimation
Estimated FMH, coefficient of variation (CV), and standard deviation were all 
calculated using Microsoft Excel software. The significance of difference between 
means of multiple validation mixtures and samples from D+ and D- fetus groups 
was calculated by ANOVA, using Microsoft Excel software.
2.7.2 ELISA and qPCR
Fold changes from raw data were calculated using Microsoft Excel software. 
Normality of fold change data was determined using Kolmogorov-Smirnoff, and 
significance of means between D+ and D- fetus groups with independent T test.. 
SPSS software was used for these calculations (SPSS Inc, Chicago, Illinois).
2.7.3 Combined Results
The proportion of participants undergoing fold change >1.5 detected either by 
ELISA or qPCR was calculated. The significance of the difference between 
proportions in D+ and D- fetus groups was calculated using Chi2.
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3 Results
3.1 Fetal Blood Groups
The blood groups of babies born to women participating in the study were 
obtained after all laboratory tests were completed, by interrogating the Patient 
Information System of Leeds Teaching Hospitals. All 24 fetal groups were 
available, having been determined after delivery and are listed in Table 3.1.
17/24 (70.8%) neonates were RhD+, and these participants were allocated to the 
D+ fetus group of the study; 7/24 (29.2%) neonates were RhD- and these 
participants were allocated to the D- fetus group. Typically 40% of RhD- women 
in the UK carry RhD- fetuses (NICE 2002). In this study the proportion of RhD- 
fetuses is lower than might be expected than that expected using data extracted 
from population-scale studies. This finding can be explained by the relatively 
small size of the sample in the current study..
3.2 FMH by Flow Cytometry
3.2.1 Flow Cytometry Optimization Results
Using the standard protocol (BCSH 2009), acquiring 500,000 events per test, the 
smallest simulated bleed which could be detected with a significant difference 
between the counts in the D- and test samples was 0.05% (approximately 1mL, 
Table 3.2e ) Broadly, protocols acquiring fewer events permitted similar levels of 
discrimination, though coefficients of variation were higher and the 95% 
confidence intervals were wider, suggesting that the accuracy of the test is lower 
than when more events are acquired (Tables 3.2 a-f). By considering all the 
accumulated data, collecting 1 0 6 events the sensitivity of the test was increased 
such that a simulated bleed of 0.025% (approximately 0.5mL) could be detected
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Participant Maternal ABO and Fetal ABO and RhD
number RhD group Group
1 A- AB-
2 0 - 0 +
3 0 - 0 +
4 A- 0 +
5 0 - 0 +
6 A- A+
7 A- 0 +
8 0 - 0 -
9 0 - 0 +
1 0 A- A+
1 1 A- B-
1 2 0 - A+
13 AB- A-
14 0 - A-
15 A- A-
16 A- 0 +
17 0 - A+
18 0 - A+
19 A- A+
2 0 0 - 0 +
2 1 A- 0 +
2 2 A- A-
23 A- 0 +
24 A- A+
Table 3.1 Maternal and fetal blood groups of the participants in the study. 
Participants invited to the study based on previously determined RhD- group. 
Approximately 40% of RhD- mothers in the UK carry RhD- babies, in this cohort 
29.1% of the babies were RhD-.
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with a significant difference between the number of events in positive and 
negative populations (Table 3.2f).
Using the 500,000 event protocol with a simulated bleed of 0.2% (approximately 
4mL) the confidence interval at the 95% level in this test was 0.72 (lower and 
upper limits 3.08-3.80) (Table 3.2e) with a percentage coefficient of variation 
(CV) of 8.13. Increasing the events acquired to 106 reduced both the confidence 
interval at the 95% level to 0.578 (lower and upper limits 3.19-3.77) and the % 
CV to 6.46 (Table 3.2f). Protocols acquiring fewer events had wider 95% 
confidence intervals, using 50,000 events for the simulated 0.2% bleed this was 
1.156 (lower and upper limits 2.498-3.654), %CV 14.1 (Tables 3.2 a-d ).
Based on this assessment a protocol acquiring 1x106 events was selected for 
use in this study.
3.2.2 Results of FMH Investigation on Pre-Treatment Samples
FMH estimations were performed on pre-treatment samples from all 24 
participants using the 1x106 event protocol based on the data obtained in 3.1. 
(Appendix V). In each group, some tests gave marginally higher event-counts 
with the control than with anti-D, hence indicated in negative bleed values; this is 
commonly encountered in clinical samples. In these cases the FMH values were 
set to zero for subsequent calculations.
Considering the data by D+ and D- fetus groups of the study, the range of 
detected apparent FMH, the mean FMH and standard deviation were similar in 
each group (Table 3.3). Applying the independent T test to determine the 
significance of difference in the mean FMH between means of D+ and D- fetus 
groups, indicate that the differences are not significant (p=0.779).
FMH results in the D- fetus group should have approximated to zero. Even if 
FMH had occurred, there should have been no binding of FITC-anti-D. Positive
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values up to 0.98 mL (mean 0.31 mL, SD 0.37, n=7)) in this group may be the 
result of non-specific binding of FITC anti-D to red cells or other particles in the 
samples. Similar mean and range values for the D+ fetus group (mean 0.37mL 
range 0-1.4mL, SD 0.41) were obtained and indicated that no large FMH (>4mL) 
had occurred among the cohort before the study samples were collected.
The SD obtained in the participant’s samples is much higher than that in the 
validation exercise performed, again suggesting that this protocol is insufficiently 
robust to detect or measure FMH at these levels, which are far below those 
required for routine testing performed on clinical samples (BCSH 2009).
3.3 Cytokine Measurement by Flow Cytometry
Eight cytokines were tested in all 72 samples using a multiplex assay (Figure 
3.1). Of the samples tested, fluorescence above background was detected only 
sporadically, and was above the bottom standard in only 4 tests, which were all 
for IL-17a, each in one sample from separate patients, No pattern could be 
inferred from these results (appendix VI).
Test sensitivity was adequate to detect level of circulating analyte, consistent with 
those reported by other authors who measured elevated cytokine concentrations 
by ELISA in disease states or in response to treatment (Table 3.3) (Makhseed 
2000, Jonsson 2006, Branch 2006).
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Tables 3.2a-c Results of FMH optimisation. Nominal FMH of spiked samples, 
mean measured FMH and associated standard deviation (SD) ANOVA p values 
for difference between means of negative control and each D+/D- mixture, and 
95% confidence interval (Cl) expressed for each nominal FMH size (4.0-0.2mL) 
using each flow cytometry protocol (25,000-100,000 events)
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Table 3.2a Results of fold change measurement of prepared mixtures of D+ and
D- cells mimicking FMH samples acquiring 25,000 events
Nominal FMH 
(mL)
Measured FMH 
(mL) CV (%) SD P 95% Cl
4.0 3.145 11.85 0.295 <0.005 0.962
2 . 0 2.039 7.53 0.137 <0.005 0.446
1 . 0 0.847 52.40 0.432 <0.005 1.41
0.5 0.069 81.30 0.225 0.64 0.734
0 . 2 -0.173 178.24 0.294 0.556 0.739
Table 3.2b Results of fold change measurement of prepared mixtures of D+ and 
D- cells mimicking FMH samples acquiring 50,000 event data
Nominal FMH 
(mL)
Measured FMH 
(mL) CV (%) SD P 95% Cl
4.0 3.076 .17.57 0.354 <0.005 1.156
2 . 0 1.901 23.41 0.314 <0.005 3.024
1 . 0 0.186 35.75 0.408 <0.005 1.331
0.5 -0.095 91.29 0.288 0.39 0.94
0 . 2 -0.106 181.69 0.5 0.856 1.257
Table 3.2c Results of fold change measurement of prepared mixtures of D+ and 
D- cells mimicking FMH samples acquiring 100,000 events
Nominal FMH 
(mL)
Measured FMH 
(mL)
CV (%)
SD P 95% Cl
4.0 3.365 8.71 0.226 <0.005 0.738
2 . 0 1.564 16.92 0.209 <0.005 0.681
1 . 0 1.024 29.02 0.231 <0.005 0.752
0.5 0.259 78.08 0.175 0.047 0.57
0 . 2 -0.109 298.93 0.194 0.467 0.488
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Tables 3.2d-f Results of FMH optimisation. Nominal FMH of spiked samples, 
mean measured FMH and associated standard deviation (SD) ANOVA p values 
for difference between means of negative control and each D+/D- mixture, and 
95% confidence interval (Cl), expressed for each nominal FMH size (4.0-0.2mL) 
using each flow cytometry protocol (250,000-106 events)
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Table 3.2d Results of fold change measurement of prepared mixtures of D+ and
D- cells mimicking FMH samples acquiring 250,000 events
Nominal FMH 
(mL)
Measured FMH 
(mL)
CV (%)
SD P 95% Cl
4.0 3.164 11.64 0.374 <0.005 1 . 2 2
2 . 0 2.065 4.05 0 . 2 2 1 <0.005 0.722
1 . 0 0.601 24.60 0.433 <0.005 1.413
0.5 0.573 126.68 0.515 0.063 1.41
0 . 2 -0.228 129.04 0.794 0.649 1.997
Table 3.2e Results of fold change measurement of prepared mixtures of D+ and 
D- cells mimicking FMH samples acquiring 500,000 events
Nominal FMH 
(mL)
Measured FMH 
(mL)
CV (%)
SD P 95% Cl
4.0 3.446 8.13 0 . 2 2 2 <0.005 0.723
2 . 0 1.9 16.01 0.24 ,0.005 0.782
1 . 0 0.96 21.23 0.175 <0.005 1.242
0.5 0.207 66.35 0.154 0.065 0.499
0 . 2 0.082 136.6 0.18 0.419 0.3224
Table 3.2f Results of fold change measurement of prepared mixtures of D+ and 
D- cells mimicking FMH samples acquiring 106 events.
Nominal FMH 
(mL)
Measured FMH 
(mL)
CV(%)
SD P 95% Cl
4.0 3.479 6.46 0.177 <0.005 0.578
2 . 0 1.883 10.14 0.156 <0.005 0.51
1 . 0 0.925 16.80 0.136 <0.005 0.442
0.5 0.283 74.00 0.171 0.031 0.565
0 . 2 0.055 100.96 0.16 0.389 0.403
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Analyte
Concentration in lowest detected standard sample
(pg/mL)
IFN-y 18.16
IL-1 (3 10.35
IL-4 9.58
IL-10 9.62
IL- 6 9.63
IL-12p70 8.54
IL-17A 16.38
TNF-a 10.3
Table 3.3 Lower level of detectability of analytes tested by cytokine flow 
cytometry
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3.4 The Measurement of IL-1 p, IL-1ra, and TGF-01 by ELISA in Participant 
Plasma Samples
Three analytes were tested by ELISA; selected as the most significant changes 
in Branch’s data (2006) and IL-1 (3 to allow comparison with IL-1 ra. The raw data 
are included as Appendix VII.
All samples were assayed in duplicate and the mean absorbance of the 
replicates at 450nm calculated. The mean absorbance of the replicates at 570nm 
was calculated and subtracted from the 450nm value to compensate for optical 
variation of the wells. Standard curves were constructed for each analyte and 
the slope used to calculate the analyte concentration in the sample using 
Microsoft Excel software (Figures 3.2-3.4). Final plasma concentration was 
determined by multiplying by any dilution factor of the plasma in the test method 
(Appendix VII).
3.4.1 Results of ELISA Measurement of Concentration of IL-1 p, IL-1ra and 
TGF-p1 in Participant Plasma Samples
Fold change values were calculated by dividing the value of the analyte 
concentration in the 1 hour or 24 hour sample by that in the pre-test sample. 
Statistical analysis was performed using SPSS software version 17.0 (SPSS inc, 
Chicago, Illinois). The significance of the difference between means on normally 
distributed data was assessed using independent samples T test, normality of 
data was assessed using Kolmogorov-Smirnov test values >0.05 were assumed 
to indicate normality, and all data series in this study were found to have normal 
distribution.
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3.4.2 The Results of Measurement of IL-1 p Concentration in Participant 
Plasma Samples by ELISA
The results of ELISA assay of IL-113 concentration in the study samples are 
shown in Table 3.4. A summary of the results expressed as analyte 
concentration (Table 3.5) and fold change (Table 3.6) are included. Of the 17 
participants in the D+ fetus group and 7 participants in the D- fetus group none 
had fold change in IL-1 p concentration greater that 1.5, or below 0.5 in the 1 hour 
or 24 hour samples. There was no significant difference between means of fold 
change in D+ and D- fetus groups. Statistical analysis of IL-1 p fold change data 
is shown in Table 3.6. Correlation in the fold change results obtained for each 
participant at 1 and 24 hours was strong in both D+ and D- fetus groups 
(Pearsons’s correlation coefficient 0.714, p=0.002) the D- fetus group (0.696, 
p=0.072, therefore not significant in the D- fetus group n=7) (Figure 3.5).
Graphical representations are included of positive and negative fold changes 
(Figure 3.6), and comparing the range of fold changes in each group (Figure 3.7)
3.4.3 The Results of Measurement of IL-1ra Concentration in Participant 
Plasma Samples by ELISA
The results of ELISA assay of IL-1 ra concentration in study samples are shown in 
Table 3.7. A summary of the results expressed as analyte concentration are 
included (Table 3.8) and fold change (Table 3.9).IL-1 ra concentrations through 
the time series are shown (Figures 3.8, and 3.9). One participant in the D+ fetus 
group (1 hour sample) and one in the D- fetus group (24 hour sample) had fold 
changes of IL-1 ra of greater than 1.5 and none below 0.5. Of the two increases of 
greater than 1.5 fold, participant 7 in the D+ fetus group had a concentration of 
IL-1 ra below, but within 1SD of the group mean before treatment. The participant 
in the D-fetus group had an IL-1 ra concentration above, but within 1SD of the 
group mean. No significant difference between means of fold change in D+ and 
D- fetus groups was noted when calculated by independent T test (p=0.575 and
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0.334 respectively. (Table 3.9). Correlation in the fold change results obtained for 
each participant at one and twenty four hours was strong in the D+ fetus group 
(Pearsons's correlation coefficient 0.739, p=0.001) but not the D- fetus group 
(0.417, p=0.355) (Figure 3.10). Graphical representations are included of 
positive and negative fold changes (Figure 3.11), and comparing range of fold 
change in each group (Figure 3.12).
3.4.4 The Results of Measurement of TGF-pi Concentration in Participant 
Plasma Samples by ELISA
TGF-pi ELISA results are shown in Table 3.10, and summarised in Table 3.11. 
Fold change analysis is in Table 3.12. ELISA results through the time series are 
included (Figures 3.13 and 3.14). In the D+ fetus group, 8/17 participants had 
fold increases in TGF-pi in either the 1 hour (4) or 24 hour (4) samples, or both 
(3) and 8  had decreases below 0.5 in either the 1 hour (4), 24 hour (4) samples, 
or both (1). In the D- fetus group one participant had a fold increase in TGF-(31 
greater than 1.5 at 1 hour. No significant difference between means of fold 
change in D+ and D- fetus groups was noted by independent T test (p=0.273 and 
0.140 respectively).Correlation in the fold change results obtained with each 
participant at 1 and 24 hours was weak in the D+ fetus group (Pearsons’s 
correlation coefficient 0.327, p=0.200) but stronger in the D- fetus group (0.778, 
p=0.04). Of the 8  participants having fold increases greater than 1.5, 7 had TGF- 
pi concentrations below the group mean in the pre-anti-D sample, 2 of those 
being more than 1SD below the mean. Of the 9 participants in the D+ fetus group 
having fold decrease below 0.5, 9 had TGF-pi concentrations above the group 
mean, one of which was more than 1SD above the mean. Graphical 
representations are included of positive and negative fold changes (Figures 3.15, 
3.16), and comparing range of fold change in each group (Figure 3.17).
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IL-1 beta ELISA (pg/mL)
Sample Fold change
Before anti-D 1 hour 24 hour 1 hour 24 hour
1 26.125 24.458 36.125 0.94 1.38
2 33.625 31.958 25.292 0.95 0.75
3 31.125 31.958 28.625 1.03 0.92
4 31.958 26.125 31.125 0.82 0.97
5 28.625 26.958 29.458 0 94 1.03
6 38.625 29.458 30.292 0.76 0.78
7 41.125 23.625 23.625 0.57 0.57
8 30.292 29.458 31.125 0.97 1.03
9 39.458 32.792 36.958 0.83 0.94
1 0 28.625 27.792 28.625 0.97 1 . 0 0
1 1 27.792 33.625 31.125 1 . 2 1 1 . 1 2
1 2 26.958 28.625 31.125 1.06 1.15
13 26.125 24.458 27.792 0.94 1.06
14 30.269 25.653 27.961 0.85 0.92
15 26.423 27.192 22.576 1.03 0.85
16 29.500 27.961 28.730 0.95 0.97
17 29.500 24.884 27.192 0.84 0.92
18 24.115 24.115 26.423 1 . 0 0 1 . 1 0
19 27.192 30.269 37.192 1 . 1 1 1.37
2 0 37.961 31.807 45.653 0.84 1 . 2 0
2 1 29.500 32.576 32.576 1 . 1 0 1 . 1 0
2 2 34.115 16.423 15.653 0.48 0.46
23 14.115 15.653 14.115 1 . 1 1 1 . 0 0
24 12.576 12.576 14.115 1 . 0 0 1 . 1 2
Table 3.4 Analyte concentrations in pre-treatment, 1 hour and 24 hour post­
treatment samples, and fold changes from pre-treatment and 1 and 24 hour 
samples of IL-1 p detected by ELISA. Shading indicates participants with D+ 
fetuses.
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Figure 3.6 Distribution of positive and negative fold changes in IL-1 (3 among 1 
hour and 24 hour samples, in D+ fetus group (a) and D- fetus group (b). Fold 
change of 0  represents no change in this figure.
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Figure 3.7 Fold change in IL-1 p detected by ELISA in D+ and D- fetus groups in 1 
hour and 24 hour samples. Fold change of 1 represents no change.
Independent T test, significance of difference between means of D+ and D- fetus 
groups: 1hour p=0.806, 24 hours p=0.846
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IL-1 ra ELISA (pg/mL)
Sample Fold change
Before anti-D 1 hour 24 hour 1 hour 24 hour
1 226.50 2 0 1 . 0 0 206.00 0.89 0.91
2 683.00 692.00 536.00 1 . 0 1 0.78
3 326.00 245.50 283.00 0.75 0.87
4 322.00 324.50 317.50 1 . 0 1 0.99
5 777.00 858.00 799.00 1 . 1 0 1.03
6 586.50 649.00 742.00 1 . 1 1 1.27
7 260.00 435.50 363.00 1 . 6 8 1.40
8 735.50 762.00 895.50 1.04 1 . 2 2
9 454.00 252.50 351.50 0.56 0.77
1 0 387.00 275.50 297.50 0.71 0.77
1 1 6 8 8 . 0 0 842.50 1077.00 1 . 2 2 1.57
1 2 363.00 407.00 430.00 1 . 1 2 1.18
13 286.50 254.50 333.50 0.89 1.16
14 772.31 828.08 713.46 1.07 0.92
15 228.46 252.31 169.23 1 . 1 0 0.74
16 371.54 358.46 358.85 0.96 0.97
17 558.85 483.85 582.31 0.87 1.04
18 223.46 239.23 206.15 1.07 0.92
19 307.31 321.15 420.00 1.05 1.37
2 0 290.00 255.38 267.69 0 . 8 8 0.92
2 1 267.31 273.08 230.77 1 . 0 2 0 . 8 6
2 2 386.92 446.54 460.77 1.15 1.19
23 211.54 189.62 180.77 0.90 0.85
24 268.85 314.23 289.62 1.17 1.08
Table 3.7 Analyte concentrations in pre-treatment, 1 hour and 24 hour post­
treatment samples, and fold changes from pre-treatment and 1 and 24 hour samples 
of IL-1 ra detected by ELISA. Shading indicates participants with D+ fetuses.
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IL-1 ra (pg/mL)
D+ fetus group n=17 D- fetus group n=7
Range Mean SD Range Mean SD
Pre 211.5-777.0 391.6 165.8 226.5-772.3 474.9 247.5
1 hour 189.6-858.0 386.7 185.7 201.0-842.5 512.4 290.5
24 hour 180.8-799.0 391.5 178.3 169.2-1077.0 550.8 351.7
Table 3.8 Summary of analyte concentration results for IL-1 ra measured by ELISA
Group Interval Range of 
Fold change
Mean
Fold
change
SD Significance of difference 
between means in D+ vs D- fetus 
groups (independent T test)
D+ fetus
group
n=17
1 hour 0.56-1.71 1 . 0 0 0.24 p=0.575
24 hours 0.77-1.40 1 . 0 0 0 . 2 0 p=0.334
D- fetus 
group n=7
1 hour 0.89-1.22 1.05 0.13 : i
24 hours 0.74-1.57 1 . 1 0 0.27
Table 3.9 Statistical analysis of IL-1 ra ELISA results, (Fold change fold change, SD 
standard deviation)
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Figure 3.8 IL-1 ra concentration measured by ELISA in samples collected before anti- 
D administration and 1 hour and 24 hours afterwards, in D+ fetus group (n=17). The 
mean line for the group is shown in black .
116
1200
1000
800
O)
600
400
 mean
200
pre-anti-D 1 hour 24 hour
Figure 3.9 IL-1 ra concentration measured by ELISA in samples collected before 
anti-D administration and 1 hour and 24 hours afterwards, in D- fetus group (n=7). 
The mean line for the group is shown in black.
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Figure 3.12 Fold change in IL-1 ra detected by ELISA in the D+ and D- fetus 
groups in 1 hour and 24 hour samples. Fold change of 1 represents no change in 
this figure.
Independent T test, significance of difference between means of D+ and D- fetus 
groups: 1hour p=0.575, 24 hours p=0.534
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TGF-31 ELISA (pg/mL)
Sample Fold change
Before anti-D 1 hour 24 hour 1 hour 24 hour
1 35266.67 47688.89 15400.00 1.35 0.44
2 48644.44 17488.89 3466.67 0.36 0.07
3 50044.44 22533.33 26911.11 0.45 0.54
4 51800.00 15577.78 60555.56 0.30 1.17
5 54644.44 48044.44 49622.22 0 . 8 8 0.91
6 79911.11 47088.89 12555.56 0.59 0.16
7 2 2 2 2 2 . 2 2 13488.89 23622.22 0.61 1.06
8 73288.89 43555.56 50244.44 0.59 0.69
9 34866.67 19866.67 7600.00 0.57 0 . 2 2
1 0 27044.44 44022.22 47533.33 1.63 1.76
1 1 33155.56 55955.56 11444.44 1.69 0.35
1 2 11600.00 45622.22 29888.89 3.93 2.58
13 73822.22 42288.89 28666.67 0.57 0.39
14 65622.22 25111.11 23933.33 0.38 0.36
15 79511.11 51733.33 19288.89 0.65 0.24
16 52600.00 35600.00 12644.44 0 . 6 8 0.24
17 25066.67 39400.00 No result 1.57 No Value
18 10977.78 30400.00 21488.89 2.77 1.96
19 50622.22 21288.89 32555.56 0.42 0.64
2 0 37266.67 61733.33 43755.56 1 . 6 6 1.17
2 1 18355.56 17133.33 63733.33 0.93 3.47
2 2 71577.78 39644.44 32511.11 0.55 0.45
23 11044.44 41800.00 7022.22 3.78 0.64
24 29266.67 48888.89 23777.78 1.67 0.81
Table 3.10 Analyte concentrations in pre-treatment, 1 hour and 24 hour post­
treatment samples, and fold changes from pre-treatment and 1 and 24 hour 
samples of TGF-(31 detected by ELISA. Shading indicates participants with D+ 
fetuses.
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Figure 3.16 Distribution of positive and negative fold changes in TGF-pi among 
1 hour and 24 hour samples, in D- fetus group (a) and D- fetus group (b). Fold 
change of 0  represents no change.
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Figure 3.17 Fold change in TGF-p1 detected by ELISA in D+ and D- fetus groups 
in 1 hour and 24 hour samples, fold change of 1 represents no change. 
Independent T test, significance of difference between means of D+ and D- fetus 
groups: 1hour p=0.273, 24 hours p=0.140.
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3.5 Results of RNA Extraction and RNA Assay for IL-1ra and TGF-p1 by 
qPCR
3.5.1 RNA extraction
The quantity and purity of extracted RNA was measured on each sample using a 
nanodrop 1000 instrument (Thermo Scientific Ltd) Light from a pulsed xenon 
lamp was passed through a 1pL sample of RNA in aqueous solution. The 
absorbance was measured at 230nm, and the concentration of RNA calculated 
by applying Beer-Lambert’s law: (http//:nanodrop.com/library.nd-1000).
C=(Axe)b
Where
c= concentration of RNA (ng/pL)
A=absorbance
E=wavelength dependent extinction coefficient (40 for RNA)
B=path length
An example of the Nanodrop 1000 output is included ( Figure 3.18). Quantities of 
isolated RNA are listed in Appendix VIII.
3.5.2 Selection of analytes and endogenous controls
Based on ELISA results suggesting changes in the concentration of IL-1 ra and 
TGF-pi after treatment these two analytes were selected for analysis by qPCR.
Comparative qPCR to assess gene expression, as applied in this study, requires 
the use of an endogenous control gene, that is unlikely to vary during the study 
and against which study genes can be compared. Three widely used 
endogenous controls, GAPDH, Cyclophilin, and p actin were selected and 
assessed against cDNA isolated from 6  samples from the study along with the
128
study analytes. Mean CT and standard values were similar for all three genes; 
GAPDH had the lowest SD (Appendix IX) and was selected for use in the 
remainder of the study.
3.5.3 Validation of PCR response using cDNA dilution templates
The PCR response was validated with dilutions of pooled cDNA from the sample 
tested against each analyte and the endogenous control gene. An example of the 
amplification plot is included (Figure 3.19) and all results (Appendix X ). A plot of 
the response curves indicates good linearity and the gradients of the lines 
indicate high PCR performance, a slope of 3.3 representing 100% efficiency 
(Figure 3.20).
129
Measure
Re-blank
Blank
Print Screen
Print Report
Recording
Show Report
Measurement complete
User
10/29/2009 1:09 PM 
Default
Exit
Overlay control j Clear graph each Sample
1.41 =
1.20-
1.00-
<D
§ 0.80-
-2ocn
§  0.60-
££
o  0.40-
0.20-
0.00-
Wavelength nm
Sample Type RNA-40
Sample ID rna sample 2
Sam ple#: 2
230 C | nm A b s j 0.588
A-26010 mm path* 1.265 
A-28010 mm path 0.599 
260/280: 2.11 
260/230 2.15
ng/uL 50.6
3.5.2 BB749 0.03/96/24
Figure 3.18 RNA quantification, Nanodrop output showing 
absorbance profile of extracted RNA. The concentration of RNA is calculated 
from the absorbance of light at 230 nm wavelength, the purity estimated from the 
ratio of absorbance at 260:280nm, ratios greater than 2  are considered to show 
high purity for RNA preparations
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Figure 3.19 Determination of primer PCR efficiency by template dilution. 
Amplification plot for theTGF-(31 dilution template, the number of PCR cycles (x 
axis), fluorescence (y axis). The CT values at which fluorescence produced by 
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pre-determined threshold. Curves represent replicates of cDNA undiluted (N) and 
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3.5.4 qPCR Results IL-1ra
ACT values for IL-1ra for each participant are shown for the 3 time points in the 
study (Figures 3.21 and 3.22). In the D+ fetus group, five participants had fold 
change greater than 1.5 (one at 1, hour, four at 24 hours), in the D- fetus group 
two participants had fold changes >1.5 (one at 1 hour one at 24 hours), and one 
had a fold decrease < 0.5. Of the participants having a 1.5 fold or greater 
increase, one had a concentration of IL-1 ra below the group mean in the pre-anti- 
D sample.
Summaries of ACT values, and fold change data are included (Tables 3.13,
3.14). No significant difference between means of fold change in D+ and D- fetus 
groups was noted. Correlation in the fold change results obtained with each 
participant was weak and not significant in the D+ and D- fetus groups 
(Pearsons’s correlation coefficient 0.298, p=0.246, and 0.131, p=0.78) (Figure 
3.23). Fold increases and decreases in IL-1 ra are shown (Figure 3.24) and the 
distribution of fold changes in each test group are shown (Figure 3.25)
3.5.5 qPCR Results TGF-P1
ACT values for TGF-p1 for each participant are shown in time sequence (Figures 
3.26 and 3.27). In the D+ fetus group, 5 participants had fold change greater than
1.5 (1 at 1 hour, 4 at 24 hours), in the D- fetus group no participants had fold 
changes >1.5. Three participants had fold decreases below <0.5. None of the 
participants with fold increase >1.5 had an initial ACT below the group mean. 
Summaries of ACT values, and fold change data are included (Tables 3.15,
3.16). No significant difference between means of fold change in D+ and D- fetus 
groups was noted. Correlation in the fold change results obtained with each 
participant was weak and not significant in the D+ fetus group (Pearsons’s 
correlation coefficient 0.408, p=0.104) and strong but not significant in the D- 
fetus group (0.840, p=0.18) (Figure 3.28). Fold increases and decreases in TGF- 
p1 are shown (Figure 3.29) and the distribution of fold changes in each test 
group are shown (Figure 3.30)
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IL-1 ra (ACT)
D+ fetus group D- fetus group
Range Mean SD Range Mean SD
Pre 1.12-3.95 2.60 0.65 0.91-3.14 2.33 0.73
1 hour 2.02-3.71 2.73 0.47 0.31-3.66 2.65 1 . 1 0
24 hour 0.91-3.36 2.52 0.80 1.26-4.29 2.51 0.91
Table 3.13 Summary of mRNA measurement results by qPCR for IL-1 ra
Group Interval Range of
Fold
change
Mean
Fold
change
SD Significance of difference 
between means in D+ vs D- fetus 
groups (independent T test)
D+ fetus
group
n=17
1 hour 0.46-2.23 0.99 0.44 P=0.428
24 hours 0.45-4.14 1.29 0.97 P=0.452
D- fetus 
group n=7
1 hour 0.36-1.53 0.84 0.35
24 hours 0.27-1.69 1 . 0 0 0.45
Table 3.14 Statistical analysis of IL-1 ra qPCR results (SD standard deviation)
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Figure 3.21 IL-1 ra mRNA (ACT) measured by qPCR in samples collected before 
anti-D administration and 1 hour and 24 hours afterwards, in D+ fetus group 
(n=17). The mean line for the group is shown in black.
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Figure 3.22 IL-1 ra mRNA (ACT) measured by qPCR in samples collected before 
anti-D administration and 1 hour and 24 hours afterwards, in D- fetus group 
(n=7). The mean line shown is calculated from entire cohort.
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groups. Trend lines (D+ fetus group solid line, R2=0.09 D- fetus group broken 
line, R2=0.02) drawn by Microsoft Excel
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Figure 3.24 Distribution of positive and negative fold changes in IL-1 ra among 1 
hour and 24 hour samples, detected by qPCR in the D- fetus group. Fold change 
of 0  represents no change in this figure.
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Figure 3.25 Fold change in IL-1 ra detected by qPCR in the D+ and D- fetus 
groups in 1 hour and 24 hour samples. Fold change of 1 represents no change in 
this figure. The mean for each group is represented by a black line 
Independent! test, significance of difference between means of D+ and D- fetus 
groups: 1hour p=0.428, 24 hours p=0.452.
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TGF-p1 (ACT)
D+ fetus group D- fetus group
Range Mean SD Range Mean SD
Pre 1.50-5.33 4.51 0.99 3.82-5.17 4.49 0.45
1 hour 1.91-6.27 4.60 0 . 8 8 4.50-5.76 4.94 0.47
24 hour 3.05-6.44 4.67 0.91 4.40-6.11 4.99 0 . 6 6
Table 3.15 Summary of mRNA measurement results by qPCR for TGF-(31
Group Interval Range of
Fold
Change
Mean
Fold
change
SD Significance of difference 
between means in D+ vs D- fetus 
groups (independent T test)
D+ fetus
group
n=17
1 hour 0.52-2.05 1 . 0 0.36 p=0.280
24 hours 0.06-3.8 1.25 1 .0 1 p=0.258
D- fetus 
group n=7
1 hour 0.43-1.21 0.82 0.35
24 hours 0.27-1.37 0.79 0.36
Table 3.16 Statistical analysis of TGF-p1 qPCR results,( SD standard deviation)
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Figure 3.29 Distribution of positive and negative fold changes in TGF-p1 among 
1 hour and 24 hour samples, detected by qPCR in the D- fetus group, fold 
change of 0 represents no change in this figure.
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Figure 3.30 Fold change in TGF-(31 detected by qPCR in D+ and D- fetus groups 
in 1 hour and 24 hour samples, fold change of 1 represents no change in this 
figure. The mean for each group is represented by a black line 
Independent T test, significance of difference between means of D+ and D- fetus 
groups: 1hour p=0.425, 24 hours p=0.452
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3.6 Combined Results for ELISA and qPCR for IL-1ra and TGF-p1
For the two analytes included in the study, which have been assessed by both 
ELISA and qPCR, the results can be combined. This approach allows a more 
complete view of cytokine responses to anti-D prophylaxis, than can be achieved 
using either assay, and 1 and 24 hour samples in isolation. Using combined data 
allows assessment of secreted protein, and changes in DNA transcription to up- 
regulate expression in response to anti-D prophylaxis. The combined results are 
shown for 1 hour samples (Figures 3.31 and 3.32) and 24 hour samples (Figures 
3.33 and 3.34)
If the ELISA and qPCR data in Table 3.17 are considered together for IL-1 ra then 
6/11 participants in the D+ fetus group have a fold change >1.5 (one detected by 
ELISA, five by qPCR), and 2/7 participants in the D- group have fold changes 
>1.5 (Two by qPCR, one of which was also detected by ELISA). Applying Chi2 to 
this finding p=0.682 indicating that the difference between the groups is not 
significant (Table 3.17).
If the TGF-P1 data are considered in the same way 10/17 participants in the D+ 
fetus group have fold change increases>1.5 (5 detected by ELISA only, 2 by 
qPCR only, 3 by both techniques) and 1/7 participants in the D- fetus group (both 
ELISA and qPCR). Applying Chi2 to this finding p=0.047 indicating that the 
difference between the groups is significant (Table 3.17). Combined results are 
summarized in table 3.18.
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Group ELISA qPCR Combined
ELISA+qPCR
P
IL-1 ra D+ fetus group n=17 1 5 6 0.682
D- fetus group n=7 1 2 1
TGF-P1 D+ fetus group n=17 8 5 10 0.047
D- fetus group n=7 1 0 1
Table 3.17 Samples with fold change >1.5 detected by ELISA or qPCR .
p values calculated by Chi2 for the frequency of fold change >1.5 detected by 
ELISA or qPCR in the D+ and D- fetus groups.
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Test group
Participant IL-1 beta ELISA IL-1 ra ELISA TGF beta ELISA IL-1 raqP C R TGF beta qPCR
Number 1 hour 24 hour 1 hour 24 hour 1 hour 24 hour 1 hour 24 hour 1 hour 24 hour
2 0.95 0.75 1.01 0.78 0.36 0.07 0.96 0.86 0.88 0.82
3 1.03 0.92 0.75 0.87 0.45 0.54 1.24 0.99 1.08 1.29
4 0.82 0.97 1.01 0.99 0.30 1.17 0.81 0.87 1.05 1.00
5 0.94 1.03 1.10 1.03 0.88 0.91 1.21 0.82 2 05 1.17
6 0.76 0.78 1.11 1.27 0.59 0.16 0.79 2.82 1.10 3.51
7 0.57 0.57 1.68 1.40 0.61 1.06 0.53 0.55 0.55 0.46
9 0.83 0.94 0.56 0.77 0.57 0.22 0.55 0.90 0.70 1.18
10 0.97 1.00 0.71 0.77 1.63 1.76 0.85 0.53 0.81 0.56
12 1.06 1.15 1.12 1.18 3.93 2.58 1.37 1.82 1.20 1.64
16 0.95 0.97 0.96 0.97 0.68 0.24 0.46 0.44 0.52 0.52
17 0.84 0.92 0.87 1.04 1.57 1.00 0.96 1.46 1.40 1.78
18 1.00 1.10 1.07 0.92 2.77 1.96 0.99 4.14 1.25 3.80
19 1.11 1.37 1.05 1.37 0.42 0.64 1.49 0.98 1.01 0.97
20 0.84 1.20 0.88 0.92 1.66 1.17 2.23 2.13 0.75 0.06
21 1.10 1.10 1.02 0.86 0.93 3.47 0.91 1.20 0.71 0.93
23 1.11 1.00 0.90 0.85 3.78 0.64 0.57 1.01 0.88 1.19
24 1.00 1.12 1.17 1.08 1.67 0.81 0.85 0.45 0.98 0.36
Control group
1 0.94 1.38 0.89 0.91 1.35 0.44 0.85 0.74 0.82 0.84
8 0.97 1.03 1.04 1.22 0.59 0.69 0.90 1.23 0.90 0.95
11 1.21 1.12 1.22 1.57 1 69 0.35 0.77 1.69 1.21 1.37
13 0.94 1.06 0.89 1.16 0.57 0.39 0.36 1.10 0.26 0.46
14 0.85 0.92 1.07 0.92 0.38 0.36 1.53 0.79 1.08 0.70
15 1.03 0.85 1.10 0.74 0.65 0.24 0.67 0.27 0.43 0.27
22 0.48 0.46 1.15 1.19 0.55 0.45 0.76 1.15 1.02 0.94
Table 3.18 .Illustrating fold change by analyte, and assay method in D+ and
D- fetus groups. Colour codes used for fold change are included as a key
below
Fold change key
>3____________
2 to 3_________
1.5 to 2________
1 to 1.5________
0.75 to 1_______
0.4 to 0.75 
0 to 0.4
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4 Discussion
4.1 Acceptance and rejection of hypotheses
The objective of this study was to test two pairs of hypotheses 
Hypothesis 1
H0 There is no significant difference in cytokine expression in maternal 
circulation before and after DGG
and
Hi There is a significant difference in cytokine expression in maternal 
circulation before and after DGG
Based on the combined data that in section 3.6 the null hypothesis is not 
rejected
Hypothesis 2
H0 There is no significant difference in cytokine expression in maternal 
circulation after DGG in the presence or absence of D+ cells
and
Hi There is a significant difference in cytokine expression in maternal 
circulation after DGG in the presence or absence of D+ cells.
The results of FMH measurement were insufficiently accurate to allow this 
hypothesis to be considered.
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4.2 Methodology of the study
Three quantitative assays were applied as part of this study. The choices of 
techniques and analytes were made on the basis of economy, pragmatism 
and the objective of validating, and rigorously investigating changes in 
cytokine expression induced by anti-D administration in order to provide an 
insight into the mechanism of action of AMIS. Multiplex bead assays are the 
most recent of the applied techniques to be described, and have been 
considered to offer a rapid, cost effective approach to cytokine measurement 
(Young 2008). The cytokines chosen for assay by this technique were those 
considered most likely to show change, based on existing literature being 
incorporated into the study to increase the breadth and potentially the value of 
the research. Any of these analytes showing marked alteration in expression 
after treatment would have been included amongst those for further 
investigation by ELISA or RT-qPCR. In fact, the level of the analytes assayed 
by cytokine flow cytometry was below the minimum level of detectability. This 
is consistent with the findings of other authors (Branch 2006), and might be 
considered to indicate that treatment had no effect on these analytes. It 
should be considered that cytokines are capable of biological function at very 
low concentrations at the local cellular level, which may not be reflected in 
cytokine concentration in the circulation (Mantovani 2000).
ELISA is considered to be the standard technique for cytokine measurement 
offering high sensitivity, and was selected for analysis of 3 mediators of 
inflammation in this study. The technique is more time consuming, and more 
expensive that cytokine flow cytometry (Young 2008). The calculated analyte 
concentrations in participant’s plasma were broadly consistent with those 
obtained by other authors (Makhseed 2000, Jonssen 2006, Branch 2006).
IL-1 (3 was assayed by ELISA and cytokine flow cytometry. Concentrations of 
IL-1 (3 were detected by ELISA up to 45.6pg/mL, which if reproduced by 
cytokine flow cytometry would have been above the concentrations of the 4th 
standard, however no IL-1 (3 was detected by cytokine flow cytometry.
Reasons offered for dissimilar performance of bead array assays when
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compared to standard ELISA include: variations in specificity and avidity of 
monoclonal antibodies used in the technique and cross-reactions from the 
other reagents used in the multiplex test (Elshal 2006). Although detection of 
low levels of one analyte were seen to be less effective than ELISA, it is 
reasonable, based on the detection of standards to assume that none of the 
analytes assayed by flow cytometry; IFN-y. IL-1 p, IL-4, IL-6, IL-10, IL-12p70, 
IL-17A, TNF-a had radical increases in concentration during the 24 hours 
after treatment.
qPCR was included in the study to determine whether there was a change in 
cytokine gene transcription in circulating nucleated cells, indicating, the source 
of the cytokines in samples with elevated plasma concentration, as well as 
offering greater sensitivity than the measurement of plasma protein. qPCR 
has been employed in a semi-quantitative and more recently fully quantitative 
basis for cytokines and many other analytes (Bustin 2002). In this study the 
techniques for extraction of mRNA, reverse transcription to cDNA and the 
PCR process were found to be robust and straightforward using bespoke kits 
(Applied Biosystems Ltd), though the manual platform meant the processes 
were very time consuming. Replicate reproducibility and dilution template 
were good for IL-1 ra, and TGF-(31. The tests kits were however relatively 
expensive and this precluded the analysis of other analytes in this study.
Poor correlation between results of ELISA and RT-qPCR were obtained, as 
expressed by fold change. This may relate to the biology of cytokine release, 
TGF-(31 is stored and secreted in vivo in a non-active form as a complex with 
Latency Associated Protein, as a result there is poor correlation between 
TGF-pi transcription message levels and amounts of secreted protein, 
suggesting post transcriptional or translational regulation of TGF-(31 
expression (Li 2006). Other authors have reported generally poor correlation 
between cytokine levels and fold change as detected by ELISA, RT-qPCR 
and cytokine flow cytometry, though studies of patterns of expression in 
longer time series using cultured and stimulated cell lines, with higher
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concentrations of analytes in culture supernatant liquid have had better results 
(Favre 1997).
The use of multiple techniques, ELISA and qPCR for the assessment of 
cytokine expression, offers the opportunity to confirm the concentration of 
plasma protein with measurement of transcribed mRNA, in particular in in vitro 
or ex vivo experimental models in which protein synthesis and release are 
closely and temporally linked.
In an in vivo model such as that in the current study, in which the source of 
secreted cytokine, and the mechanism for release is not known, the link 
between plasma protein and transcribed mRNA may not be so strong, and an 
alternative approach to the use of multiple techniques may be considered.
The secretion of cytokines into the plasma may reflect the release of pre- 
sythesised and stored material in response to specific stimulus (e.g TGF-P1 in 
Th3 lymphocytes). In this case any increase in specific mRNA expression may 
occur after the plasma cytokine burst as protein is synthesised to replace 
secreted protein. Alternatively, cytokine secretion may be the result of de novo 
protein synthesis in nucleated cells following immunomodulatory signalling 
which typically would occur around 24 hours later. The timing of any cytokine 
burst in an in vivo model is therefore difficult to predict, and may vary between 
individuals. The brief nature of cytokine burst leaves the possibility that any 
time series without continuous monitoring, such as the present study, may fail 
to detect cytokine responses
For these reasons, in this study data, from ELISA and qPCR, as well as being 
considered separately were combined, with fold change values in D+ and D- 
fetus groups, greater than 1.5 detected by either technique at either time point 
were compared. Only by this approach were significant differences in TGF-(31 
expression detected between D+ and D- fetus groups. This may indicate that 
in an in vivo model of investigation of anti-D prophylaxis neither ELISA or 
qPCR alone is sufficiently informative, or that in an extended study offering a
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larger sample size with more sample points in the time series either or both 
techniques may provide significant findings.
One of the objectives of the study was to determine a link between the 
presence of fetal D+ cells and cytokines in response to anti-D injection. Two 
strategies were employed to achieve this: firstly determination of the fetal D+ 
group at delivery and allocation of participants to study arms based on fetal 
group, and secondly detection of circulating D+ cells in the maternal blood 
samples. No large FMH were detected (>4mL) in the study samples. These 
are most commonly encountered in the third trimester of pregnancy, 
particularly at the time of delivery (BCSH 2009). Poor results were obtained 
chiefly to high and variable background counts. This may be attributable to 
intrinsic failure of the techniques to acquire such high counts of events in 
clinical samples without accompanying background counts. This would 
confound the detection of low levels of D+ cells. Alternatively the high 
background may have been the result of contamination from consumables or 
reagents used, though high backgrounds were not particularly apparent in the 
validation exercise.
Without further investigation, particularly with a view to increasing data 
acquisition without exacerbating confounding high background counts, it may 
be that flow cytometry cannot reliably detect FMH at the minimum level 
required to elicit a maternal alloimmune response.
In planning this study, the use of acid elution (AE) for detecting FMH was 
considered and rejected. AE has a reputation for false positive results and for 
inaccuracy but is considered by some authors to be more sensitive than FC 
and may have been a useful addition to this study (BCSH 2009).
It has been suggested that molecular means are employed to detect FMH 
(Branch 2006). As naked fetal DNA is routinely detectable in maternal plasma 
from 18 weeks gestation in all pregnancies (Avent 2002) without any transfer 
of fetal cells to the maternal circulation it is hard to see how this strategy could 
be applied successfully.
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4.3 Limitations of the Study
The results of this study can only be generalised to individuals, or groups, 
meeting the inclusion criteria, and undergoing the same treatment. In fact 
though anti-D prophylaxis is almost universal in the UK, and other developed 
countries at 28 weeks, much less typical is the choice of the intravenous 
administration route. Intramuscular administration is more widely practiced, 
but is unpopular amongst recipients as it is painful, and is notoriously poor 
and variable as a means to introduce anti-D immunoglobulin rapidly to the 
maternal circulation, especially when the dose is inadvertently delivered into 
fatty tissue (MacKenzie 2006).
The present study differs from that of Branch (2006) by the means of anti-D 
administration, the inclusion of a control group the use of qPCR, and the 
elapsed time between treatment and administration (48 hours in Branch’s 
study). The more rapid and predictable delivery of anti-D into the maternal 
circulation prompted the use of a 1 hour and 24 hour sample regime. This 
appears to have been justified as fold changes in TGF-pi were recorded in 
the D+ fetus arm 1 hour samples in ELISA (7/17) and qPCR (1/17) and the 24 
hour samples ELISA (4/17) and qPCR(4/17). The selection of this sampling 
regime was based on previous indications of response times to anti-D (Branch 
2006) and IVIg (Semple 2007), tempered by pragmatism in establishing a 
regime for sample collection consistent with recruiting a sufficiently large 
cohort for the study by making reasonable demands on participants attending 
for repeat sampling.
Cytokines have short circulating half lives. It is unlikely that FMH would occur 
spontaneously in the 24 hour period, from treatment to sampling, among the 
cohort so any cytokine response to the interaction of administered anti-D and 
fetal D+ cells is likely to result from fetal D+ cells already in the maternal 
circulation. In the absence of ongoing antigen supply, the cytokine response is 
likely to be a single short term event, in contrast to cytokine responses to
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chronic conditions such as disease or pregnancy. It is impossible from the 
evidence of this study to determine whether more participants had cytokine 
responses which were not detected because they occurred before, outside the 
time points of the study. In Branch’s study samples were taken 48 hours after 
anti-D was administered by intramuscular injection, as other authors have 
commented that may have resulted in failure to detect important responses 
(Semple 2007).
The decision to use the mothers of D- infants as the control group had 
significant benefits to the study. These women received exactly the same care 
as those in the D+ fetus arm, and it is reasonable to expect that they would, 
as a result have the same, if any, non-specific responses. This offers better 
study design that using a placebo control such as saline offered to another 
group of women (attendees at a glucose tolerance test clinic were considered 
for this control). In addition excellent blinding characteristics were established 
by this strategy as the fetal D group was unknown to participants and the 
investigators at the time of sampling, and at the time that laboratory assays 
were performed. The strategy for controlling the study did however prevent 
any control of the number of women in treatment and control arms. In the UK 
40% of D- mothers deliver D- infants. It might be expected therefore that 9 or 
10 of the cohort of 24 would form the control arm. In fact, only 7 (29.2%) did 
so, making the data from the control arm less easy to interpret, potentially 
reducing the statistical significance of the study findings. This finding of a 
lower than expected proportion of D- fetuses in this cohort may reflect the 
small sample size.
The inclusion criteria of the study were deliberately set very broadly. Any 
woman of 28-32 weeks gestation, receiving anti-D prophylaxis who was willing 
to participate was recruited. The strategy was adopted partly to avoid any 
discrimination as required for ethics approval, and to maximise generalisability 
of the findings; but also as a response to robust and frequent warnings from 
clinical colleagues who warned that recruitment would be problematic. No 
attempt to exclude women with pre-existing alloantibodies was made (in fact 
there were none) or any women suffering from infections. It is possible
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therefore those cytokine responses may be due to changes other than the 
treatment under study.
4.4 Findings of the study
Studies on changes in cytokine profile after administration of exogenous IgG 
include those on IVIg and anti-D antibody when administered to treat ITP. 
Changes detected in the expression of inflammatory mediators in those 
studies are indicative of the need to investigate similar effects in AMIS, when 
used to prevent alloimmunisation to the RhD antigen, but caution must be 
exercised in comparing the findings. In particular the immunological processes 
associated with the underlying condition must be considered. IVIg is 
administered as an anti-inflammatory agent to treat autoimmune conditions 
such as ITP which occur in a pro-inflammatory immune environment. In 
contrast HDFN occurs in a Th2 dominated immune environment (Ragupathy
2001). The regulation of cytokines and their receptors and for FcR cannot 
therefore be directly compared.
In addition, the doses of anti-D administered in treating ITP (50-75pg/kg) are 
much higher than those in anti-D prophylaxis (300pg, typically 4pg/kg). Finally 
the quantity and supply of antigen is markedly different. In ITP, D antigen is 
present in constant excess on the patient’s red cells, by contrast in anti-D 
prophylaxis, antigen dose from FMH is typically small and sporadic.
There is evidence that small doses of exogenous, specific IgG can cause 
powerful pathological responses. Anti-HLA IgG antibodies inadvertently 
administered in small quantities in blood products can elicit a powerful 
immune response, causing transfusion related acute lung injury (TRALI) an 
uncommon, but significant cause of post transfusion morbidity and mortality. 
Typically these reactions occur after the transfusion of plasma rich products, 
but have been recorded after transfusion of concentrated red cells containing 
less that 20mL of plasma. Approximately 95% of the IgG in Rhophyllac is of 
specificities other than RhD. (Rhophyllac package insert). The potential 
biological effects of this immunoglobulin are largely unexplored.
More directly comparable with the current study are the results of the 
investigation of Branch et al. (2006). In that study ELISA was used to measure
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plasma cytokines, found TGF-p1 fold changes of >1.5 in 4/10 (40%) of 
participants at 48 hours after IM anti-D administration. These findings are 
comparable with those of the current study with 7/17 (41%) participants 
carrying D+ fetuses having similar fold change in TGF-(31 at 1 hour, and 4/17 
(25%) at 24 hours. The lower proportion of TGF-(B1 responses at 24 hours in 
the current study may result from more immediate dispersal of anti-D 
administered by the IV route.
It is important to note that a high proportion (7 of 8) of the participants having 
TGF-(31 fold changes of >1.5 had a starting antigen concentration below the 
group mean, though 7 out of 8 went on to exceed the group mean in either 1 
hour or 24 hour samples. Similarly of those having a change below 0.5 all had 
starting concentrations above the group mean. It is possible therefore that 
some of these observations represent regression to the mean (Field 2003). 
The mean TGF-(31 concentration in the D- fetus arm is significantly higher 
than that in the D+ arm (difference between means of D+ and D- fetus group, 
p=0.007 independent T test). This observation might indicate that a 
suppressive process has been initiated by the maternal immune system even 
before anti-D is administered.
IL-1 ra increases in the current study and Branch’s are similar (1/17 at 1 hour 
and 24 hours, compared with 1/10 at 48 hours). IL-1 ra has been reported to 
be more markedly elevated after anti-D administration to ITP patients (Semple
2002), and it has been suggested that short term IL-1 ra responses may have 
been missed due to sample timing in Branch’s study (Semple 2007). The 
current study includes a 1 hour samples (3 hour in the study of Semple 2002), 
and has not detected a significant increase in plasma IL-1 ra in the D+ fetus 
arm. This may reflect a lack of IL-1 ra response in this study though, 4/17 
(24%) of participants in the D+ fetus had a >1.5 fold increase in IL-1 ra mRNA, 
indicative of increased cytokine synthesis. A longer time series may have 
detected increased plasma IL-1 ra levels.
If, as hypothesised, the change to cytokine profiles requires the presence of 
fetal D+ cells and exogenous anti-D it is unsurprising that not all participants
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respond. Estimates vary of the proportion of women at 28 weeks who have 
circulating D+ cells from 10% to 45% (Woodrow 1996, Urbaniak 1999). The 
quantity of fetal D+ cells required to stimulate an antibody response is 
unclear, the quantity required to elicit a cytokine response in the presence of 
anti-D is untested.
When ELISA and RT-qPCR results are combined, the results of the current 
study indicate that the numbers of participants undergoing fold change 
increases in TGF-(31 is significant (p=0.047). Though IL-1 ra fold change 
increases of similar magnitude were observed in some participants, the 
findings were not statistically significant (p=0.682).
This study offers new knowledge on the effects of anti-D immunoglobulin on 
cytokine profiles, in particular on TGF-01. It is undeniable that the treatment 
has been overwhelmingly successful in reducing maternal alloimmunisation to 
the D antigen, and hence HDFN, though our lack of understanding of that 
mechanism has limited developments in safety, improved supply and our 
ability to translate the success into parallel areas of HDFN. The challenge of 
replacing anti-D retrieved from fractionated plasma, collected from volunteer 
blood donors with a monoclonal alternative has exercised researchers and the 
pharmaceutical industry for many years. The potential benefits are manifold, 
improving product safety and supply. Anti-D is regarded as a relatively safe 
product, but any blood product produced from pools of human plasma has the 
potential for widescale infection of recipients with pathogens which have 
escaped the screening and fractionation process. Anti-D fractionated from 
human donor plasma is currently available in adequate supply in the UK, and 
other developed countries, but the effect of the continuing global spread of 
vCJD on anti-D supply is uncertain, and is potentially catastrophic. The 
availability of a plentiful supply of effective synthetic anti-D would have a 
significant effect on management of HDFN.
It is striking in reviewing reports of studies into the efficacy of monoclonal IgG 
anti-D that the chief criterion for selection of clones for trial was the ability to 
clear D+ red cells from the circulation of D- volunteers (Beliard 2006). No
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assessment of the effect of the antibodies on immune mediators including 
cytokines was made. None of the monoclonal or recombinant anti-D 
preparations so far trialled for prophylaxis have proved sufficiently reliable for 
routine clinical use, and to date no explanation for that failure has been 
obtained.
TGF-p1 is a powerful and versatile modulator of immunity, capable of impact 
at almost every stage of the humoral response (Li 2006). If, as this study 
suggests, its secretion is increased as a response to exogenous anti-D 
antibody then it may have a systemic role in AMIS. Understanding the role 
and mechanism of TGF-p1 induction by exogenous anti-D might affect the 
selection of monoclonal antibodies for future trials. Improved knowledge of 
specific characteristics of Fc effector regions might allow synthesis of IgG anti- 
D capable of eliciting the full range of effects of human donor derived product.
The success of anti-D prophylaxis in preventing RhD alloimmunisation has 
caused a shift in focus to HDFN caused by other antibodies, in particular anti- 
c, and anti-K. Alloimmunisation to red cells antigens other than RhD has been 
reported to occur in 0.15-1.1% of pregnant women (Koelewijn 2009). There is 
no strategy to prevent alloimmunisation to these antigens other than 
conservative transfusion, and no treatment to mitigate against antibodies 
stimulated by FMH. Though HDFN mediated by these antibodies is still less 
common and generally less severe than that caused by anti-D, fetal mortality 
occurs every year in the UK. In consequence understanding of the 
mechanism of AMIS may, in time, lead to prophylaxis for these antibodies as 
a routine.
Finally, transfusion scientists and clinicians are occasionally challenged by the 
management of the pregnancies of women who express qualitative variants of 
the RhD antigen. These women are capable of mounting an alloimmune 
response to red cells expressing normal D antigen, but their own cells, which 
outnumber fetal cells from FMH, bind administered exogenous anti-D 
administered for prophylaxis (Lubenko 1989). The issue of whether to 
administer anti-D, and at what dose has never been resolved. Understanding
163
the mechanism of action by which AMIS is effective would inform the 
management of these cases.
4.5 Recommendations for further research
It is perhaps inevitable that a small scale, practitioner-lead study with some 
findings of interest, concludes with a series of recommendations for further 
research.
This should in the first instance focus on addressing the limitations of the 
current study. In particular developing a more sensitive and reliable means of 
detecting and quantifying FMH to allow comparison with measured cytokine 
response. Recruiting a larger cohort, particularly in the control group, has the 
potential to improve statistical robustness, and resolve issues associated with 
regression to the mean in the current study. Expanding the range of analytes, 
in particular by RT-qPCR, and the sensitivity of the tests applied should be 
informative, and should be more so with a larger cohort. A better 
understanding of the link between FMH and cytokine response might be 
achieved by targeting women known to have undergone FMH. Recruiting a 
sufficiently large cohort and dealing with the additional variables of trauma 
and a wider range of gestational age would be problematic, though 
achievable. Such a cohort of women being treated as in-patients might also 
permit a more complete and extensive time series of samples to be obtained 
to detect brief cytokine spikes.
If the indications of cytokine mediated mechanisms in AMIS are confirmed by 
such studies, then focus might shift to assessment of monoclonal antibodies 
for clinical trial, and attempting to compare efficacy in clinical trial with any 
cytokine response elicited. If shifts in TGF-pi expression can be 
demonstrated as a marker for successful AMIS, improving accessibility of 
cytokine assays might offer a diagnostic tool in timely confirmation that AMIS 
has been achieved in challenging cases.
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4.6 Conclusion
Blood group serologists, interested clinicians, and some immunologists have 
for more than two generations explained the efficacy of AMIS through rapid 
clearance of opsonised red cells. It is understandable that the effect of reliable 
immunomodulation, and the evidence are linked in a causal manner without 
strong supporting evidence. Indeed questioning the mechanism of AMIS 
brings the risk of abandonment of a valuable, cost effective, and 
experimentally elegant therapy. It is only when the observer is armed with a 
sense of the bewildering complexity, the multiple effector mechanisms 
conferring insuring redundancy, and the exquisite specificity of the human 
immune system that improbability of such a simplistic explanation for the 
conundrum of AMIS is apparent.
The first clinical applications of AMIS were based on experiments made on 
observations made in vivo, which occurred when the science of immunology 
was emergent and largely uninformed at the molecular or cellular level. That 
the practice has been so spectacularly effective has made challenge of the 
assumptions, made at its inception, a heresy. Failure to make that challenge 
in the context of new knowledge is a dereliction of duty, and more importantly 
a failure to expand and extend the established practice of AMIS into therapies 
for existing candidates that are safer and more efficacious, as well as new 
treatments for those who currently have none.
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requirem ents of the Research Governance Framework for Health and Social Care 
which is m andatory fo r all NHS em ployees. This docum ent m ay be accessed on the 
D epartm ent o f Health w ebsite  at h ttp ://www .dh.qov.uk/research
R&D approval is therefore given on the understanding that you com ply w ith the 
requirements o f the Framework as listed in the attached sheet “Conditions of 
Approval".
If you have any queries about this approval please do not hesitate to contact the 
R&D D epartm ent on te lephone 0113 392 2878.
Indemnity Arrangements
The Leeds Teaching Hospita ls NHS Trust participates in the NHS risk pooling 
scheme adm in istered by the NHS Litigation Authority 'C lin ica l Negligence Scheme 
for NHS T rusts ' for: (i) m edical professional and/or m edical m alpractice liability; and 
(ii) general liability. NHS indem nity fo r negligent harm  is extended to researchers 
w ith an em ploym ent contract (substantive or honorary) w ith the Trust. The Trust
Chairman M artin  Buckley Chief Executive Maggie Boyle
The Leeds Teaching Hospitals incorporating; Chape! A llcrton Hospital CooU idge Hospital I.m is  Chest Clinic 
Leeds Dental Institute Soaaoft Hospital St James’s University Hospital The General Infirmary at Lwds 
W harfodsle Hospital
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only accepts liab ility  fo r research activity that has been m anageria lly approved by the 
R&D Departm ent.
The Trust there fore  accepts liability fo r the above research pro ject and extends 
indem nity fo r negligent harm  to cover you as principal investigator and the 
researchers listed on the R&D approval form  provided tha t each m em ber o f the 
research team  has an em ploym ent contract (substantive or honorary) w ith the Trust. 
Should there be any changes to the research team  please ensure that you inform  the 
R&D Departm ent and that s/he obtains an em ploym ent contract w ith the Trust if 
required.
Yours sincerely
Dr Dawn Lawson 
R&D Manager
Approved documents
The docum ents reviewed and approved are listed as fo llows
Document Version Date of document 1
Protocol i
SSI Form 5.5 24/01/08
CMT Approval 17/01/08
NHS REC Application Form 5.5 24/01/08 I
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Appendix IV
Research Participant Information Sheet
The effect o f anti-D immunoglobulin administration on serum cytokine
levels
We would like to invite you to take part in a research study. Before you decide you need to 
understand why the research is being done and what it would involve for you. Please take time to 
read the following information carefully. Talk to others about the study if  you wish.
Anti-D is given to pregnant women who ore Rh (Rhesus) negative to prevent babies in current and 
subsequent pregnancies becoming ill. The treatment is both safe and effective, it has been given to 
many thousands of women, but we still do not have some o f the information we need about how 
anti-D works.
We cannot promise the study will help you but the information we get may help to prevent 
haemolytic disease in babies.
In this study we need to measure the levels o f substances (cytokines) in the blood, which are part o f 
the immune system. We will measure cytokine levels before and after anti-D is given. In addition we 
need to measure these same substances in some women who do not receive anti-D.
If you agree to participate we will take a sample o f blood just before you receive anti-D, and take 
another sample 1 hour afterwards. About 24 hours a fter your injection is given we will collect one 
further sample. The second and third samples would be collected by nurses at the Blood 
Transfusion Centre at Seacroft Hospital. We can pay travel expenses, or arranoe a local taxi to get 
you to and from the centre.
Participation in the study wilt not affect the treatment that you or your baby receives.
It is up to you to decide whether to participate. If you do we will describe the study and go through 
this information sheet which we will then give to you at your 28 week clinic appointment. We will 
then ask you to sign a consent show you have agreed to take part You are free to withdraw at any 
time, without giving a reason. This would not affect the standard o f care you receive. If you withdraw 
from the study, we will destroy all your identifiable samples, but we will need to use the data 
collected up to your withdrawal.
If you have a concern about any aspect o f this study, you should ask to speak to the researcher 
who will do his best to answer your questions. If you remain unhappy and wish to complain formally, 
you can do this through the NHS Complaints Procedure. Details can be obtained from the hospital.
All information which is collected about you during the course o f the research wilt be kept strictly 
confidential, and any information about you which leaves the hospital/surgery wilt have your name 
and address removed so that you cannot be recognised).
All research in the NHS is looked at by an independent group of people, called a Research Ethics 
Committee to protect your safety, rights, wellbeing and dignity. This study has been reviewed and 
given favourable opinion by York Hospitals Research Ethics Committee.
Mark Williams, Leeds Blood Centre, Bridle Path Leeds, LS15 7TW, Tel 0113 214 8675 
26/6/08 version ctS.O
Centre Number: EX08/8592
Study Number 08/H1311/22
Patient identification number
Consent Form
Title of Project: The effect of anti-D immunoglobulin administration on serum cytokine
profiles
Name of Researcher: Mark Williams
Please initial box
1, I confirm that I have read and understand the information sheet for the above study. 
I have had the opportunity to consider the information, ask questions and have had 
these answered satisfactorily.
2, I understand that the participation is voluntary and that I am free to withdraw at any 
time without giving any reason, without my medical care or legal rights being 
affected.
4, I agree to take part in the above study
Name of patient Date Signature
Name of person taking consent Date Signature
When completed 1 copy for patient, 1 for researcher site fiie, 1 (original) for medical notes
□
□
I understand that relevant sections of my medical notes and data collected during my
study may be looked at by the researcher, from regulatory authorities, or from the ------
NHS Trust, where it is relevant to my taking part in this research. I give permission 
for these individuals to have access to my records □
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Appendix V Results of FMH estimation on pre-treatment samples
rticipant
umber
Events in positive region
Events in negative 
region % in positive region corrected vol
Fetal D 
group
Total Total
1 829 571 0.0258 0.566568 D-
2 1186 546 0.064 1.40544 D+
3 856 263 0.0593 1.302228 D+
4 506 578 -0.0072 -0.158112 D+
5 770 649 0.0121 0.265716 D+
6 215 39 0.0176 0.386496 D+
7 521 853 -0.0332 -0.729072 D+
8 799 677 0.0122 0.267912 D-
9 954 931 0.0023 0.050508 D+
10 879 864 0.0015 0.03294 D+
11 1161 989 0.0172 0.377712 D-
12 525 336 0.0189 0.415044 D+
13 357 437 -0.008 -0.17568 D-
14 831 975 -0.0144 -0.316224 D-
15 857 409 0.0448 0.983808 D-
16 755 620 0.0135 0.29646 D+
17 561 360 0.0201 0.441396 D+
18 939 849 0.009 0.19764 D+
19 1130 1330 -0.02 -0.4392 D+
20 911 629 0.0282 0.619272 D+
21 301 264 0.0037 0.081252 D+
22 543 585 -0.0042 -0.092232 D-
23 1045 874 0.0171 0.375516 D+
24 421 267 0.0154 0.338184 D+
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FMH results sorted by fetal RhD group
D-fetus D+ Fetus
FMH value FMH value
(mL) participant no (mL) participant no
0.566568 1 1.40544 2
0.267912 8 1.302228 3
0.377712 11 0 4
0 13 0.265716 5
0 14 0.386496 6
0.983808 15 0 7
0 22 0.050508 9
0.03294 10
0.415044 12
0.29646 16
0.441396 17
0.19764 18
0 19
0.619272 20
0.081252 21
0.375516 23
0.338184 24
0.313714 Mean 0.365182 Mean
Standard Standard
0.368421 deviation 0.415867 Deviation
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Appendix VIII RNA quantification data ng/mL
1 . 1 98.6 1 . 2 87.2 1.3 1 1 . 6
2 . 1 101.3 2 . 2 81.2 2.3 102.5
3.1 82.6 3.2 6 6 . 1 3.3 96.6
4.1 74.5 4.2 64.4 4.3 79.6
5.1 6 6 . 6 5.2 52.9 5.3 35.9
6 . 1 114.4 6 . 2 70.5 6.3 6 8 . 8
7.1 62.4 7.2 92.2 7.3 136.3
8 . 1 55.9 8 . 2 89.7 8.3 78.9
9.1 108.3 9.2 78.9 9.3 6 8 . 6
1 0 . 1 71.7 1 0 . 2 90.5 10.3 77.5
1 1 . 1 49.8 1 1 . 2 47.9 11.3 63.7
1 2 . 1 148.7 1 2 . 2 97.7 12.3 76.9
13.1 110.3 13.2 110.5 13.3 88.9
14.1 141.8 14.2 61.3 14.3 107.5
15.1 42 15.2 43 15.3 56.6
16.1 117.5 16.2 165.7 16.3 113.2
17.1 117 17.2 90.8 17.3 146
18.1 * 18.2 81.2 18.3 75.7
19.1 131.1 19.2 118.1 19.3 92.7
2 0 . 1 72.5 2 0 . 2 67.6 20.3 81.7
2 1 . 1 80.5 2 1 . 2 17.9 21.3 j 56.5
2 2 . 1 276.3 2 2 . 2 150.7 22.3 159.4
23.1 98.7 23.2 89.4 23.3 150.6
24.1 66.4 24.2 103 24.3 67.7
RNA extractions 2,4,5 November 2009
Rtempus RNA extraction kit product no 4378996 Lot 0908015 
* no RNA detected by nanodrop
Appendix IX Endogenous control selection
Sample Endogenous Ct Endogenous Ct Endoge
Name control Ct Mean control Ct Mean control
Sample 1 Gap 17.7246 17.6405 Cyc 17.3807 17.2848 B act
Sample 1 Gap 17.5564 17.6405 Cyc 17.1889 17.2848 B act
Sample 2 Gap 17.2832 17.1934 Cyc 16.9376 16.8539 B act
Sample 2 Gap 17.1035 17.1934 Cyc 16.7703 16.8539 B act
Sample 3 Gap 17.4102 17.2633 Cyc 17.2845 17.2254 B act
Sample 3 Gap 17.1164 17.2633 Cyc 17.1662 17.2254 B act
Sample 4 Gap 17.7276 17.6723 Cyc 17.3871 17.4822 B act
Sample 4 Gap 17.6169 17.6723 Cyc 17.5773 17.4822 B act
Sample 5 Gap 17.2123 17.1391 Cyc 16.8673 16.7985 B act
Sample 5 Gap 17.0658 17.1391 Cyc 16.7298 16.7985 B act
Sample 6 Gap 17.5796 17.5704 Cyc 17.4456 17.4235 B act
Sample 6 Gap 17.5613 17.5704 Cyc 17.4013 17.4235 B act
mean 17.41315 mean 17.17805 mean
SD 0.236185 SD 0.273671 SD
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Appenc ix X Dilution template data
Dilution CT
GAP DH
1 17.86455
1 0 20.68525
1 0 0 24.2107
1 0 0 0 27.2651
IL-1ra
1 20.04115
1 0 23.57535
1 0 0 25.9145
1 0 0 0 29.6282
TGF beta
1 22.19335
1 0 25.438
1 0 0 28.4327
1 0 0 0 31.87545
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